Structure, Mechanism and Inhibition of the human Glutaminyl Cyclase by Kupski, Oliver

Structure, Mechanism and Inhibition
of the human Glutaminyl Cyclase
Georg-August-University Göttingen
Faculty of Chemistry
Participated in the Graduate Programme:
Metal Sites in Biomolecules
PhD Thesis




born on 07. July 1984
4th April 2016

Members of the Thesis Committee
Prof. Dr. rer. nat. Kai Tittmann (Reviewer)
Department of Molecular Enzymology
Schwann Schleiden Research Center
Georg-August-University Göttingen
Prof. Dr. rer. nat. Franc Meyer (Reviewer)
Institute for Inorganic Chemistry
Georg-August-University Göttingen
Prof. Dr. rer. nat. Derek Logan
Department of Biochemistry and Structural Biology
Center for Molecular Protein Science
Lund University
Members of the Extended Examination Board
Prof. Dr. rer. nat. Ricardo Mata
Department of Computational Chemistry and Biochemistry
Institute of Physical Chemistry
Georg-August-University Göttingen
Prof. Dr. rer. nat. Claudia Höbartner
Institute of Organic and Biomolecular Chemistry
Georg-August-University Göttingen
Dr. rer. nat. Franziska Thomas
Department of Chemical Biology and Peptide Design
Institute of Organic and Biomolecular Chemistry
Georg-August-University Göttingen
Dr. rer. nat. Fabian Commichau
Department of General Microbiology
Institute of Microbiology and Genetics
Georg-August-University Göttingen
Statutory Declaration
Herewith I declare that I prepared this thesis “Structure, Mechanism and Inhibition of Hu-
man Glutaminyl Cyclase” independently and with no other sources and aids than quoted.







1 List of Figures 1
2 List of Tables 4
3 Abbreviations and Symbols 6
Abbreviations 6
4 Introduction 10
4.1 Pyroglutamic Acid - A Key Metabolite Within the Human System . . . . . 10
4.2 Glutaminyl Cyclase - An Enzyme Responsible For Pyroglutamic Acid For-
mation and Its Evolution . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
4.3 Physiological Function of Mammalian Glutaminyl Cyclase . . . . . . . . . . 14
4.4 Glutaminyl Cyclase And Its Role in Neurodegenerative Diseases . . . . . . 15
4.5 Reaction Mechanism of Human Glutaminyl Cyclase . . . . . . . . . . . . . 19
4.6 Human Glutaminyl Cyclase - Target Enzyme For Drug Development . . . . 22
4.7 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
5 Materials and Methods 24
5.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.1.1 Chemicals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
5.1.2 Enzymes, Markers and Kit systems . . . . . . . . . . . . . . . . . . . 25
5.1.3 Peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.1.4 Bacterial Strains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.1.5 Oligonucleotides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
5.1.6 Plasmids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
5.1.7 Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
5.1.8 Columns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
5.1.9 Commodities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.2.1 Molecular Biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.2.1.1 Polymerase Chain Reaction (PCR) . . . . . . . . . . . . . . 29
5.2.1.2 Cleavage of DNA with Restriction Enzymes . . . . . . . . . 29
v
Contents
5.2.1.3 Agarose Gel Electrophoresis . . . . . . . . . . . . . . . . . 30
5.2.1.4 Blunt-End Ligation of DNA Fragments . . . . . . . . . . . 30
5.2.1.5 Concentration and Purity Determination of DNA . . . . . 30
5.2.1.6 Plasmid Transformation into Chemocompetent E.coli Cells 30
5.2.1.7 Preparation of Plasmid DNA from E.coli Cells . . . . . . . 31
5.2.1.8 DNA Sequencing . . . . . . . . . . . . . . . . . . . . . . . . 31
5.2.2 Protein Chemistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
5.2.2.1 Overexpression of the GST-hQC Fusion Protein in E.coli
BL21 Star Cells . . . . . . . . . . . . . . . . . . . . . . . . 31
5.2.2.2 Purification of the GST-hQC Fusion Protein . . . . . . . . 32
5.2.2.3 Purification of Untagged hQC . . . . . . . . . . . . . . . . 33
5.2.2.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophore-
sis (SDS-PAGE) . . . . . . . . . . . . . . . . . . . . . . . . 33
5.2.2.5 Preparation of Cobalt(II)-Substituted hQC . . . . . . . . . 34
5.2.2.5.1 Generation of Apo-hQC . . . . . . . . . . . . . . . 34
5.2.2.5.2 Reconstitution of Cobalt(II) within the Active Site 34
5.2.2.6 Determination of Protein Concentration . . . . . . . . . . . 34
5.2.3 Kinetic Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
5.2.3.1 Coupled Spectroscopic Steady-State Assay . . . . . . . . . 35
5.2.3.2 Continuous Calorimetric Activity Assay for Human Glu-
taminyl Cyclase using Isothermal Titration Calorimetry . . 36
5.2.3.2.1 pH-Dependency of Human Glutaminyl Cyclase at
Constant Ionic Strength . . . . . . . . . . . . . . . 39
5.2.3.2.2 Kinetic Characterization of Human Glutaminyl
Cyclase Inhibitors . . . . . . . . . . . . . . . . . . 40
5.2.3.3 Fast Kinetics Stopped-Flow UV/Vis Spectroscopy . . . . . 40
5.2.4 Biophysical Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
5.2.4.1 UV/Vis Absorption Spectroscopy . . . . . . . . . . . . . . 41
5.2.4.1.1 Titration of Cobalt to Apoenzyme . . . . . . . . . 42
5.2.4.1.2 Stability of Cobalt Substituted Human Glutaminyl
Cyclase . . . . . . . . . . . . . . . . . . . . . . . . 42
vi
Contents
5.2.4.2 Quantitative Characterization of the Thermodynamics of
Binding Events using Isothermal Titration Calorimetry . . 42
5.2.4.3 Conformational Stability of Human Glutaminyl Cyclase in
Dependence of pH or Temperature using Circular Dichro-
ism Spectroscopy . . . . . . . . . . . . . . . . . . . . . . . . 43
5.2.4.4 Oligomerization State of Human Glutaminyl Cyclase Ex-
amined via Analytical Ultracentrifugation . . . . . . . . . . 45
5.2.5 Liquid Chromatography – Mass Spectrometry (LC-MS) . . . . . . . 45
5.2.6 X-ray Crystallography . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.2.6.1 Crystallization and Data Collection . . . . . . . . . . . . . 46
5.2.6.2 Structure Determination and Refinement . . . . . . . . . . 46
6 Results and Discussion 48
6.1 Expression and Purification of the ∆34 Deletion Variant of Human Glu-
taminyl Cyclase Results in a Correctly Folded Soluble Monomer . . . . . . 48
6.2 Development of a New Steady-State Assay . . . . . . . . . . . . . . . . . . . 51
6.2.1 Motivation for Development of a Direct Continuous Enzymatic As-
say for Human Glutaminyl Cyclase . . . . . . . . . . . . . . . . . . . 51
6.2.2 Introduction and Overview of the Continuous Calorimetric Assay . . 52
6.2.3 First Kinetic Characterization Utlilizing Calorimetry Results in Re-
liable Kinetic Parameters . . . . . . . . . . . . . . . . . . . . . . . . 53
6.2.4 Verification of Applicability of the Continuous Calorimetric Assay . 55
6.3 Kinetic Characterization of Physiologic and Pathophysiologic Substrates . . 56
6.3.1 Catalytic Efficiency of N-terminal Glutaminyl Substrates in Depen-
dence of the pH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
6.3.2 Kinetic Characterization with Different Physiological Substrates In-
dicates Importance of a Specific Amino Acid Pattern . . . . . . . . . 59
6.3.3 Kinetic Characterization of the Pathophysiological Substrate Shows
Remarkably Decreased Catalytic Efficiency . . . . . . . . . . . . . . 61
6.3.4 Cyclization Reaction of N-Terminal Glutaminyl/Glutamyl Peptides
are Spatially Separated . . . . . . . . . . . . . . . . . . . . . . . . . 63
6.3.5 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
vii
Contents
6.4 The Role of the Metal Ion in Terms of Stability and Catalysis . . . . . . . . 65
6.4.1 Substitution of Zinc Against Cobalt Resulted in a Spectroscopically
Active Glutaminyl Cyclase . . . . . . . . . . . . . . . . . . . . . . . 66
6.4.2 Incorporated Cobalt Within the Active Site of Human Glutaminyl
Cyclase Shows a Moderate Tetrahedrally Coordination . . . . . . . . 68
6.4.3 Coordinated Zinc Ion Plays a Role in Stabilization of the Overall
Structure of Human Glutaminyl Cyclase . . . . . . . . . . . . . . . . 69
6.4.4 Zinc Ion Within the Active Site of hQC in Resting State Shows a
Tetrahedral Coordination . . . . . . . . . . . . . . . . . . . . . . . . 70
6.4.5 Monodental Binding of N-terminal Glutaminyl Substrates Results
in a Tetrahedral Coordination . . . . . . . . . . . . . . . . . . . . . . 72
6.4.6 The Cyclization Product of N-terminal Glutaminyl/Glutamyl Sub-
strates Binds monodentally to the Catalytic Zinc Ion . . . . . . . . . 75
6.4.7 Coordination of the N-terminal Glutamyl Substrate Revealed a Car-
boxylate Shift . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
6.4.8 Coordination Geometry of the Metal Ion Within the Active Site
Depends on Binding of Glutaminyl/Glutamyl Substrates - Role in
Catalysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
6.4.9 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
6.5 Design and Characterization of a Potent Inhibitor for Human Glutaminyl
Cyclase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
6.5.1 The First Described Imidazole Based Inhibitor for Human Glu-
taminyl Cyclase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
6.5.2 Screening for a New Metal Binding Group for Glutaminyl Cyclase
Revealed a Carbohydrazide Function as a Potential Candidate . . . 88
6.5.3 X-Ray Structure of the Potential Carbohydrazide Inhibitor Bound
by Human Glutaminyl Cyclase Revealed a Five-Fold Coordination . 93
6.5.4 Binding of the Potential Inhibitor by Human Glutaminyl Cyclase is
an Entropically Driven Process . . . . . . . . . . . . . . . . . . . . . 98
6.5.5 Summary - Future Aspects - Combining Backbone Group of PBD150
with the Carbohydrazide Function . . . . . . . . . . . . . . . . . . . 99
viii
Contents




11 Curriculum vitae 140
ix
List of Figures
1 List of Figures
List of Figures
4.1 Chemical structure of pyroglutamic acid (5-oxo-L-proline) . . . . . . . . . . 10
4.2 Comparison of the tertiary structure of human glutaminyl cyclase and
leucine aminopeptidase of Aeromonas proteolytica . . . . . . . . . . . . . . . 12
4.3 Active site alignment of APAP and hQC . . . . . . . . . . . . . . . . . . . . 13
4.4 Overview of catalyzed reactions by hQC . . . . . . . . . . . . . . . . . . . . 16
4.5 Schematic overview of the involvement of hQC during Alzheimer’s disease
development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
4.6 Catalytic cycle of hQC catalyzing N-terminal glutaminyl substrates . . . . . 20
5.1 General overview of the spectrophotometric coupled steady-state assay . . . 35
6.1 Characterization of hQC via SDS-PAGE . . . . . . . . . . . . . . . . . . . 49
6.2 Far-UV spectra and thermal unfolding of hQC . . . . . . . . . . . . . . . . 50
6.3 Schematic overview of the direct continuous activity assay for an exothermic
reaction utilizing isothermal titration calorimetry . . . . . . . . . . . . . . . 53
6.4 Conversion of the N-terminal glutaminyl reference substrate Gln-Gln cat-
alyzed by hQC detected by calorimetry . . . . . . . . . . . . . . . . . . . . 54
6.5 Determination of molar reaction enthalpy after complete substrate conver-
sion in presence of different product concentrations . . . . . . . . . . . . . . 56
6.6 Catalytic efficiency of hQC in dependence of the pH . . . . . . . . . . . . . 57
6.7 Cyclization reaction of N-terminal glutaminyl-/glutamyl substrates cat-
alyzed by hQC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
6.8 Scheme of protonation states for N-terminal glutaminyl/glutamyl substrates 63
6.9 Scheme of regulated exocytosis and cyclization reaction localization of N-
terminal glutaminyl/glutamyl substrates catalyzed by hQC . . . . . . . . . 64
6.10 Difference spectra of Co(II)-hQC in dependency of the cobalt concentration 66
6.11 Time-resolved absorption spectra and activity assay of Co(II)-hQC . . . . . 67
6.12 Thermal unfolding of Co(II)-hQC and apoenzyme . . . . . . . . . . . . . . 70
6.13 Overview of the overall crystal structure of hQC in resting state with a
detailed side view of the active site . . . . . . . . . . . . . . . . . . . . . . . 71
1
List of Figures
6.14 Time resolved UV/Vis absorption spectra of Co(II)-hQC while catalyzing
the tetrapeptide QFRH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
6.15 Crystal structure of hQC in complex with the tetrapeptide QFRH . . . . . 75
6.16 Crystal structure of hQC in complex with the product pEFRH . . . . . . . 76
6.17 Time resolved UV/Vis absorption spectra of Co(II)-hQC after mixing with
the tetrapeptide EFRH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
6.18 EPR spectra of Co(II)-isoDromeQC after incubation with N- terminal glutaminyl-
/glutamyl substrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
6.19 Crystal structure of hQC in complex with the tetrapeptide EFRH . . . . . 80
6.20 Crystal structure of isoDromeQC in complex with the tetrapeptide EFRH . 81
6.21 Proposed model for an induced carboxylate shift of N-terminal glutamyl
substrates coordinated to the catalytic zinc ion of hQC . . . . . . . . . . . . 84
6.22 Chemical structure of the hQC inhibitor PBD150 . . . . . . . . . . . . . . . 86
6.23 Crystal structure of human glutaminyl cyclase in complex with the inhibitor
PBD150 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
6.24 Kinetic characterization of hQC in presence of the inhibitor E(γ-hydrazide)FA 92
6.25 Crystal structure of hQC in complex with the inhibitor E(γ-hydrazide)FA . 93
6.26 Scheme of the Berry pseudorotation of the coordination center within the
active site of hQC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
6.27 Thermodynamic binding studies of E(γ-hydrazide)FA binding to hQC . . . 100
7.1 Overview of the different protein folds of glutaminyl cyclase from animalia,
plantae and bacteria kingdom . . . . . . . . . . . . . . . . . . . . . . . . . . 103
8.1 Vector map of pGEX-6P-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
8.2 Amino acid sequence of the fusion protein GST-hQC35−361 . . . . . . . . . 111
8.3 Amino acid sequence of hQC35−361 . . . . . . . . . . . . . . . . . . . . . . . 112
8.4 Kinetic characterization of hQC utilizing the spectroscopic coupled assay . 112
8.5 Controls for determination of the overall molar reaction enthalpy of hQC
after substrate depletion under changing conditions . . . . . . . . . . . . . . 113
8.6 Three-dimensional analysis of substrate depletion and product inhibition
for hQC utilizing the continuous calorimetric activity assay . . . . . . . . . 113
8.7 hQC catalyzed cyclization reaction of N-terminal glutaminyl substrates
measured via the continuous calorimetric activity assay . . . . . . . . . . . 114
2
List of Figures
8.8 Difference spectra of Co(II)-hQC in dependency of the cobalt concentration 115
8.9 Kinetic studies of cobalt association and dissociation . . . . . . . . . . . . . 115
8.10 Active site alignment of hQC and isoDromeQC . . . . . . . . . . . . . . . . 116
8.11 CD-spectra of hQC, Co(II)-hQC and apoenzyme before and after thermal
denaturation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
8.12 Thermodynamic characterization of binding of E(γ-hydrazide)FA to hQC
via isothermal titration calorimetry . . . . . . . . . . . . . . . . . . . . . . . 117
8.13 Three-dimensional analysis of E(γ-hydrazide)FA binding to hQC . . . . . . 117
8.14 Kinetic characterization of hQC in presence of different inhibitors using the
calorimetric activity assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
3
List of Tables
2 List of Tables
List of Tables
5.1 Temperature protocol for PCR reaction . . . . . . . . . . . . . . . . . . . . 29
5.2 ITC setup for single injection experiments . . . . . . . . . . . . . . . . . . . 39
5.3 Used concentrations for the continuous calorimetric activity assay . . . . . . 39
5.4 Final concentration of compounds after mixing in the measurement cell . . 41
5.5 Used ITC setup and protein-ligand concentrations for thermodynamic char-
acterization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
5.6 Settings of the CD-spectrometer for the thermal denaturation. . . . . . . . 45
5.7 Substrate soaking conditions and data collection information for all pre-
sented crystal structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
6.1 Determined kinetic parameters for hQC catalyzing N-terminal glutaminyl
substrates in dependence of the pH . . . . . . . . . . . . . . . . . . . . . . . 58
6.2 Determined kinetic parameters for hQC catalyzing N-terminal glutaminyl/glutamyl
substrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
6.3 Overview of tested inhibitors for hQC . . . . . . . . . . . . . . . . . . . . . 89
7.1 Overview of kinetic parameters of glutaminyl cyclase from different domains
of life catalyzing N-terminal glutaminyl substrates . . . . . . . . . . . . . . 102
8.1 Determined bond length of the metal complex in hQC after coordination of
different ligands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
8.2 Determined angles of the metal complex in hQC after coordination of dif-
ferent ligands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
8.3 Crystallographic data and refinement statistics for hQC in resting state and




3 Abbreviations and Symbols
Abbreviations
Aß Amyloid-beta peptide
Aspec Specific activity in U/mg
AD Alzheimer’s disease
APAP Aminopeptidase from Aeromonas proteolytica
APS Ammonium peroxodisulfate










dp Differential power in µcal/s
EDTA Ethylenediaminetetraacetic acid








hQC Human glutaminyl cyclase
IPTG Isopropyl ß-D-1-thiogalactopyranoside
ITC Isothermal titration calorimetry
kcat Turnover number in s−1
6
ABBREVIATIONS







mRNA Messenger ribonucleic acid
MW Molecular weight
MWCO Molecular weight cut-off
NaCl Sodium chloride
NADH Nicotinamide adenine dinucleotide (reduced form)
NAD+ Nicotinamide adenine dinucleotide (oxidized form)
ßNA Beta-naphthalene
NTP Nucleoside-5’-triphosphate
NaH2PO4 Sodium dihydrogen phosphate
OD Optical density
PCR Polymerase chain reation
PHENIX Python-based hierarchical environment for integrated
Xtallography
pH Negative logarithm of [H+]
pKa Negative logarithm of the acid constant
PMSF Phenylmethylsulfonyl fluoride
rpm revolutions per minute
SDS Sodium dodecyl sulfate





UV/Vis Ultraviolet visible spectroscopy
Vmax Maximum reaction rate in U/mg
7
ABBREVIATIONS
w/v Volume per volume
w/v Weight per volume
XDS X-ray detector software
Zn Zinc
∆H Change in enthalpy
∆S Change in entropy





4.1 Pyroglutamic Acid - A Key Metabolite Within the Human System
All mono-/multi-cellular organisms in the kingdom of life undergo a multitude of important
cellular processes like energy production and storage, cell respiration, cell transport and
intercellular interactions. This great variety of cellular processes needs to be regulated
by essential mechanisms in order to respond to external environmental influences and
to maintain homeostasis. One mechanism for regulation of cellular activity are post-
translational modifications, which include covalent, enzymatic modifications of proteins
and peptide species during or after protein biosynthesis. Some of the proteins and peptide
species are directly modified at their amino acid side chains or at the corresponding C-
or N- termini during protein biosynthesis, while other species are post-translationally





ssible post-translational modifications are for example pro-
teolytic cleavage of regulatory subunits of proteins, covalent
linkage of organic or inorganic functional groups, addition of
lipids and modification of amino acids. As a result of a post-
translational modification the bioactivity of a certain protein
or peptide species is drastically altered. One example for a
post-translational modification of amino acids is the forma-
tion of pyroglutamic acid (5-oxo-L-proline) (Fig. 4.1) from
glutamine or glutamic acid. Pyroglutamic acid was first dis-
covered in 1882 by heating a glutamic acid containing so-
lution up to 180 ◦C, leading to an accelerated spontaneous
cyclization reaction of the amino acid to pyroglutamic acid by the loss of one molecule of
water [1]. Pyroglutamic acid is an essential compound within living cells and is formed
by degradation of glutathione, spontaneous cyclization of activated glutamic acid during
glutathione biosynthesis and by degradation of proteins containing pyroglutamic acid at
the N-terminus [2]. It was reported that many proteins or small peptides, especially neu-
ropeptides, contain an N-terminal pyroglutaminyl residue [3]. The physiological role of
this modification is to increase protein resistance from degradation by aminopeptidases,
thereby extending the half-life of a given peptide species or mediating receptor binding,
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which is important for cell signaling for instance [4]. In literature it was described that
especially human neuropeptides like thyrotropin releasing hormone (TRH), neurotensin
and orexin A harbor an N-terminal pyroglutamyl residue [2]. For decades it was believed
that formation of pyroglutamic acid at the N-terminus of proteins and peptide species
results from spontaneous cyclization of N-terminal glutamic acids (knon = 1.0 ± 0.4 ×
10−9 s−1 [5]) and glutamines (knon = 1.7 ± 0.2 × 10−6 s−1 [5]) until the enzymatic for-
mation was firstly described in the year 1963 [5]. This observation of an enzymatically
driven pyroglutamic acid formation led to the focus on that enzyme class to decipher its
reaction mechanism and its physiological importance in the post-translational processing
of peptides and protein species.
4.2 Glutaminyl Cyclase - An Enzyme Responsible For Pyroglutamic Acid
Formation and Its Evolution
The first described enzyme that was capable to catalyze the intramolecular cyclization
reaction based on an N-terminal glutamine to pyroglutamic acid was isolated from the
latex of the tropical plant Carica papaya and named glutaminyl cyclase [6]. The analo-
gous enzyme of animal origin was later identified in the pituitary of mammals with the
same catalytic proficiency [7, 8]. Shortly after demonstrating an occurrence of glutaminyl
cyclase in mammals the primary structure of the enzyme from Homo sapiens and Bos
primigenius taurus was elucidated [9, 10]. The physiological role of glutaminyl cyclases
from mammals was reported to modify neuropeptides like hormones at their N-terminus
post-translationally by catalyzing the conversion of an N-terminal glutamine to pyroglu-
tamic acid. In addition, identification of a high structural homology of human glutaminyl
cyclase (hQC) to bacterial zinc-dependent aminopeptidases resulted in the first impres-
sion of the tertiary structure of the enzyme [11]. The most accurately studied enzyme of
this family is the leucine aminopeptidase from the marine bacterium Aeromonas prote-
olytica (APAP) [12–14], which in turn was used to model the tertiary structure of hQC
in silico based on its sequence and structure [15]. Aminopeptidases specifically cleave the
N-terminal residue from polypeptide chains and are involved in the metabolism within
a living cell. However, tertiary structure of the monomeric leucine aminopeptidase de-
termined by X-ray crystallography is characterized by a twisted eight-stranded β-sheet
consisting of partly parallel and antiparallel β-sheets (Fig. 4.2 A) [16]. Additionally, the
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central β-sheet is surrounded by a number of α-helices, which is a typical characteristic
of proteins of the zinc-hydrolase superfamily [17]. Moreover, the active site of the leucine
aminopeptidase is located at the protein surface in a cavity including two coordinated zinc
ions. Zinc ions are coordinated by five highly conserved residues (His-Asp-Glu-Asp-His)









ß3 ß4 ß5 ß6
ß1 ß2










Figure 4.2: Comparison of the tertiary structure of human glutaminyl cyclase and leucine
aminopeptidase of Aeromonas proteolytica. (A) Crystal structure of APAP (PDB entry: 1RTQ) and
(B) hQC. β-sheets are depicted in red and α-helices in blue. Zinc ions are represented as black spheres.
Under the respective crystal structure the corresponding topology diagram was added. Amino-/Carboxy-
terminus and β-sheets are marked for each protein structure, respectively. Topology maps were generated
with the web server PDBsum [18].
Validity of the in silico determined tertiary structure of hQC was later confirmed by
X-ray crystallography [19, 20] and comparison of both crystal structures of hQC and
APAP verified the proposed homology. The tertiary structure of hQC contains a central
twisted six-stranded β-sheet, which forms the hydrophobic core of the protein, as it has
been observed in the case of APAP (Fig. 4.2 B). Again, the central twisted β-sheet of hQC
includes of two antiparallel and four parallel β-strands surrounded by ten α-helices. These
typical characteristics highlighted the affiliation of hQC to the metallopeptidase protein
superfamily with the exception to catalyze different type of reactions. However, active
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site alignment of the crystal structures of APAP and hQC revealed a high conservation
of the metal coordinating amino acid residues, but in case of hQC only one zinc ion was
coordinated within the cavity at the protein surface (Fig. 4.3). Coordinating external
ligands of the metal complex within the active site of hQC involves the residues His330,
Asp159 and Glu202, while the fourth coordination site was occupied by a water molecule.
This fact was quite surprising because the active site of hQC could provide the necessary
coordinating amino acid residues to coordinate hypothetical two zinc ions. Therefore, it
was assumed that the remaining amino acid residues adopted new functional tasks during
evolution.
Figure 4.3: Active site alignment of
APAP and hQC. The acitve site of APAP
is shown in grey, whereas the active site
of hQC is represented in yellow. Zinc ions
(Zn) and water molecules (Wa) are depicted
in the corresponding colour of the respec-
tive active site. Dashed lines indicate co-
ordination bonds (APAP = black, hQC =
red). Amino acid residues and their corre-
sponding positions are named respectively,
in which the first number represents the
amino acid position in APAP and the sec-
ond one in hQC. Presented structure of
APAP was modeled from PDB entry 1AMP.
Another indication of a structural relationship of hQC with zinc-dependent peptidases
was the identification of an intramolecular disulfide bond [21]. The hQC as well as the
APAP have in their primary structure two highly conserved cysteine residues, which form
the disulfide bond at oxidizing conditions. In the case of APAP, the disulfide bond is
involved in the formation of the active site, in which an interaction with the first amino
acid side chain of the substrate occurs. As a result of the formed disulfide bond, enzymatic
specificity of APAP is effected and additionally the structural integrity of the active site
[16]. Analysis of both crystal structures showed that the disulfide bond is located close
to the protein surface in case of APAP, while for hQC it is located near the hydrophobic
core of the protein. Due to the location of the disulfide bond in hQC it was assumed that
it is not directly involved in the formation of a catalytically active structure. This was
demonstrated by kinetic experiments with hQC and a disulfide deficient variant, in which
both enzyme types showed same catalytic efficiency [22]. Experimental data of thermal
and chemical unfolding of hQC and the disulfide deficient variant demonstrated differences
in their corresponding transition curves, suggesting a stabilizing role for the disulfide bond
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in terms of conformational stability.
However, one of the most important experimental evidences for an evolutionary relation-
ship of hQC with APAP was the identification of a metal-dependency for catalysis [23].
The requirement of the zinc ion for hQC activity was displayed by time-dependent incu-
bation of the enzyme with the heterocyclic chelator 1,10-phenanthroline [23]. Removal of
the zinc ion from the active site resulted in inactive hQC, indicating the importance of the
metal ion for N-terminal pyroglutamic acid formation catalyzed by hQC. This context
makes it extremely likely that animal glutaminyl cyclase evolutionarily derived from a
bacterial peptidase.
In addition, MALDI-TOF mass spectrometry and crystal structure of recombinant glu-
taminyl cyclase expressed in Pichia pastoris confirmed an N-glycosylation site (Asn49),
which is located at the protein surface [21, 22]. Glycosylated hQC has a molecular mass of
42.8 kDa, while complete deglycosylation with endoglycosidase Hf resulted in a molecular
mass of 38.8 kDa [21]. Apparently, the structural nature of the protein was not influenced
by the cleavage of the oligosaccharides and did not affect enzyme catalysis. This was
further confirmed by the expression of enzymatically active hQC in Escherichia coli, in
which no glycosylation event occured [11, 21]. Thus, it was suggested that lacking the
glycosylation event could lead to a reduced solubility of the protein [22].
4.3 Physiological Function of Mammalian Glutaminyl Cyclase
It was suggested that the ubiquitous presence of glutaminyl cyclase in the animal kingdom
could be important in various regulatory processes, for instance, cell signaling. Numer-
ous regulatory peptides have already been isolated from animal tissues, which harbor an
N-terminal pyroglutamyl residue [24, 25] probably caused by a post-translational modifi-
cation. First indications of an enzymatically driven formation of N-terminal pyroglutamic
acid were observed by mixing N-terminal glutaminyl peptides with extracts from bovine
pituitary [8]. For this study, gonadotropin-releasing hormone (GnRH) and thyrotropin-
releasing hormone (TRH) were used as N-terminal glutaminyl peptides, harboring an N-
terminal pyroglutamyl residue after incubation with extracts from bovine pituitary. TRH
acts as a neurotransmitter and modulator of the central nervous system and triggers syn-
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thesis and release of thyrotropin in the hypophysis, while GnRH stimulates secretion of
gonadotropins, which is important for male and female sexual functionality [26, 27]. In ad-
dition, northern blot analysis of glutaminyl cyclase mRNA distribution in bovine pituitary
revealed high expression levels of the enzyme in brain and peripheral endocrine and ex-
ocrine glands [10]. Furthermore, it was postulated that the post-translational cyclization
of glutamines at the N-terminus of small peptides presumably occurs within the regulated
secretory pathway [28]. A possible post-translational modification within the regulated
secretory pathway was indicated by a co-localization of glutaminyl cyclase with TRH and
GnRH in secretory vesicles in the pituitary and hypothalamus. The cellular localization
of the enzyme and the putative substrates in the regulated secretory pathway suggesting a
role of glutaminyl cyclase in the synthesis of various hormones and neuropeptides, thereby
directly involved in hormone maturation.
It was shown that biological activity of some hormones and neuropeptides depends on an
N-terminal pyroglutamyl residue. An unmodified glutamine at the N-terminus of these
hormones and neuropeptides results in a loss of binding affinity to their specific receptors,
which would consequently interrupt cellular communication [24, 29]. Besides the impor-
tance of pyroglutamic acid at the first N-terminal amino acid position of some neuropep-
tides to develop an active conformation for receptor binding, it increases hormone stability.
Due to the pyroglutaminyl-lactam ring the N-terminus loses its alkalinity, which is an es-
sential feature for many aminopeptidases to recognize potential substrates. Therefore, the
N-terminus of hormones and neuropeptides becomes resistant to non-specific proteolysis.
Thus, bioactivity of the peptides is drastically enhanced by increasing their half-life. In
summary, involvement of glutaminyl cyclase in the synthesis of a variety of peptides with
regulatory function allocates the enzyme an essential role in hormone metabolism.
4.4 Glutaminyl Cyclase And Its Role in Neurodegenerative Diseases
Although the physiological function of pyroglutamic acid and glutaminyl cyclase seems to
be essential for generation of biologically active structures of hormones and neuropeptides,
several reports demonstrated that formation of pyroglutamic acid is also connected with
pathophysiological processes, especially in amyloidogenic diseases (Fig. 4.4) [30]. In this




Alzheimer’s disease is a progressive, neurodegenerative and, until today, an incurable
disease, which occurs predominantly in patients of the middle and advanced age. The
disease was described by the German physician Alois Alzheimer for the first time in 1906,
until his observations and results were published in 1907 [31]. An autopsy of the brain of a
deceased woman in middle age, who suffered from severe memory problems and confusion,
was performed in which he identified dense deposits around the outside of nerve cells
of the central nervous system. Worldwide, about 44 million people are suffering from
typical symptoms of this disease, which includes memory loss, loss of speech and judgment,
personality changes and mood swings [32].
glutamic acid (Glu)
Figure 4.4: Overview of catalyzed reactions by hQC. N-terminal glutamine of small peptides are
converted in an irreversible cyclization reaction to pyroglutamic acid (physiological reaction). In addition,
the enzyme catalyzes in a pathophysiological side reaction also glutamic acid at the N-terminus of the
processed Aβ peptide.
Brains of individuals with advanced symptoms are characterized by increased deposits
of amyloid plaques in the neocortical regions of the brain [33]. Amyloid plaques mainly
consist of beta-amyloid peptide species, which are formed by processing of the amyloid
precursor protein (APP) (Fig. 4.5) [34]. APP is a highly conserved ubiquitous transmem-
brane protein, which is expressed in most mammalian tissues with the highest levels found
in the nervous system and whose physiological function is not yet completely described.
One reason could be that APP is a very heterogeneous molecular species, resulting from
different splice variants of mRNA and various post-translational modifications like glyco-
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sylation and phosphorylation [35, 36]. During and after transport of the APP through the
secretory pathway, the protein can be cleaved in different ways by α-/β-/γ-secretase [37].
Proteolytic cleavage of the soluble extracellular part of the protein by α-secretase results
in a so-called C-83 fragment, which remains at the plasma membrane (non-amyloidogenic
pathway) (Fig. 4.5) [38]. Another way of APP processing involves proteolytical cleavage
by β- and γ-secretase (amyloidogenic pathway). The proteolytic cleavage by β-secretase
activity results in a slightly smaller secreted fragment (APPβ) and a larger transmem-
brane portion (C-99 fragment). The C-99 fragment is subsequently cleaved by γ-secretase
activity within the transmembrane portion. A number of different potential proteolytic in-
terfaces for γ-secretase activity results in various small amyloidogenic peptide species (Aβ
peptides), which differ in their sequence length. Furthermore, after proteolytic processing
by β- and γ-secretase each Aβ peptide harbors an N-terminal glutamyl residue. Under
normal circumstances these different Aβ peptides, whose physiological function is to date
unknown, can be degraded proteolytically by exopeptidases. However, if the different Aβ


























Figure 4.5: Schematic overview of the involvement of hQC during Alzheimer’s disease de-
velopment. The transmembrane APP gets processed by β-/γ-secretase to beta-amyloid peptides varying
in length, but each peptide species harbors an N-terminal glutamic acid. Once there is a co-localization
of the beta-amyloid peptides and hQC the N-terminal glutamic acid gets converted to pyroglutamic acid.
For a long time it was believed that unmodified Aβ peptides have a tendency to aggregate
[39] and that an increased formation of the peptides is associated with accelerated progres-
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sion of the Alzheimer’s disease [40, 41]. In later studies, the presence of a pyroglutamyl
residue was described at the N-terminally truncated Aβ peptide species [30] and further
proven that the majority of the deposited amyloidogenic plaques consists of the modified
form [42, 43]. Because of the relative high percentage of the pyroglutamyl modified Aβ
peptides in the amyloidogenic plaques, it was concluded that these peptides could play
a crucial role in the formation of the disease, especially in the initial phase [44]. Indeed,
investigating the aggregation behavior of modified Aβ peptide species showed that these
were more prone to aggregation than unmodified Aβ peptide species [45]. One possible
explanation is that the solubility of the pyroglutamyl modified Aβ peptide is drastically
decreased at physiological pH compared to unmodified Aβ peptide species, which, in turn,
increases the aggregation propensity [46, 47]. Due to these properties and the dominant
presence of modified amyloid peptides in amyloidogenic plaques, it is presumed that these
molecular species could form the initial deposits and therefore accelerates the emergence
and progression of the disease [44, 48].
In addition to the enhanced aggregation and toxicity of modified Aβ peptide due to the
N-terminal pyroglutamyl residue, it is believed that the modification of the N-terminus
leads to an increased stability to proteolytic degradation [49]. First cell culture experi-
ments with modified and unmodified Aβ peptide species showed a reduced degradation of
Aβ peptide species harboring an N-terminal pyroglutamyl residue [50]. Moreover, recent
works demonstrated that different proteolytic enzyme activities, such as pyroglutamyl
aminopeptidase and glutamyl aminopeptidase, decrease with age [51, 52]. This would in
turn mean a slowed degradation of modified and unmodified Aβ peptide species. One
possible explanation of the origin of Alzheimer’s disease is a general dysfunction of the
N-terminal degradation of unmodified Aβ peptide species by aminopeptidases [49]. Due
to the reduced degradation of the Aβ peptide species an increased concentration of inter-
mediates for aggregation arise, leading finally to the toxic amyloidogenic plaques.
However, it is still unclear how the modification of N-terminal glutamic acid to pyroglu-
tamic acid occurs in vivo. After proteolytic cleavage of the APP by β- and γ-secretase
each Aβ peptide species harbor a glutamyl residue at its N-terminus. Unlike pyroglutamyl
formation of N-terminal glutamine catalyzed by hQC, enzymatic cyclization of N-terminal
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glutamic acid at physiological conditions are not described so far. Therefore it was con-
cluded that pyroglutamyl formation of N-terminal glutamyl residues occurs spontaneously
until various derivatives of glutamic acid were tested in presence/absence of hQC [3]. It
was shown that N-terminal glutamyl residues were not prone to spontaneous cyclization,
but in presence of hQC the N-terminal pyroglutamyl residue was detected, indicating a
specific conversion catalyzed by the enzyme. An inhibition of the hQC would lead to a
decreased formation of modified Aβ peptide species and could therefore serve as a way to
slow down the manifestation of Alzheimer’s disease.
4.5 Reaction Mechanism of Human Glutaminyl Cyclase
The elucidation of the reaction mechanism of enzyme catalysis is an essential prerequi-
site for the development of potent inhibitors. Structures for potential enzyme inhibitors
could be derived from intermediates during enzyme catalysis or already optimized in-
hibitor structures. The hQC is, due to their physiological and possibly pathophysiological
function, a potential target for enzyme drug development. Therefore, the understanding
of the catalytic mechanism of this enzyme is of great importance.
Two possible mechanisms of hQC catalysis were predicted in the past, which fundamen-
tally differed in their modes of action [53]. First, the catalysis of the formation of a
covalent intermediate (acyl-enzyme intermediate) could occur. In this mechanism a nu-
cleophilic residue of the active site, for example an activated cysteine residue, attacks the
γ-amide group of the N-terminal glutamine of the substrate. The acyl-enzyme intermedi-
ate is formed and ammonia is released (acylation). In a second step, the α-amino group of
glutamine attacks nucleophilically the γ-carbonyl. The product is released and the initial
state is resumed (deacylation). Catalysis of hQC would be in this case in accordance with
the mechanism of catalysis of serine/cysteine proteases or γ-glutamyl cyclotransferases.
The second alternative mechanism is based on a non-covalent reaction catalyzed by hQC
(Fig. 4.6). Due to an intramolecular nucleophilic attack of the α-amino group at the
γ-carbonyl of an N-terminal glutamine the substrate forms a tetrahedral, non-covalently
enzyme-bound intermediate, which decomposes into ammonia and the pyroglutamyl pep-
tide. Accordingly, hQC would exercise the catalytic function by binding of the substrate,
which promotes a nucleophilic attack, and the stabilization of the tetrahedral intermediate.
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Initial studies on hQC from pig pituitary suggested that the enzyme might possess thiol
groups which are essential for catalysis [7]. However, identification of a disulfide bridge
in hQC lead to exclusion of covalent catalysis with participation of cysteine residues [21].
In addition, glutaminyl cyclases of mammals showed no inhibition by serine modifying


































































Figure 4.6: Catalytic cycle of hQC catalyzing N-terminal glutaminyl substrates. First step
is the formation of the Michaelis-Menten complex via binding of the substrate. Thereby it displaces the
coordinated water molecule and occupies the fourth coordination site of the catalytic zinc. The catalytic
zinc ion acts as a Lewis acid, pulls out electrons from the γ-carbonyl moiety of the N-terminal glutamine,
thereby activating the γ-carbonyl carbon electrophilically. In addition, Glu201 activates via acid-base
catalysis the α-amino group, which in turn gets more nucleophilic. Afterwards, the α-amino group performs
a nucleophilic attack on the γ-carbonyl carbon, leading to a short-lived tetrahedral intermediate. Next, an
intrinsic proton transfer to the potential leaving group via a conserved hydrogen bond network is performed
to subsequently release ammonia and the product.
The enzyme catalyzes the stereospecifical cyclization of N-terminal glutaminyl residues in
its physiological reaction and exhibits high selectivity for substrates with aromatic amino
acids in the second N-terminal amino acid position [54]. Moreover, hQC showed a pH-
dependence for N-terminal glutaminyl substrates, which are preferentially converted at
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alkaline pH-values, especially at pH 8.0 [15]. It was shown in steady-state pH-dependency
experiments that the Michaelis-Menten constant (KM) was influenced at pH-values above
8.0, indicating that hQC can bind the substrate only in the N-terminal deprotonated state.
The pH-dependence of the catalytic activity depends therefore on the protonation state
of the α-amino group of the substrate.
Studies of the substrate specificity of hQC and its structural relationship to the zinc-
dependent aminopeptidase family led to the first hypothesis of the mechanism of catalysis
and the role of the metal ion [54]. The related zinc-dependent aminopeptidase has two
metal ions within their active site, which resumes different tasks during catalysis. For in-
stance, to polarize the scissile peptide bond by interacting with the carbonyl oxygen or to
increase the nucleophilicity of the attacking water molecule. Most importantly, binding of
the oxanion to stabilize the tetrahedral intermediate, which resulted from the nucleophilic
attack. In the case of aminopeptidase from APAP, which has the highest structural homol-
ogy to the animal glutaminyl cyclases, these tasks are performed mainly by one zinc ion in
the active site, while the other metal ion is only used to fix the N-terminal amino nitrogen
during catalysis. However, pyroglutamyl formation catalyzed by hQC differs compared to
the mechanism of APAP. First, in contrast to the hydrolysis reaction of APAP, which
removes the first N-terminal amino acid residue, the cyclization reaction of hQC is an
intramolecular reaction. Second, the activation of the attacking nucleophile, which is an
essential part in the catalytic cycle of APAP, is not necessary for hQC, because the free
N-terminal nitrogen has a strong nucleophilicity. Despite these differences, partial reaction
steps of the catalytic mechanisms of APAP and hQC could be the same. For example,
in both cases the reaction is an addition elimination mechanism (SN2t). A zinc ion in
the active site of hQC could therefore polarize the γ-carbonyl group of the substrate to
increase the electrophilicity of the carbonyl carbon and, additionally, stabilize the oxanion
interaction of the resulting tetrahedral intermediate after the nucleophilic attack of the
α-amino group.
Crystal structures of APAP clearly showed two coordinated zinc ions in the active site,
whereas for hQC only one zinc ion was identified even though the coordinating amino
acid residues are highly conserved in both enzymes [16, 20]. As already mentioned, it
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was assumed that the non-coordinating amino acids in hQC adopted new functions dur-
ing evolution. This was demonstrated by site-directed mutagenesis experiments, in which
substitution resulted in a non-functional enzyme (Asp248) or reduced catalytic activity
(His140) [55]. Due to the position of Asp248 in the crystal structure it was concluded that
it forms together with Glu201 and Asp305 a conserved hydrogen bond network, which is
crucial for proton shuttling from the α-amine group of the tetrahedral intermediate to the
γ-amide amino group (Fig. 4.6).
Nevertheless, a detailed reconstruction of the catalytic steps of the reaction is not yet
possible. For instance, the short-lived tetrahedral intermediate is only postulated, but so
far not experimentally confirmed.
4.6 Human Glutaminyl Cyclase - Target Enzyme For Drug Development
Involvement of hQC activity in the formation of pyroglutamyl peptides and its essential
role in the initial phase of Alzheimer’s disease makes it a potential candidate for phar-
macological drug development. The primary interest of the development of glutaminyl
cyclase inhibitors are agents suppressing the formation of toxic pyroglutamyl peptides at
the N-terminus of Aβ peptides. By the inhibition of the glutaminyl cyclase activity in
neuronal cells of the central nervous system of Alzheimer’s disease patients would presum-
ably prevent formation of N-terminal glutamyl cyclization. Thus, the Aβ peptide species
would be unprotected against proteolysis by aminopeptidases. Accordingly, an increased
degradation of the peptides would be the result, which in turn would contribute to de-
creased plaque formation.
Different attempts were performed with compounds which were described in literature to
form a complex with metal ions to inhibit hQC activity competitively. It was shown that
compounds especially on imidazole-based structure are promising interaction partners for
the zinc ion within the active site of hQC [23, 56]. As a consequence, different imidazole
derivatives were successfully tested as competitive inhibitors for hQC. Although, these
compounds still need to be investigated and optimized in terms of their toxicity, the




Due to the fact that all described inhibitors for hQC are imidazole-based, which is a
common metal chelator, further usage could led to off-target inhibition of other metal-
loenzymes within the human metabolism. This interference with other metal-dependent
enzymes, like dipetidyl peptidase 4, might cause severe side effects. Therefore, the long-
term goal of this field of investigation is the development of enzyme specific and mechanism
based hQC inhibitors. If possible, the potential inhibitor should adopt a molecular struc-
ture which mimics a reaction intermediate or transition state in the trajectory of hQC
catalysis. A transition state intermediate during hQC catalysis would be the postulated
tetrahedral intermediate. This tetrahedral transition state intermediate is highly ener-
getic, short-lived and generally reacts to further intermediate states. Specific binding of
inhibitors to hQC might be achieved by mimicking sterical and conformational features of
the reaction intermediate or a transition state. Strong competitive binding of the inhibitor
to hQC should drastically reduce turnover of hQC, especially formation of pyroglutamyl
modified Aβ peptides.
Another part of this work is the elucidation of the physiological (glutaminyl) and patho-
physiological (glutamyl) reaction of hQC. To obtain information about catalytic efficien-
cies of the physiological and pathophysiological reaction, glutaminyl-/glutamyl substrates
catalyzed by hQC need to be kinetically characterized. In addition, elucidation of the
binding mode of the physiological and pathophysiological substrates should give deeper
insight in the catalytic variability of hQC. These investigations should clarify how the
enzyme mechanistically accomplishes to catalyze two different substrates.
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Acrylamide (30 %) Carl Roth GmbH & Co KG, Karlsruhe
Acetic acid Carl Roth GmbH & Co KG, Karlsruhe
Agar AppliChem GmbH, Darmstadt
Agarose low EEO AppliChem GmbH, Darmstadt
Ammonium peroxodisulfate Carl Roth GmbH & Co KG, Karlsruhe
Ammonium sulfate Carl Roth GmbH & Co KG, Karlsruhe
Adenosine triphosphate Carl Roth GmbH & Co KG, Karlsruhe
Bromophenol blue sodium salt AppliChem GmbH, Darmstadt
Carbenicillin disodium salt Carl Roth GmbH & Co KG, Karlsruhe
Chelex-100 Resin Bio-Rad Laboratories, Inc., USA
Cobalt(II)-chloride Sigma-Aldrich, Steinheim
Coomassie-Brilliant blue G-250 AppliChem GmbH, Darmstadt
Disodium hydrogen phosphate Carl Roth GmbH & Co KG, Karlsruhe
DTT AppliChem GmbH, Darmstadt
EDTA AppliChem GmbH, Darmstadt
Ethanol Sigma-Aldrich, Steinheim
Ethidium bromide Carl Roth GmbH & Co KG, Karlsruhe
Ethylene glycol AppliChem GmbH, Darmstadt
Glycerol anhydrous AppliChem GmbH, Darmstadt
Hellmanex Sigma-Aldrich GmbH, Steinheim
Hydrochloric acid (37 %) Carl Roth GmbH & Co KG, Karlsruhe
Imidazole AppliChem GmbH, Darmstadt
IPTG AppliChem GmbH, Darmstadt
Isopropanol AppliChem GmbH, Darmstadt
L-Glutathione reduced Carl Roth GmbH & Co KG, Karlsruhe
Magnesium sulfate Carl Roth GmbH & Co KG, Karlsruhe
Magnesium chloride hexahydrate Carl Roth GmbH & Co KG, Karlsruhe
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MES AppliChem GmbH, Darmstadt
NADH Sigma-Aldrich GmbH, Steinheim
Naphtalene-2-sulfonamide Sigma-Aldrich GmbH, Steinheim
Phenyl phosphorodiamidate Sigma-Aldrich GmbH, Steinheim
Peptone/tryptone AppliChem GmbH, Darmstadt
PMSF AppliChem GmbH, Darmstadt
Polyethylene glycol 400 AppliChem GmbH, Darmstadt
SDS AppliChem GmbH, Darmstadt
Sodium chloride AppliChem GmbH, Darmstadt
Sodium dihydrogen phosphate dihydrate Carl Roth GmbH & Co KG, Karlsruhe
Sodium hydroxide AppliChem GmbH, Darmstadt
TEMED Carl Roth GmbH & Co KG, Karlsruhe
Tris ultrapure AppliChem GmbH, Darmstadt
Yeast extract AppliChem GmbH, Darmstadt
Zinc sulfate AppliChem GmbH, Darmstadt
α-Ketoglutaric acid disodium salt Sigma-Aldrich, Steinheim
1,4-Dioxane Sigma-Aldrich, Steinheim
1,10-phenanthroline monohydrate Carl Roth GmbH
2-Mercaptoethanol Carl Roth GmbH & Co KG, Karlsruhe
5.1.2 Enzymes, Markers and Kit systems
Enzymes, Markers and Kit systems Supplier
DNase I AppliChem GmbH, Darmstadt
dNTP mix (10 mM) MBI Fermentas, St. Leon Rot
DpnI (10 U/µl) Thermo Scientific GmbH, Schwerte
Gene RulerTM 1 kb DNA ladder 0, 5 µg/µl Fermentas GmbH, St.Leon-Rot
L-Glutamic dehydrogenase from bovine liver Sigma-Aldrich, Steinheim
Lysozyme (25000 U/mg) AppliChem GmbH, Darmstadt
NotI (10 U/µl) Thermo Scientific GmbH, Schwerte
NucleoSpin R© Gel and PCR Clean-up Macherey-Nagel GmbH & Co. KG, Düren
NucleoSpin R© Plasmid Macherey-Nagel GmbH & Co. KG, Düren
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Phusion Green High-Fidelity DNA Poly-
merase (2 U/µl)
Thermo Scientific GmbH, Schwerte
PreScission Protease Self-expressed and purified
SalI (10 U/µl) Thermo Scientific GmbH, Schwerte
T4 DNA Ligase (5 U/µl) Thermo Scientific GmbH, Schwerte
Unstained protein molecular weight standard Fermentas GmbH, St.Leon-Rot
6x DNA Loading Dye Fermentas GmbH, St.Leon-Rot
5.1.3 Peptides
Peptides Supplier
Gln-Gln (QQ) Innovagen AB, Lund
Ala-Phe-Ala (AFA) Innovagen AB, Lund
Glu-Phe-Arg-His (EFRH) Innovagen AB, Lund
Gln-Phe-Arg-His (QFRH) Innovagen AB, Lund
pGlu-Phe-Arg-His (pEFRH) Innovagen AB, Lund
Gln-Leu-Tyr-Glu-Asn (QLYEN) (Neurotensin1−5) Innovagen AB, Lund
Gln-His-Trp-Ser-Tyr (QHWSY) (GnRH1−5) Innovagen AB, Lund
Gln-Pro-Leu-Pro-Asp (QPLPD) (OrexinA1−5) Innovagen AB, Lund
Glu(γ-hydrazide)-Phe-Ala (E(γ-hydrazide)FA) Fraunhofer Institute, Halle
5.1.4 Bacterial Strains
Bacterial strain Genotype Supplier
E.coli DH5α F− Φ80lacZ∆M15 ∆(lacZY argF) U169 recA1 endA1
hsdR17 (r−K m
+
K) phoA supE44 λ− thi-1 gyr A96 relA1
Invitrogen,
Karlsruhe
E.coli XL1-blue F′ recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1
lac [proAB lacIqZ ∆M15 Tn10 (TetR)]
Stratagen,
Heidelberg
E.coli BL21 Star F− ompT dcm hsdS(r−B m
−
B) gal [malB+]K−12(λS) Invitrogen,
Karlsruhe
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5.1.5 Oligonucleotides
Oligonucleotide Sequence 5’ → 3’
hQC30−361 SalI for ggccatgcgtcgactcAGTCCGAGTGCCTCAGCCTGGC
hQC30−361 NodI rev CCTACAAGTCTTTGTGTTGGAATATCTTCATTTGTAA
gcggccgcgcatggcc
hQC35−361 opti. rev GGAAGTTCTGTTCCAGGGGCCC
hQC35−361 opti. for GCCTGGCCAGAGGAGAAGAATTACC
Sequencing primer 1 for GGGCCTTGTGCAACCCAC
Sequencing primer 2 rev GCACAACATGTTGGGTGGTTG
Sequencing primer 3 for GAATTCATCGGCTCTTCG
5.1.6 Plasmids
Plasmid Characteristics Selection marker
pQE-31 Expression of SUMO-hQC30−361 CarbenicillinR
pGEX-6P-1 Expression of PreScission Protease CarbenicillinR
pGEX-6P-1 Expression of GST-hQC35−361 CarbenicillinR
5.1.7 Devices
Device Supplier
Absorbance Photomultiplier R928 Applied Photophysics, UK
Äkta Prime Plus GE Healthcare, Munich
Äkta Purifier GE Healthcare, Munich
Centrifuge Avanti HP-30 I (Rotor JA-30.50) Beckmann Coulter, Krefeld
Circular dichroism spectropolarimeter Applied Photophysics Ltd., UK
Conducting meter FiveEasy Mettler-Toledo, Giessen
Gel documentation system Herolab GmbH, Wiesloch
Incubation shaker, Unitron Infors AG, Switzerland
ITC 200 MicroCalorimeter Microcal, Northampton, USA
Microfluidizer 110S Microfluidics, USA
NanoDrop2000 Thermo Scientific, Schwerte
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pH-Meter 7110 Inolab-WTW, Weilheim
SDS gel electrophoresis SE250 Hoefer, Holliston, USA
SX18 MV stopped-flow spectrometer Applied Photophysics, UK
Thermocycler TProfessional Biometra, Göttingen
Thermomixer comfort Eppendorf, Hamburg
Unitron Plus AJ252 incubator Infors HT, Switzerland
UV-Vis Spectrometer, V-650 Jasco GmbH, Groß-Umstadt
X-ray MM-007 rotating-anode generator Rikagu Corp., USA
X-streamTM 2000 Cryogenic Crystal Cooler Rikagu Corp., USA
X-ray Mar 345dtb image plate detector Rikagu Corp., USA
5.1.8 Columns
Columns Supplier
Glutathione Sepharose R© 4 FF (16/10) GE Healthcare, Munich
Source 30Q (16/10) GE Healthcare, Munich
HiPrepTM 26/10 Desalting GE Healthcare, Munich
5.1.9 Commodities
Commodities Supplier
CrystalCap HT cryoloop Hampton Research, USA
CrystalCap HT vial Hampton Research, USA
UV- and CD-cuvettes Hellma, Müllheim
Spin-X R© UF concentrator (30,000 MWCO) Corning, USA
VDXmTM crystallization plates with sealant Hampton Research, USA
0.2 µm Filter Sartorius, Göttingen
0.22 µm PES Bio-Rad Laboratories, Inc., USA
18 mm Circular cover slides - siliconized Jena Bioscience GmbH, Jena
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5.2 Methods
5.2.1 Molecular Biology
5.2.1.1 Polymerase Chain Reaction (PCR)
PCR [57] was used for amplification of the QCPT gene from the pQE-31 vector as well
as for cloning the gene of interest into the multiple cloning site of the pGEX-6P-1 vector.
A standard PCR reaction contained 1x HF buffer, 200 µM dNTP mix, 5-50 ng template
DNA, 125 pmol 5’-phosphorylated sense and antisense primer and 1 U Phusion DNA Poly-
merase. In addition, PCR was also used to optimize the gene construct for crystallization
by deletion of specific nucleic acids. In this case a standard PCR reaction contained 1x
HF buffer, 200 µM dNTP mix, 5 ng template DNA, 0.5 pmol 5’-phosphorylated sense and
antisense primer and 1 U Phusion DNA Polymerase. For the described PCR reactions the
following temperature protocol was used (Tab. 5.1).
Table 5.1: Temperature protocol for PCR reaction. A denaturation, an-
nealing and elongation step counts as one cycle, respectively. After each cycle the
temperature increases by the specified ∆T value. A final denaturation and final elon-
gation step also counts as one cycle.
Step Temperature [◦C] Time [s] Cycles ∆T [◦C]
Initial denaturation 98 30
Denaturation 98 10 10 0.5
Annealing 70 30 10 0.5
Elongation 72 75 10 0.5
Final denaturation 98 10 20
Final Elongation 72 90 20
Storage 4
5.2.1.2 Cleavage of DNA with Restriction Enzymes
For insertion of the QCPT gene into the multiple cloning site of the target vector, re-
striction enzymes NotI and SalI were used to digest the pGEX-6P-1 vector and insert.
DNA restriction was performed according to the manufacturer’s manual of the used en-
donucleases.
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5.2.1.3 Agarose Gel Electrophoresis
To analyze generated PCR products by size-dependent separation, horizontal agarose gel
electrophoresis [58] was performed. During this study gels with an agarose content of 1 %
(w/v) in 1x TAE buffer (40 mM Tris, 1 mM EDTA, 20 mM acetate, pH 8.5) were used.
Prior to gel electrophoresis, DNA samples were mixed with 6x loading dye and loaded onto
the gel. After electrophoresis the gel was incubated in a 2 µg/ml ethidium bromide bath
for 10 min. For visualization of the DNA ethidium bromide was excited at λ = 285 nm
in a gel documentation system. To estimate separated DNA-fragments a DNA standard
ladder was always co-electrophoresed.
5.2.1.4 Blunt-End Ligation of DNA Fragments
For ligation of two DNA fragments T4 DNA Ligase was used according to the manu-
facturer’s manual. In addition, to stop the ligation reaction, it was incubated for 10 min
at 65 ◦C. Afterwards, 5 U of DpnI were added and incubated over night at 37 ◦C to digest
the original methylated plasmid. To inactivate DpnI, the reaction was incubated for 5 min
at 80 ◦C.
5.2.1.5 Concentration and Purity Determination of DNA
DNA concentrations were determined spectroscopically using a NanoDrop2000. The ab-
soption at 260 nm was used with the following correlation to determine the concentrations:
1 A260 Unit of dsDNA =̂ 50 µg/ml in H2O (1)
To guarantee a high purity grade the A260/A280 ratio should always be in a range of 1.8
≤ A260/A280 ≤ 2.0. An A260/A280 < 1.8 indicates a contamination with proteins and
aromatic substances and an A260/A280 > 2 is an indicator for RNA contamination.
5.2.1.6 Plasmid Transformation into Chemocompetent E.coli Cells
Generation of chemical competent E. coli cells for transformation were prepared according
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to a standard protocol [59] and stored in 50 µl aliquots at -80 ◦C for several months. For
transformation of the plasmid into chemocompetent E. coli cells 200-400 ng of the target
vector DNA was added to the cells and gently mixed, followed by an incubation step for
20 min on ice. Next, cells were heat shocked at 42 ◦C for 60 s and subsequently cooled
down on ice for 2 min. For a slow regeneration of the E.coli cells and to express the cor-
responding antibiotic resistance genes, 1 ml of nonselective LB-media (10 g/L tryptone,
5 g/L yeast extract and 5 g/L NaCl) [60, 61] was added and incubated at 37 ◦C for 1 h
and 650 rpm. Positive clones were streaked out equally onto LB-agar plates supplemented
with 100 µg/ml carbenicillin as selection marker.
5.2.1.7 Preparation of Plasmid DNA from E.coli Cells
For isolation of the target plasmid 5 ml LB medium was incubated with E.coli cells contain-
ing the desired plasmid and incubated shaking over night at 30 ◦C and 200 rpm. Plasmid
preparation was performed according to the manufacturer’s manual of the NucleoSpin R©
Plasmid kit and obtained plasmids were stored at -80 ◦C.
5.2.1.8 DNA Sequencing
Plasmid DNA was sequenced by a company (Seqlab, Göttingen, Germany) to verify the
correctness of the generated construct. For this purpose, 20 pmol of the sequencing primer
with 500 ng vector DNA were sent to the company according to their sample shipment
requirements.
5.2.2 Protein Chemistry
5.2.2.1 Overexpression of the GST-hQC Fusion Protein in E.coli BL21 Star Cells
For expression of the fusion protein one single colony was used to inoculate a 30 ml
LB-media culture (10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl) [60] with 100
µg/ml carbenicillin as selection marker and incubated at 37 ◦C and 200 rpm overnight
in an incubation shaker. The overnight culture was in turn used to inoculate a 200 ml
LB-media culture, again supplemented with 100 µg/ml carbenicillin as selection marker,
to an OD600 of 0.1 and incubated at 37 ◦C and 200 rpm for 5 h. The 500 ml LB-media
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containing main cultures were supplemented each with 100 µg/ml carbenicillin and 10 µM
ZnSO4. The trace element was added to ensure that the active site of hQC is fully occu-
pied and prepared according to a standard protocol [62]. Main cultures were inoculated
to an OD600 of 0.1, followed by an incubation step at 37 ◦C and 200 rpm in an incubation
shaker until an OD600 of 0.6 was reached. Subsequently, cultures were rapidly cooled down
to 16 ◦C until an OD600 of 0.8 was reached. Gene expression was induced by the addition
of 100 µM IPTG followed by an incubation step at 16 ◦C and 200 rpm for ∼65 h. After
the incubation period had elapsed, cells were harvested by a centrifugation step at 4800
rpm for 30 min at 4 ◦C. The harvested cells were either directly used or stored at - 80 ◦C
until usage.
5.2.2.2 Purification of the GST-hQC Fusion Protein
For a standard purification all steps were performed at 8 ◦C. First, a 60-80 g cell pel-
let was resuspended in 3 ml lysis buffer (300 mM NaCl, 50 mM NaH2PO4, 1 mM DTT,
5 µg/µl DNaseI, spatula tip lysozyme, pH 7.5) per gram cell pellet, followed by an in-
cubation step for 10 min under constant stirring. Finally, cells were disrupted by three
passages through a microfluidizer. After removal of cell debris by a centrifugation step
at 17.500 rpm for 30 min at 4 ◦C, obtained supernatant was loaded onto a Glutathione
Sepharose R© 4 FF (16/10) column equilibrated with loading buffer (300 mM NaCl, 50 mM
NaH2PO4, 1 mM DTT, pH 7.5). After a washing step with 100 ml ATP washing buffer
(300 mM NaCl, 50 mM NaH2PO4, 1 mM DTT, 5 mM ATP, 5 mM MgSO4, pH 7.5) the
fusion protein was eluted with an elution buffer (300 mM NaCl, 50 mM NaH2PO4, 20
mM L-Glutathione reduced) and fractions containing the fusion protein were pooled. To
prepare cleavage of GST-tag from hQC, fusion protein was dialyzed against two liter dial-
ysis buffer (300 mM NaCl, 50 mM NaH2PO4, pH 7.5) under constant stirring to remove
the reduced L-Glutathione. For the actual cleavage, PreScission Protease was added in a
1:200 ratio (PreScission : fusion protein) to the fusion protein and incubated under gentle
shaking for four hours. Afterwards, protein solution was filtered with a 0.2 µm filter and
prepared for the next purification step.
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5.2.2.3 Purification of Untagged hQC
Again, all purification steps were performed at 8 ◦C. To remove the GST-tag, the protein
solution was loaded a second time onto a Glutathione Sepharose R© 4 FF (16/10) column
equilibrated with dialysis buffer. The flow-through fractions containing hQC were pooled
and dialyzed against two liter low salt buffer (50 mM NaH2PO4, pH 7.5, conductivity
5.63 µS/cm) to remove chloride ions. Afterwards, the protein solution was loaded onto
an anion exchange Source 30Q (16/10) column, which was already equilibrated with low
salt buffer. When the protein solution was completely loaded and the UV-signals (254
nm and 280 nm) showed a stable signal, a linear gradient (300 ml, 0 - 100 % B) with
high salt buffer (1 M NaCl, 50 mM NaH2PO4, pH 7.5, conductivity 41.24 µS/cm) was
started. Fractions containing pure hQC were pooled and concentrated with a Spin-X R©
UF concentrator (30,000 MWCO) to the desired volume and molarity. Afterwards, pre-
pared hQC was analyzed via SDS-PAGE to check the purity grade. Finally, the enzyme
was dialyzed against one liter storage buffer (50 mM Tris/HCl, pH 8.0) and stored on ice
for 1-2 months without losing activity.
5.2.2.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
For analysis of purified hQC SDS-PAGE was performed relying on a protocol of Laemmli
and Weber [63, 64]. SDS gels with a 1 mm thickness contained a stacking part (5 %
acrylamide, 1 % SDS, 125 mM Tris, pH 6.8) and a separation part (12 % acrylamide, 1
% SDS, 375 mM Tris, pH 8.8). Both parts were step-wise polymerized by adding 0.3 %
APS and 0.3 % TEMED. Before the protein samples were loaded onto the stacking gel,
they were mixed with SDS sample buffer (25 % (w/v) glycerol, 2 % (w/v) SDS, 0.02 %
(w/v) Bromophenol blue, 100 mM Tris, pH 6.8) in a 1:1 ratio and incubated at 96 ◦C
for five minutes. Gels ran with 1 mA/cm2 in SDS running buffer (200 mM glycine, 25
mM Tris, 3.5 mM SDS, pH 8.3) until the front of the loading dye reached the bottom
of the gel. Next, the gels were stained with Coomassie Brilliant Blue (0.25 % Coomassie
Brilliant Blue, 30 % ethanol, 6 % acetic acid) for 10 min and afterwards decolorized with
a destaining solution (30 % ethanol, 10 % acetic acid) for additional 10 min.
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5.2.2.5 Preparation of Cobalt(II)-Substituted hQC
5.2.2.5.1 Generation of Apo-hQC
For stopped-flow experiments, a modified protocol provided by Probiodrug [23] was used
for substitution of zinc against spectroscopically active cobalt within the catalytic site of
hQC. To generate apoenzyme, hQC was stepwise dialyzed at 8 ◦C against 250, 250 and
500 ml chelating buffer (300 mM NaCl, 50 mM NaH2PO4, 5 mM EDTA, 5 mM 1,10-
phenanthroline, pH 7.5) for 4, 4 and 16 h, respectively. Next, to remove all chelating
reagents, the apoenzyme was dialyzed against a total volume of three liters metal-free
buffer (50 mM Tris/HCl, 25 g/l Chelex-100, pH 8.0) at 8 ◦C. To ensure removal of the
active site zinc ion, the apoenzyme was tested for activity (see 5.2.3.1) and should show
< 1 % residual activity compared to the holoenzyme. In addition, absorption at 260 nm
was checked to guarantee complete elimination of 1,10-phenanthroline. After removal of
the zinc ion and generation of the apoenzyme all used commodities, storage conditions of
solutions as well as further working steps were performed under metal-free conditions.
5.2.2.5.2 Reconstitution of Cobalt(II) within the Active Site
The apoenzyme was desalted against substitution buffer (50 mM NaH2PO4, 100 mM
NaCl; pH 6.8) with a HiPrepTM 26/10 Desalting column and afterwards diluted to a fi-
nal concentration of 40 µM. In order to reconstitute the active site of hQC with cobalt
the apoenzyme was incubated at room temperature for 15 min with a 6-folded excess of
CoCl2 (f.c 240 µM). After incorporation of cobalt within the active site of hQC the so-
lution showed an optically change from colorless into light pink. Next, Co(II)-hQC was
desalted against storage buffer (50 mM Tris/HCl, pH 8.0) and the specific activity was
measured to check if Co(II)-hQC has comparable activity compared to Zn(II)-hQC (see
5.2.3.1).
5.2.2.6 Determination of Protein Concentration
Concentration of hQC was measured spectroscopically at 280 nm with a NanoDrop2000.
In order to calculate the protein concentration of hQC, the experimentally determined mo-
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lar extinction coefficient (εhQC = 55869 M−1 cm−1) and the molecular weight (MWhQC
= 37511 g/mol, ProtParam) were used. The molar extinction coefficient was determined
according to an established protocol [65].
5.2.3 Kinetic Methods
5.2.3.1 Coupled Spectroscopic Steady-State Assay
Enzymatic activity of hQC for conversion of substrates harboring an N-terminal Gln
into pGlu was monitored spectrophotometrically in a coupled steady state assay using
the auxiliary enzyme GLDH [66]. The assay is based on the coupling of ammonia, which
is formed and released after cyclization of N-terminal glutamine residues, to the GLDH.
It is important that detection of ammonia by this assay is proportional to the decrease
of absorbance at λ = 340 nm over time. Here, NADH gets oxidized to NAD+, which
shows no absorbance at this range (Fig. 5.1A). The coupled steady-state assay is shown
in Fig. 5.1B schematically.
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Figure 5.1: General overview of the spectrophotometric coupled steady-state assay. (A)
UV/Vis spectra of NAD+/NADH. NADH has an absorption maximum at λ = 340 nm, whereas NAD+
does not absorb in this range. (B) Schematic representation of the coupled steady-state assay. Catalysis
of N-terminal glutamine to pyroglutamic acid (pGlu) by hQC is linked to the formation of glutamate (Glu)
using the auxiliary enzyme glutamate dehydrogenase (GLDH).
A typical standard reaction with a total volume of 500 µl at saturated conditions consists
of 50 mM Tris/HCl, pH 8.0, buffer, 0.3 mM NADH (KM = 0.024 mM [66]), 15 mM α-
ketoglutaric acid (KM = 0.7 mM [66]), 2.5 mM Gln-substrate and 30 U/ml GLDH. The
reaction was started by adding 1 µg of hQC and measured at 30 ◦C. To calculate the
specific activity (Aspec), change in absorbance per minute (∆E/min), total volume of the
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reaction (Vtotal), path length of the cuvette (d), molar extinction coefficient of NADH
(εNADH = 6200 M−1 cm−1 at 340 nm), volume of hQC solution added into the cuvette
(VE) and hQC concentration of the stock solution (cstock) were used according to Eq. 2
Aspec =
∆E/min · Vtotal · 1000
d · εNADH · VE · cstock
(2)
Dependency of the initial rates on the substrate concentration were analyzed according to
Eq. 3, where Vmax is the maximum rate, KM the Michaelis-Menten constant and [S] the
concentration of the substrate.
v = Vmax · [S]
KM · [S]
(3)
Data analysis and curve fitting was done with the SigmaPlot software.
5.2.3.2 Continuous Calorimetric Activity Assay for Human Glutaminyl Cyclase using
Isothermal Titration Calorimetry
An alternative kinetic assay, using Isothermal titration calorimetry (ITC), which is rapid,
simple and precise, was facilitated for this study. It has been already known that calorime-
try can be used to measure released or consumed heat during enzymatic activity [67] and
that the observed thermal power is directly proportional to the rate of an enzymatic re-
action [68].
Conversion of substrate to product by a catalyst generates or releases heat, which corre-
sponds to the molar reaction enthalpy ∆H of the reaction. This ∆H for a defined substrate
amount can be directly obtained from the total heat of an ITC experiment at the time
point when substrate or enzyme is injected and the reaction starts and proceeds further
until the substrate is completely converted into product. The change in thermal power
while substrate is depleted over time can be continuously monitored and therefore heat
(Q) is measured as a function of time and defined as the differential thermal power (dp).




5 MATERIALS AND METHODS
To obtain the experimental ∆H-value, it is necessary to integrate the different dp-values
and divide the sum of all integrals by the total substrate amount n(S)total. For simplifica-
tion n(S)total is defined as the initial substrate concentration at time point zero [S]0 and
the total Volume V of the measurement cell.






To ensure accurate overall integral calculation of the reaction, it is necessary to generate a
high number of small integrals. Thereby, every generated data point (dpt), which displays
a dp-value at a defined time point, has to be multiplied with the spacing (s) of each





dpt · s (6)
Every square formed integral is defined by the different spacing- and dp-values, thereby
generating an approximated overall surface integral, which describes the catalyzed con-
version of substrate (S) to product (P). The introduced/dissipated amount of energy is
described by the surface area of each integral and needs to be translated into a defined
amount of substrate into product for each interval t (nt(P ) by dividing the area against




It is necessary to accumulate product formation from t0 − t to determine total product





Due to the fact that the initial substrate amount n0(S) is known and every substrate
molecule is irreversibly converted into one product molecule, it is possible to calculate
the amount of substrate molecules nt,total(S) at each time point t by using the following
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To finally display the substrate concentration at every time point (ct(S)) on the x-axis
for the Michaelis-Menten plot, it is necessary to use the previously calculated amount
of substrate molecules nt,total(S) at each time point and divide it by the volume of the





Next, to calculate the reaction velocity at a given time point (vt) every corresponding




At last, to define the y-axis the reaction velocity at a given time point (vt) needs to be








Now, the specific activity or turnover number can be plotted against the substrate con-
centration ct(S) and is fitted according to the Michalis-Menten equation (see eq. 3), if the
reaction follows the kinetics of the Michaelis-Menten model.
For a conventional reaction all solutions were degassed and filtered. In addition, the sam-
ples were centrifuged at 15.000 rpm for 10 min at 4 ◦C. The reference cell of the ITC device
was filled with water. Sample concentrations and ITC setup were utilized as described in
Tab. 5.2 and Tab. 5.2. Data analysis and curve fitting was performed with the Excel and
SigmaPlot softwares.
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Table 5.2: ITC setup for single injection experiments.
Gln-substrates Glu-substrates
Number of injections 2 2
Sample cell temperature [◦C] 30 30
Ref. power [µcal/s] 5 5
Initial delay [s] 60 120
Stirring speed [rpm] 500 500
Spacing injection 1 [s] 3600 20000
Spacing injection 2 [s] 120 300
Injection volume [µl] 10 10
Filter period [s] 5 5
Table 5.3: Used concentrations for the continuous calorimetric activity
assay. Volumes of the sample cell and the injection syringe are 204,5 µl and 40 µl,
respectively.
Sample cell concentration pH Injec. syringe concentration pH
QQ 2 mM 8.0A hQC 1 µM 8.0A
QFRH 2 mM 8.0A hQC 1 µM 8.0A
EFRH 3 mM 6.8B hQC 60 µM 6.8B
QLYEN 2 mM 8.0A hQC 1 µM 8.0A
QHWSY 2.5 mM 8.0A hQC 1 µM 8.0A
QGPWL 1 mM 8.0A hQC 10 µM 8.0A
QPLPD 3 mM 8.0A hQC 10 µM 8.0A
A solutions were buffered in 50 mM Tris/HCl.
B solutions were buffered in 30 mM Tris/HCl and 20 mM MES
5.2.3.2.1 pH-Dependency of Human Glutaminyl Cyclase at Constant Ionic Strength
Reactions were prepared as described previously (see chapter 5.2.3.2). To enable a wide
buffer capacity with constant ionic strength from pH 5.5 to 9.5, the normal measuring
buffer was replaced by a three component buffer consisting of 0.05 M acetic acid, 0.05
M MES, 0.1 M Tris [69]. Data points were fitted according to the following equation, in
which v stands for the reaction velocity, pH for the negative logarithm of the molarity of
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the H+ ions and pKa for the negative logarithm of the acid dissociation constant Ka.
v = vmax ·
1
1 + 10(pKa1−pH) + 10(pKa2−pH)
+ vmin (14)
5.2.3.2.2 Kinetic Characterization of Human Glutaminyl Cyclase Inhibitors
For characterization of different inhibitors for hQC a standard reaction was prepared
as described previously (see chapter 5.2.3.2). As a variation, the substrate with a de-
fined concentration of the inhibitor was loaded together into the measurement cell. To
determine the inhibition constant Ki, obtained data points of the Michaelis-Menten plot
were analyzed accordingly to Dixon [70]. The Dixon plot represents the reciprocal ini-
tial reaction velocity v, which is plotted against the inhibitor concentration [I] at various
fixed concentrations of substrate [S]. Intersections of obtained linear regressions were cal-
culated to obtain the inhibition constant Ki. In addition, experimental data was plotted
three-dimensionally and obtained data points were fitted according to Eq. 15 [71].
v = Vmax · [S]





5.2.3.3 Fast Kinetics Stopped-Flow UV/Vis Spectroscopy
To gather information about the overall enzymatic reaction and the coordination number
via the electronic environment of the substituted cobalt ion within the active site of hQC,
an Applied Photophysics SX18 MV stopped-flow spectrophotometer with a photo diode
array was used. For this purpose, different substrates were rapidly mixed with the enzyme
with a dead response time of 1.5 milliseconds. Enzyme and substrates were mixed in a
one to one volume ratio within the 20 µl measurement cell of the stopped-flow device with
an optical path length of 10 mm. Time-resolved spectra were collected in equidistant time
intervals in a wavelength range from 185 - 723 nm. Experiments were performed at 10 ◦C
for glutaminyl substrates and for glutamyl substrates at 30 ◦C. For each data collection
the first 0.1 s was measured with 10 data points and the following 150 s with 200 data
points. Final concentrations of enzyme and substrates after mixing are shown individually
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in Tab. 5.4.
Before usage, syringes and the measurement cell of the stopped-flow device were incubated
in a solution containing 2 % Hellmanex and 5 mM EDTA for 20 min to remove free metal
ions. After washing the system sufficiently with water a spectrum of the acquired buffer
was measured. Subsequently, a spectrum of the cobalt substituted enzyme was recorded
before it was rapidly mixed with the substrate. Obtained spectra were buffer- and protein-
corrected by utilizing the softwares SX-Prodata Viewer and SigmaPlot 11.
Table 5.4: Final concentration of compounds af-
ter mixing in the measurement cell.









A solutions were buffered in 50 mM Tris/HCl.
B solutions were buffered in 30 mM Tris/HCl and 20
mM MES
5.2.4 Biophysical Methods
5.2.4.1 UV/Vis Absorption Spectroscopy
All UV/Vis spectra were measured between 300 - 700 nm with an acquisition speed of 100
nm/min in a Jasco V-650 spectrophotometer. A quartz cuvette with a path length of 1
cm and a band width of 1 nm was used for all measurements. Furthermore, measurements
were performed at 25 ◦C with a data pitch of 1 nm. All utilized solutions were treated
with Chelex-100 before usage to guarantee metal-free conditions. Difference spectra were
generated by subtracting free cobalt and protein spectra from the recorded one.
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5.2.4.1.1 Titration of Cobalt to Apoenzyme
Ten titration steps, each containing one microliter of 14 - 24 mM CoCl2, were titrated into
a total volume of 1 ml 40 µM apoenzyme. Afterwards, samples were incubated for 4 min
and subsequently, spectra were measured in the spectrophotometer. Titration experiments
were performed at alkaline (50 mM Tris/HCl, pH 8.0) and weak acidic (50mM NaH2PO4,
300 mM NaCl, pH 6.8) conditions. To quantify cobalt incorporation, absorption at 550
nm (Amax) of the corrected spectrum was plotted against the cobalt concentration. In
order to determine the dissociation constant (Kd) data was fitted according to:
A = Amax · [Co]
Kd · [Co]
(16)
5.2.4.1.2 Stability of Cobalt Substituted Human Glutaminyl Cyclase
To see if the cobalt ion forms a stable complex within the active site hQC, 40 µM apoen-
zyme were supplemented with 144 µM CoCl2 and incubated for defined time points until
spectrum was measured.
5.2.4.2 Quantitative Characterization of the Thermodynamics of Binding Events using
Isothermal Titration Calorimetry
To obtain thermodynamic parameters of interactions in solution, the binding event of
small ligands to glutaminyl cyclase were studied utilizing Isothermal Titration Calorime-
try. In this study ITC was used to investigate the interaction between hQC and different
potential inhibitors. Instead of measuring stepwise changes in the enthalpy of interaction
during the course of multiple titration steps only a single titration step was carried out to
obtain the overall enthalpy of the binding process.
Before measurement, the enzyme was dialyzed against one liter 50 mM Tris/HCl, pH 8.0,
for 12 hours at 8◦C. In addition, the ligand was dissolved in the identical dialysis buffer.
Concentrations and ITC setup are listed in Tab. 5.5. Data analysis was performed with
MicroCal Analysis and SigmaPlot software.
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Because the overall binding enthalpy and the association constant are determined experi-
mentally the remaining thermodynamic parameters were calculated according to Eq. 17.
∆G = −RT · ln(Ka) = ∆H − T∆S (17)
∆G = Gibbs energy changes
∆H = Enthalpy changes
∆S = Entropy changes
T = Absolute temperature in Kelvin
Ka = Association constant [M−1]
R = Ideal gas constant (8.314 · 10−3 kJ mol−1 K−1)
Table 5.5: Used ITC setup and protein-ligand concentra-
tions for thermodynamic characterization.
Number of injections 3
Injection syrringe 25 mM Q(hydrazide)-FA
Sample cell 0.08 mM hQC
Sample cell temperature [◦C] 30
Ref. power [µcal/s] 10
Stirring speed [rpm] 500
Spacing after injection [s] 300
Injection volume [µl] 5
Filter period [s] 2
5.2.4.3 Conformational Stability of Human Glutaminyl Cyclase in Dependence of pH
or Temperature using Circular Dichroism Spectroscopy
Numerous intra-molecular interactions of proteins, e.g. formation of disulfide bridges
between cysteines or hydrogen bonds among different amino acid residues, ensure con-
formational stability and define secondary structure elements. If a protein molecule un-
dergoes an unfolding transition due to breakup of these intra-molecular interactions, it
loses its secondary structure elements. This transition can be monitored via a Chiras-
can CD-spectropolarimeter. The CD-signal arises if the absorption of the left- and the
right-circular polarized light of an asymmetric optical center are unequal and and gets
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diminished due to protein unfolding. To quantify secondary structure elements in de-
pendence of pH-value, CD-spectra were recorded for hQC in the far UV/Vis range. In
addition, thermal stability of hQC was analyzed by inducing a continuous temperature
transition from 20◦C to 96◦C.
In case for pH-stability experiments of hQC, spectra were recorded in one nanometer steps
in the far UV/Vis range from 190-280 nm with a path length of one millimeter at 30◦C.
For measurements 0.1 mg/ml hQC was diltued into a 10 mM potassium phosphate buffer
with varing pH-values from 6.16-8.45.
For thermal stability experiments 0.1 mg/ml Zn(II)-hQC, Co(II)-hQC or apoenzyme di-
luted in 10 mM Tris/HCl, pH 8.0, were characterized. Settings of a typical measurement
are listed in Tab. 5.6. Additionally, to compare the native and denaturated enzyme, CD-
spectra were taken before and after temperature transition. The midpoint of the thermal
transition was determined according to Eq. 18 [72].
y =


















y = CD-signal at 196 nm
yf , yu = Intercepts of pre- and posttransition baselines
mf ,mu = Slopes of pre- and posttransition baselines
T = Temperature in Kelvin
Tm = Midpoint of the thermal unfolding curve
∆Hm = Enthalpy change for unfolding at Tm
R = Ideal gas constant
This equation holds true for determination of the midpoint for reversibly unfolding pro-
teins. However, for irreversibly unfolding proteins the thermal transition depends on the
heating rate and exposure time at a certain temperature, which is the case for glutaminyl
cyclase. As a consequence, the determined thermal transition midpoints are an apparent
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value. Nevertheless, the midpoints are adequate measures for a comparative examination.
Table 5.6: Settings of the CD-




Data interval 0.5 ◦C
Heating rate 2.0 ◦C/min
Tolerance 0.2 ◦C
Wavelength [λ] 196 nm
Time per point 12 s
Path length 1 mm
Data analysis and curve fitting was done with the SigmaPlot software.
5.2.4.4 Oligomerization State of Human Glutaminyl Cyclase Examined via Analytical
Ultracentrifugation
In order to get a quantitative analysis of the oligomerization state of glutaminyl cyclase
in solution, analytical ultracentrifugation [73] was used. All experiments in this study
were performed by Prof. Dr. Ute Curth from the Institute for Biophysical Chemistry,
Hannover Medical School.
5.2.5 Liquid Chromatography – Mass Spectrometry (LC-MS)
Target protein was digested with trypsin via in-gel digestion as described in literature
[74, 75]. For protein identification, liquid chromatography was coupled to an Orbitrap
Velos Pro mass spectrometer (Thermo Scientific). Chromatographically eluting peptides
were online ionized by nano-electrospray (nESI) using the Nanospray Flex Ion Source
(Thermo Scientific) at 2.4 kV and continuously transferred into the mass spectrometer.
LC-MS method programming and data acquisition was done with the software XCalibur
2.2 (Thermo Scientific). For protein identification MS/MS2 data were searched against
a human FASTA-database expanded for the amino acid sequences of interest using the
Proteome Discoverer software and the SequestHT search engine. All LC-MS experiments
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were performed by Dr. Oliver Valerius from the Department of Molecular Microbiology
and Genetics, Georg-August-University Göttingen.
5.2.6 X-ray Crystallography
5.2.6.1 Crystallization and Data Collection
In order to crystallize hQC the hanging drop vapor diffusion method was used. Therefore,
common 24-well crystallization plates with sealant were applied and each well was sealed
by putting a silanized cover glass on top of the well. Before crystallization the enzyme
was rebuffered in crystallization buffer containing 50 mM Tris/HCl amd NaCl, pH 8.0.
The N-terminal shortened version of human glutaminyl cyclase was subjected to initial
crystallization trials at a concentration of 10 mg/ml as described recently [20]. Diffracting
crystals grew within one week at 25 ◦C in 1.6 M ammonium sulfate, 4 % 1,4-dioxane and
0.1 M MES, pH 6.5, by mixing equal volumes of the enzyme solution and the reservoir.
Prior flash cooling with liquid nitrogen, generated crystals were incubated in a cryopro-
tectant solution containing reservoir solution supplemented with 25 % (v/v) glycerol, 5
% (v/v) PEG 400 and 10 µM zinc sulfate. In case of substrate soaking experiments the
cryoprotectant solution was additionally supplemented with the corresponding substrate
and protein crystals were incubated at room temperature for a defined time (Tab. 5.7).
Data collection of different crystal structures was performed at different synchrotron facil-
ities and resulting oscillation images were integrated, merged, and scaled using XDS [76,
77]. Zn(II)-hQC35−361 in absence of substrate crystallized in trigonal space group R32
with unit cell parameters of a = b = 119 Å, c = 333 Å and α = β = 90◦, γ = 120◦ and
harbors two molecules per asymmetric unit.
5.2.6.2 Structure Determination and Refinement
Initial phases for each structure were obtained by the molecular replacement method with
Phaser [78] using the structure of the already resolved hQC (Protein Data Bank code
2AFM) as search model. Refinement calculations were performed with PHENIX [79] using
standard parameters and after each refinement cycle the model was manually checked and
rebuilt using Coot [80] until final resolution was reached. Refinement with PHENIX also
46
5 MATERIALS AND METHODS
included adding solvent molecules like water automatically. At least, ligands were added
into the three dimensional model manually via Coot. Peptide-dependent ligands were
build using UCSF Chimera [81], which already included all necessary restrains. As an
exception, restraints for the product pEFRH for refinement with PHENIX were generated
with the PRODRG server [82]. For the ligand E(γ-hydrazide)FA the peptide was added
via Coot first and after a refinement cycle the hydrazide function was introduced into the
side chain of the glutamine by modeling an additional amino group into the corresponding
mFo-DFc electron density map. The corresponding bond lengths of the hydrazide function
relied on standard bond lengths derived from the Cambridge Structural Database (CSD).
Validation of the refined models was carried out using Coot and MOLPROBITY and
preparation of figures was performed with PYMOL.
Table 5.7: Substrate soaking conditions and data collection information for all
presented crystal structures.
Structure Soaking conditions Beamline Resolution
[Å]
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6 Results and Discussion
6.1 Expression and Purification of the ∆34 Deletion Variant of Human
Glutaminyl Cyclase Results in a Correctly Folded Soluble Monomer
The coding sequence of human pituitary glutaminyl cyclase (QPCT) [9], which is opti-
mized for codon usage in Escherichia coli cells, was used during this study. Chromosomal
location of the QPCT gene is at position 2p22.2 in the human genome and has an open
reading frame of 1086 bases, coding for a protein sequence consisting of 361 amino acids
with a molecular weight of 40,8 kDa. For this study the first 34 N-terminal amino acids
were deleted to generate a ∆34 deletion variant. It was shown that these first 34 N-terminal
amino acids encode only for secretion signal, which has no impact on the catalytic activ-
ity or on the tertiary protein structure of the enzyme [21]. Furthermore, native human
glutaminyl cyclase (hQC) is a glycoprotein (N-glycosylation site at Asn49) harboring a
disulfide bond near the catalytic site. Recent studies have shown that this disulfide bond
has a stabilizing function and is not essential for catalytic activity [22]. Due to the lack of
post-translational modifications, leading to no glycosylation and disulfide bond formation
event, solubility problems occur during expression in a prokaryotic host. Protein solubility
predictions with the ccSOL omics webserver [83] resulted in low heterologous solubility
chances of hQC expressed in Escherichia coli. To overcome the problems of low recovery
and heterogeneity of the recombinant ∆34 deletion variant of hQC the protein-coding
sequence was cloned into the pGEX-6P-1 expression vector (Fig. 8.1). The pGEX-6P-1
expression vector encodes for a glutathione S-transferase (GST) affinity tag (MW = 26
kDa), which is located in front of the generated ∆34 deletion variant of hQC and allows
purification of hQC via affinity chromatography [84]. The resulted GST-hQC fusion pro-
tein consists of 555 amino acids (Fig. 8.2) with a predicted molecular weight of 63.3 kDa,
whereas hQC after removal of the GST-tag consists of 327 amino acids (Fig. 8.3) with
a predicted molecular weight of 37.3 kDa. Although low solubility and frequent hetero-
geneities (e.g. chaperones like GroEL) make especially protein purification difficult, it was
possible to overcome these problems by utilizing optimized affinity and anion-exchange
chromatography steps. As a result, the enzyme was purified to homogeneity in the mil-
ligram scale with a yield of 0.2 mg per one gram cell mass (Fig. 6.1). Mass spectrometry
(data not shown; cooperation with Dr. Oliver Valerius from the University of Göttingen)
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and circular dichroism measurements verified successful purification of hQC. Circular
dichroism spectrum of mature hQC (Fig. 6.2 A) highly corresponds to the spectra of the
proteins expressed in yeast and insect cell systems [21, 85], indicating a correctly folded
protein. Moreover, characterization via circular dichroism showed two minima at 208 and
222 nm, indicating high content of α-helices in the overall structure. Recent studies have
shown that tertiary structure of hQC consists of 47 % α-helices [21], thereby greatly differ
compared to glutaminyl cyclase from Carica papaya, which adopts an all-beta fold with























Figure 6.1: Characterization of hQC via SDS-PAGE. Overview of expression and different
purification steps of hQC. Protein bands of hQC are framed in a red box. Different purification steps are
indicated in brackets with a description on top of each line.
In order to obtain information about the oligomerization state of hQC, analytical ultra-
centrifugation was performed (data not shown; cooperation with Prof. Dr. Ute Curth
from the Hannover Medical School). The results showed a main species with a sedimen-
tation coefficient of 3.2. Based on the sedimentation coefficient value and the diffusion
broadening of the sedimenting boundary layer, a molar mass of 34 kg/mol was calculated.
Since the amino acid sequence from the calculated molar mass of the monomer is 37.3
kg/mol, it can be concluded that hQC consists predominantly as a monomer in solution.
Additionally, the Perrin friction factor was determined, which gives information about the
deviation from a spherical shape [86] and should be for a globular protein between 1.1 and
1.2. If the Perrin friction factor differs greatly from values describing globular proteins it
can be assumed that the protein structure deviates from a spherical shape, indicating a
quaternary protein structure. In case of hQC a Perrin friction factor of 1.22 was deter-
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mined. This means that the protein adopts an almost perfectly spherical form, thereby
supporting the idea of a soluble monomer.
To elucidate stability of hQC the enzyme was stepwise thermally unfolded starting from
293 K up to 369 K and monitored via recording the change of the far-UV CD-signal
(λ = 196 nm). Unfolding of hQC turned out to be an irreversible process, in which the
transition showed a sigmoidal shape (Fig. 6.2 B). Data evaluation according to a sigmoidal
model reveals an inflection point at 325 K ± 4.2. It was reported that hQC lacking the
disulfide bond has a nearly identical melting point (319 K) [22]. Furthermore, recent
studies showed in case of mutagenesis experiments for glycosylated mammalian glutaminyl
cyclase expressed in the eukaryotic host Pichia pastoris lacking the disulfide formation,
that the N-glycosylation and the zinc ion within the active site decreased thermal stability
drastically (303 K) [22]. This observation might indicate a stabilizing role of the zinc
ion for the tertiary structure of hQC (see 6.4.3). In summary, missing post-translational
modifications while expressing in Escherichia coli does not directly affect tertiary structure
of hQC, but it influences stability and solubility, thereby explaining lower protein yield
after purification. But nevertheless, hQC expressed in Escherichia coli could be used for
further studies.
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Figure 6.2: Far-UV spectra and thermal unfolding of hQC. (A) CD-spectroscopic analysis of
the secondary structure of recombinant hQC. 0.1 mg/ml of hQC was dissolved in 10 mM Tris/HCl, pH
8.0. (B) Thermal unfolding curve of hQC recorded by the change of the far-UV CD signal at 196 nm.
Measurement was performed in the same buffer as mentioned above. Data was fitted according to Eq. 18.
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6.2 Development of a New Steady-State Assay
6.2.1 Motivation for Development of a Direct Continuous Enzymatic Assay for
Human Glutaminyl Cyclase
The cyclization reaction of N-terminal glutaminyl substrates catalyzed by glutaminyl cy-
clase leads to the formation of a lactam ring. Formation of the five-membered lactam ring
of the side chain of glutamine leads to slight differences in the UV absorption at 210-220
nm, which is caused by the electronic n 7−→ π∗ transition of the amide bond. Those
differences can be in general used to continuously study catalysis of di- and tripeptide
substrates by glutaminyl cyclase. However, substrate and product of hQC have similar
spectral properties, which makes it difficult to measure the cyclization reaction directly and
continuously. Furthermore, due to strong absorption of other molecules at this UV/Vis
range, for example peptide bonds and deoxyribonucleic acid DNA, applicability of this
method is even more restricted. Therefore, hQC activity and its preference for a substrate
was investigated in former studies by a previously described assay [66], which was orig-
inally based as a time-consuming discontinuous method. Due to difficulties in detecting
product formation directly, a continuous coupled enzymatic assay was developed. This
coupled assay [54] consists of two reactions, where in the first reaction pyroglutamic acid
(pGlu) is formed by hQC and ammonia is released during the cyclization reaction. In
the second reaction ammonia and α-ketoglutaric acid are converted into glutamate by the
auxiliary enzyme glutamic dehydrogenase (GLDH) via oxidation of NADH (Fig. 5.1 B).
Hence, pyroglutamyl formation catalyzed by hQC from N-terminal glutaminyl substrates
is detected indirect spectroscopically at 340 nm by the consumption of NADH. To test
if the auxiliary enzyme GLDH is not rate-limiting in the spectroscopic assay, different
hQC concentrations were tested at saturated substrate conditions, while concentration of
GLDH remained constant. A linear relationship was observed between the activity and
the concentration of hQC for the spectroscopic coupled assay (Fig. 8.4), meaning catalysis
of the auxiliary enzyme is not rate-limiting, thereby suitable for kinetic characterization
of hQC and its various substrates. However, it was reported that hQC is also capable to
catalyze the formation of pyroglutamic acid at N-terminal glutamyl substrates [3]. During
cyclization of N-terminal glutamic acids a water molecule is released instead of ammonia.
As a consequence, the spectroscopic assay is not suitable for kinetic characterization of
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N-terminal glutamyl substrates, due to the dependence of ammonia for the oxidation of
NADH to NAD+ in the second reaction. Thus, the spectroscopic coupled assay is limited
to the detection in cyclization of N-terminal glutaminyl substrates. Therefore a direct
continuous assay was tried to be developed to monitor the cyclization reaction directly
for N-terminal glutaminyl-/glutamyl substrates. It should be mentioned that besides the
spectroscopic coupled assay a fluorometric coupled assays was additionally developed, but
it was shown to be restricted to fluorigenic substrates [87].
6.2.2 Introduction and Overview of the Continuous Calorimetric Assay
According to the previously mentioned arguments to develop an activity assay, isothermal
titration calorimetry (ITC) turned out to be reliable method for kinetic characterization of
enzymes [88] and was adopted for hQC. Generally a defined concentration of the enzyme is
loaded into the syringe, whereas the substrate is placed into the sample cell of the ITC de-
vice (Fig. 6.3). After the ITC device establishes an equilibrated baseline the first injection
will be performed, in which the enzyme is titrated into the sample cell and is rapidly mixed
to diminish mixing artefacts. Starting with the injection heat is either released (exother-
mic) or consumed (endothermic), depending on the thermodynamics of the reaction. This
change in heat is detected by the ITC device by measuring the decreasing/increasing dif-
ferential power (dp). The dp-value rudimentary describes the energy difference between
the sample cell and a reference cell which is necessary to drive the system back to its
initial state. In case of an exothermic reaction the dp increases, while for an endothermic
reaction dp decreases. At the beginning of the measurement the change in dp starts to
decrease/increase, which corresponds to the formation of the Michaelis-Menten complex,
until it reaches a maximal stable dp-signal. At this point the enzyme is completely sat-
urated with substrate, reflecting steady state conditions and maximal reaction velocity
(Vmax). Over time substrate is converted into product, meaning that the enzyme becomes
less saturated with substrate. Thereby, heat release/consumption diminishes over time,
resulting in a change of the dp-signal. In this time period the Michaelis-Menten constant
(KM) can be determined. After complete depletion of the substrate the dp-signal drives
back to its initial state. Finally, data analysis and determination of kinetic parameters
can be performed as already described previously (see chapter 5.2.3.2). In summary, the
continuous calorimetric assay seems to be in theory a suitable tool for kinetic characteriza-
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tion of N-terminal glutaminyl-/glutamyl-substrates, because the cyclization reaction can
be directly measured and is independent of optical methods.
time [s]
































































Figure 6.3: Schematic overview of the direct continuous activity assay for an exothermic
reaction utilizing isothermal titration calorimetry. Sample cell and syringe of the ITC device are
depicted schematically. The corresponding ITC data for each step is shown at the bottom. Arrows within
the ITC data indicating important regions.
6.2.3 First Kinetic Characterization Utlilizing Calorimetry Results in Reliable Kinetic
Parameters
To test the theory of the direct continuous calorimetric assay a kinetic characterization of
hQC was performed utilizing the dipeptide Gln-Gln (QQ) as a reference substrate. Pref-
erence of a substrate for an enzyme is described by the determination of the Michaelis-
Menten constant (KM), the maximal reaction velocity (Vmax), the turnover number (kcat)
and the catalytic efficiency (kcat/KM). These kinetic parameters were determined under
steady state conditions. Therefore, conversion of Gln-Gln to pGlu-Gln (pEQ) was mea-
sured over time by monitoring the rate of heat release until complete substrate depletion.
Due to the continuous monitoring of pGlu-Gln formation, turnover of hQC was measured
in the dependency of different substrate concentrations in a single measurement and con-
stants were determined as already described (see chapter 5.2.3.1).
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Figure 6.4: Conversion of the N-
terminal glutaminyl reference sub-
strate Gln-Gln catalyzed by hQC de-
tected by calorimetry. Upper plot
shows the calorimetric progress curve of
the cyclization reaction of Gln-Gln, while
below the corresponding Michaelis-Menten
plot is depicted. After thermal equilibra-
tion (60 s), hQC was injected and the
change in instrumental thermal power was
monitored until substrate depletion was
complete. The obtained kinetic parame-
ters are depicted in the Michaelis-Menten
plot, respectively. Measurements were
performed in 50 mM Tris/HCl, pH 8.0,
and concentrations were used according to
Tab. 5.3. Obtained data points from inte-
grated Michaelis-Menten kinetics were fit-
ted according to Eq. 3.
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Measurements with the reference substrate resulted in a typical calorimetric curve (Fig. 6.4),
as it was expected for the direct continuous calorimetric assay: After injection of hQC
to the dipeptide a rapid increase in instrumental thermal power occurred. Negative dp
indicating that cyclization of N-terminal glutaminyl substrates is an exothermic reaction.
Afterwards, thermal power remained constant for several minutes (200–600 s), because
the reaction was proceeding at maximal rate (steady state conditions). Substrate deple-
tion caused a decrease in rate and the power returned to its initial baseline (600–2200
s). Integration of the released heat over time of the calorimetric progress curves gave a
∆H-value of 1.82 kcal/mole, which was in turn used for calculation of rate constants (see
chapter 5.2.3.1). The rate plotted as a function of the substrate concentration generated
a continuous kinetic curve. Determined macroscopic kinetic constants were compared
with the ones from the conventional spectroscopic coupled assay described in literature.
Macroscopic kinetic constants obtained via calorimetry (KM = 0.14 ± 0.008 mM and kcat
= 24.8 ± 0.13 s−1) were almost identical compared to the already published ones (KM =
0.14 ± 0.005 mM and kcat = 20.7 ± 0.20 s−1 [54]), which were determined spectroscop-
ically. Data comparison of kinetic parameters revealed that kinetic characterization by
calorimetry serves as an excellent alternative tool for measuring substrate preferency of
hQC. However, for determination of a reliable ∆H-value to calculate substrate turnover
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and concentration at a given time point different prerequisites must be fulfilled, which are
discussed in the following section (see chapter 6.2.4).
6.2.4 Verification of Applicability of the Continuous Calorimetric Assay
To characterize enzymatic reactions kinetically by calorimetry a trustworthy molar reac-
tion enthalpy (∆H) for further calculations is required. In order to obtain reliable high-
quality kinetic data of hQC with different N-terminal glutaminyl-/glutamyl substrates via
ITC, specific prerequisites need to be fulfilled. First, the measured enzymatic reaction
must be an irreversible chemical process, meaning that the change occurs only in one di-
rection and the process will be completed. The cyclization reaction catalyzed by hQC is
assumed to be an irreversible process, in which the substrate is completely converted into
product over time (Fig. 8.5 A) and no equilibrium is established. Secondly, to determine
an experimentally reliable enthalpy of the overall reaction the conversion of substrate into
product consists of one catalysis step rather than a mixture of multiple steps. Further-
more, the process of conversion should contain the highest energy release/consumption
rate. The fact that hQC catalyzes cyclization of N-terminal glutaminyl-/glutamyl sub-
strates in a single step might indicate an experimental reliable molar reaction enthalpy.
Thirdly, released/consumed heat should be independent of the enzyme and substrate con-
centration, if they are always used in the same ratio. In case of hQC the utilized molar
ratio of enzyme to substrate was 1:2000, resulting in nearly identical ∆H-values (Fig. 8.5
B). Fourthly, the released/consumed heat per mole substrate should be independent of the
used substrate concentration and should not deviate, which was shown for hQC (Fig. 8.5
C). Fifthly, binding of additional ligands or competitive inhibitors to the enzyme, re-
sulting in reduced maximal reaction velocity by interfering during catalysis, should only
release/consume heat marginally and thereby not influencing the overall reaction enthalpy.
This could also be exhibited for the hQC system (Fig. 8.5 D). At least, the probably most
important point, no product inhibition should occur, because this would distort the deter-
mined kinetic constant, especially the Michaelis-Menten constant. To show that product
inhibition is negligible for hQC, the molar reaction enthalpy ∆H was experimentally deter-
mined in a single measurement by measuring turnover of the dipeptide Gln-Gln catalyzed
by hQC at different product concentrations (Fig. 6.5 A). For this purpose, substrate was
titrated to the enzyme in the sample cell a number of times. After complete depletion
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of the substrate a new titration was started. With each titration step the concentration
of the formed product increased. Measurements showed curves with nearly identical, but
not perfect shapes and areas indicating a weak product inhibition. In order to further
elucidate that hQC is not affected by product inhibition, data was analyzed according to
Dixon [70] (Fig. 6.5 B) and by three-dimensional plotting (Fig. 8.6) to obtain the inhibitory
constant Ki. Binding of the product (Ki = 21.4 ± 3.1 mM) is 152-fold weaker compared
to substrate (KM = 0.14 ± 0.008 mM), concluding that product inhibition is negligi-
ble. Recapitulating the facts, the continuous calorimetric assay is a reliable alternative
tool compared to the spectroscopic coupled assay with the advantage to measure directly
the cyclization reaction of hQC. Furthermore, the benefit of this assay is to kinetically
characterize glutaminyl-, as well, glutamyl substrates.
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ΔH7 = 1.97 kcal/mole Ki = 21.4 ± 3.1 mM
Figure 6.5: Determination of molar reaction enthalpy after complete substrate conversion
in presence of different product concentrations. (A) Measurements were performed in 50 mM
Tris/HCl, pH 8.0, where 5 µl of 25 mM QQ were titrated into the sample cell containing 0.5 µM hQC.
With each titration step the product concentration increased continuously. Enthalpy for each titration step
is shown respectively. (B) Product concentration is plotted against the reciprocal turnover of different
substrate concentrations according to Dixon [70]. Data points were fitted according to a linear regression.
Inhibiton constant Ki was determined by calculating the points of intersection for each linear regression.
6.3 Kinetic Characterization of Physiologic and Pathophysiologic Substrates
After hQC was purified to almost homogeneity in sufficient amounts and a new direct
continuous enzymatic assay based on calorimetry was established, substrate specificity
experiments with glutaminyl-/glutamyl substrates could be performed. Therefore, dif-
ferent physiological substrates harboring an N-terminal glutamine, but varying in the
following amino acid sequence composition were kinetically characterized. Additionally,
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kinetic characterization of pathophysiological substrates, especially the amyloid-beta (Aß)
peptide, which harbors an N-terminal glutamic acid, were also characterized.
6.3.1 Catalytic Efficiency of N-terminal Glutaminyl Substrates in Dependence of the
pH
In general, acid-base catalysis is involved in a majority of enzymatic reactions. Many
amino acid side chains of catalytic sites within enzymes donate or accept protons, resulting
in activation of nucleophilic and electrophilic groups, thereby facilitating the catalyzed
reaction to proceed by stabilizing the charges in the transition state [89]. Functional
groups that participate in acid-base catalysis are for example the alpha-amino group of an
amino acid main chain or the carboxyl group of glutamic and aspartic acids. Hence, the
protonation state of functional groups are pH dependent, enzymatic activity is sensitive
to the pH level. To investigate the effect of pH on the catalytic efficiency of hQC in terms
of physiological substrates, pH dependency experiments under constant ionic strength [69]
were performed. In a further experiment for examination whether different protonation
states of functional groups of the substrate or the active site of hQC have effects on
catalysis, the determined macroscopic constant KM was used as a measure for comparison.
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Figure 6.6: Catalytic efficiencies of hQC
in dependence of the pH. Kinetic constants
were obtained employing the continuous calori-
metric assay. Measurements were performed in
0.05 M acetic acid, 0.05 M MES and 0.1 M Tris
at 30 ◦C utilizing the reference substrate Gln-
Gln (QQ). Data points were fitted according to
Eq. 18.
Catalytic efficiency experiments in dependence of the pH showed a relative narrow and
symmetric bell shaped curve with a maximum between 7.5 and 8.1 (Fig. 6.1). The de-
termined pKa-values were 7.4 ± 0.2 and 8.3 ± 0.2, respectively. In addition, plotting
turnover number against pH resulted in pKa-values of 6.6 ± 0.2 and 9.1 ± 0.2 (Fig. 8.8
A). Differences in the pKa-values of free enzyme (catalytic efficiency vs pH) and the
enzyme-substrate complex (turnover number vs pH) lead to the assumption that the cor-
responding functional groups are located in the active site of the enzyme [71]. In addition
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to this reversible change of the dissociation equilibrium, a pH change could also cause an ir-
reversible loss of enzyme activity through denaturation of the enzyme. The loss of enzyme
activity due to denaturation of the enzyme could be excluded in pH-titration experiments
in case of hQC by observing no changes in the secondary structure via CD-spectroscopy
(Fig. 8.8 B). However, this pH-dependent experimental results are in agreement with the
already published one for hQC (pKa1 = 7.2 and pKa2 = 8.5 [54]). Interestingly, the KM
values increased up to 8-fold in acidic or more alkaline pH values (Tab. 6.1), which might
indicate that substrate affinity of N-terminal glutamines gets decreased with changing
pH-values. One possible explanation could be that the formation of the enzyme-substrate
complex is dependent on the protonation state of the α-amino group of N-terminal glu-
taminyl substrates. The published value of pKa for the α-amino group of free glutamines
in solution is 9.1 [90], which indeed fits well with the obtained pH-optimum for hQC cat-
alyzing N-terminal glutamines. At pH 8.0, main species of the α-amino group should be
predominantly deprotonated, which could be a prerequisite for substrate binding. After
binding of the substrate, the α-amino group becomes nucleophilically activated for catal-
ysis by accepting a proton from the γ-carbonyl moiety of the glutamaic acid at position
201 [55]. This could identify the α-amino group of the substrate as an acid-base catalyst
in the glutaminyl cyclase reaction, which could play an important role in binding.
Table 6.1: Determined kinetic parameters for hQC catalyzing N-terminal glutaminyl sub-
strates in dependence of the pH. Measurements were performed in 0.05 M acetic acid, 0.05 M MES
and 0.1 M Tris at 30 ◦C. Data analysis was performed as previously described (see chapter 5.2.3.2) and
kinetic parameters were determined according to Eq. 3.
pH-value kcat [s−1] KM [mM] kcat/KM [s−1 mM−1]
5.5 7.57 ± 0.70 1.12 ± 0.16 6.74 ± 0.35
6.0 9.56 ± 2.88 0.56 ± 0.09 16.69 ± 2.72
6.5 14.38 ± 1.15 0.40 ± 0.04 35.21 ± 6.79
7.0 17.97 ± 2.71 0.22 ± 0.02 81.42 ± 19.90
7.5 20.65 ± 2.09 0.16 ± 0.01 128.22 ± 11.42
8.0 22.47 ± 0.13 0.14 ± 0.01 160.50 ± 11.90
8.5 18.47 ± 1.88 0.17 ± 0.02 105.64 ± 17.31
9.0 17.26 ± 0.15 0.41 ± 0.07 43.01 ± 7.23
9.5 15.18 ± 2.95 1.28 ± 0.09 10.49 ± 0.38
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6.3.2 Kinetic Characterization with Different Physiological Substrates Indicates
Importance of a Specific Amino Acid Pattern
In order to study the catalytic mechanism of hQC and its role in metabolism a set of dif-
ferent N-terminal glutaminyl substrates were kinetically characterized. Thus, a detailed
investigation of the impact of the nature of preliminary amino acids after the N-terminal
glutamine and the length of the substrates was performed by characterizing a number
of several specifically selected physiological truncated hormones. These hormones are
at physiological conditions typical substrates of hQC by modifying their N-terminal glu-
tamine post-translationally via an intramolecular cyclization reaction. For example, the
hormone Neurotensin consists of 13 amino acids [91] and plays an endocrine or paracrine
role in the regulation of fat metabolism. The Gonadotropin-releasing hormone (GnRH),
which is ten amino acids long, is responsible for secretion of luteinizing- and follicle-
stimulating hormones from the anterior pituitary [92]. OrexinA consists of 33 amino acids
and regulates the day/night cycle and its absence would cause permanent fatigue and
narcolepsy [93]. These hormones were selected for kinetic characterization via the calori-
metric activity assay and represent only a small number hormones which are modified
by hQC. However, all hormones differ in their amino acid sequence except for the N-
terminal glutamine. The selected hormones for kinetic characterization were C-terminally
truncated and consist only of the first five N-terminal amino acids of their native sequence.
Determined kinetic constants (Tab. 6.2) and calorimetric data (Fig. 8.7) are summarized,
respectively. As expected, the catalytic efficiency varies for each hormone. For instance,
Neurotensin and GnRH showed comparable turnover (kcat), but GnRH had a 3-fold in-
creased KM value, suggesting lower substrate affinity. Furthermore, this effect is even
more pronounced in case of OrexinA, in which the KM value is 5-fold increased compared
to Neurotensin. The main difference between these hormones is the attribute of the sub-
sequent amino acid after the N-terminal glutamine. In case of Neurotensin, an aliphatic
amino acid at the second amino acid position is present, whereas for GnRH it is a polar
amino acid. As recently published, substrates of hQC containing bulky and hydrophobic
residues at the second and third N-terminal amino acid position are preferably converted
[54], indicating hydrophobic interactions within or around the active site of the enzyme.
This was pointed by a lower KM value for substrates harboring hydrophobic and aromatic
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residues at the second and third N-terminal amino acid position, especially for phenylala-
nine, compared to non-hydrophobic residues. Crystal structures of hQC showed a presence
of several nonpolar amino acids guiding the entrance to the substrate binding pocket, for
instance Trp305 and Trp207 [20]. This observation increases the likelihood that hydropho-
bic interactions support the substrate binding. In addition, characterization of full length
hormones [54] resulted in a 7- to 16-fold increased catalytic efficiency compared to the
C-terminally truncated versions, caused by a 7- to 13-fold decreased KM value. Thus,
longer substrates seem to improve catalysis, especially substrate affinity. One possible
explanation could be secondary interactions between enzyme and substrate at the protein
surface of hQC, which in turn would increase binding affinity of the substrate.
In summary, one can conclude that the equilibrium between substrate association and
dissociation is extensively shifted to the enzyme substrate complex for longer physiolog-
ical substrates harboring bulky and hydrophobic amino acids at its second amino acid
positions.
Table 6.2: Determined kinetic parameters for hQC catalyzing N-terminal glu-
taminyl/glutamyl substrates. Measurements were performed in 50 mM Tris/HCl, pH 8.0, at 30 ◦C via
the calorimetric activity assay. Data analysis was performed as previously described (see chapter 5.2.3.2)









QQ 39.2 ± 0.04 24.8 ± 0.13 0,14 ± 0.01 233.5 ± 14.6
QFRH 108.7 ± 0.52 68.6 ± 0.32 0.27 ± 0.01 254.1 ± 29.6
EFRH A 0.051 ± 0.015 0.013 ± 0.004 0.15 ± 0.02 0.086 ± 0.026
Q-ßNA 32.0 ± 1.37 20.4 ± 0.87 0.12 ± 0.01 170.0 ± 20.6
Neurotensin1−5 B 66.1 ± 0.93 48.0 ± 1.41 0.24 ± 0.01 200.0 ± 8.3
GnRH1−5 B 77.4 ± 2.15 49.1 ± 0.66 0.69 ± 0.04 71.1 ± 4.6
OrexinA1−5 B 17.7 ± 0.10 11.6 ± 0.47 1.28 ± 0.05 9.1 ± 0.7
A) Measurements were performed in 30 mM Tris/HCl and 20 mM MES, pH 6.8
B) Amino acid sequence: QLYEN (Neurotensin); QHWSY (GnRH); QPLPD (OrexinA)
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6.3.3 Kinetic Characterization of the Pathophysiological Substrate Shows
Remarkably Decreased Catalytic Efficiency
Cyclization of N-terminal glutamyl substrates catalyzed by hQC is very important in terms
of neurodegenerative diseases, but poorly investigated to date. As already mentioned (see
chapter 4.4) this pathophysiological side reaction of hQC plays a major role in the modifi-
cation of Aß peptides, resulting in toxic depositions within the brain [94, 95]. Due to the
pyroglutamyl formation at the N-terminus of Aß peptides, these peptide species become
more resistant to proteolytic degradation by aminopeptidases. In addition, hydrophobicity
of modified Aß peptides are drastically increased [45], leading to aggregation and finally
to toxic depositions. In order to gain deeper insights into the reaction mechanism of hQC
catalyzing N-terminal glutamic acids and its kinetic parameters, the tetrapeptide EFRH
was selected. The tetrapeptide EFRH represents the first four amino acids of the Aß
peptide (Aß3−6). To compare conversion of N-terminal glutaminyl-/glutamyl substrates
kinetically, the glutamic acid was substituted against glutamine in order to obtain the
tetrapeptide QFRH.
In former studies it was shown by a discontinuous assay utilizing high-performance liquid
chromatography (HPLC) that the cyclization reaction of the N-terminal glutamic acid of
EFRH catalyzed by hQC proceeds with a turnover number of 2.2 × 10−4 s−1 [5]. Accord-
ingly to these results it was estimated that cyclization of N-terminal glutamyl substrates is
10000-fold slower compared to N-terminal glutaminyl substrates. However, disadvantages
using a discontinuous assay are that the shape of the progress curve is not readily apparent,
as well as timing and volume inaccuracies might be introduced. Therefore, a first kinetic
characterization of N-terminal glutamic acids catalyzed by hQC utilizing the continuous
calorimetric assay (Fig. 6.7) was performed. Interestingly, calorimetric measurements with
hQC and EFRH performed under alkaline conditions (pH 8.0), in which the enzyme has
its pH optimum for cyclization of N-terminal glutaminyl substrates, no heat release was
detected. However, switching to weak acidic conditions (pH 6.8) heat release could be de-
tected, which resulted in a typical progress curve suggesting turnover of EFRH. Obtained
kinetic parameters showed that turnover (kcat) of EFRH is ∼5200-fold slower compared to
QFRH (Tab. 6.2), while the (KM) value is nearly identical. Thus, catalysis of N-terminal
glutamyl substrates seems dependent on the degree of the protonation state of the en-
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zyme or substrate. This theory is supported by pH dependency experiments of papaya
QC converting Glu-ßNA utilizing a discontinuous assay [3]. It was shown that papaya QC
exhibits a pH optimum of 6.0 for N-terminal glutamyl substrates, resulting in pKa values
of 4.2 for the γ-carboxylic moiety and 7.5 for the α-amino group. Accordingly, oxygens
of the γ-carboxylic moiety of the N-terminal glutamic acid are predominantly bivalently
charged around neutral and alkaline pH and thereby exercising no electrophilic carbonyl
activity (Fig. 6.8). Hence, switching to acidic conditions the γ-carboxylic moiety becomes
protonated and the electrophilic carbonyl carbon gets nucleophilically attacked by the
α-amino group. Thus, protonation of the γ-carboxylic moiety of N-terminally glutamic
acids is a prerequisite for conversion into pyroglutamic acid, which can only be achieved
under acidic conditions.
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Figure 6.7: Cyclization reaction of N-terminal glutaminyl-/glutamyl substrates catalyzed
by hQC. (A) Calorimetric progress curves of turnover of the tetrapeptide QFRH and (B) of EFRH
(Aß3−6) (upper plot) with the corresponding Michaelis-Menten plot (lower plot). Measurements were
performed in 50 mM Tris-HCl, pH 8.0, in case of QFRH and 30 mM Tris-HCl, 20 mM MES, pH 6.8, in
case of EFRH. In case of EFRH, measurements were performed at alkaline and acidic pH conditions (pH
8.0 and 6.8). The measurement at alkaline pH conditions showed no detectable heat release (inset), while
at acidic pH conditions it resulted in a typical calorimetric progress curve. This observation indicates
differences in the protonation states of the substrate or functional groups within the active site of hQC for
catalysis of N-terminal glutamyl substrates. Data analysis of calorimetric data was performed as previously
described (see chapter 5.2.3.2). Obtained data points were fitted according to Eq. 3 and determined kinetic
constants are shown in the respective plots.
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Figure 6.8: Scheme of protonation states for N-terminal glutaminyl/glutamyl substrates.
In both cases an uncharged N-terminal glutaminyl/glutamyl substrate is necessary for the cyclization
reaction, which is achieved at different pH values for each substrate. The arrow indicates the nucleophilic
attack of the α-amino group onto the electrophilic γ-carbon atom.
6.3.4 Cyclization Reaction of N-Terminal Glutaminyl/Glutamyl Peptides are
Spatially Separated
As previously described (see chapter 6.3.3), conversion of N-terminal glutamines can only
occur at alkaline pH conditions, whereas for N-terminal glutamic acids an acidic pH value
is favored. As different requirements are necessary for catalysis, the question arise how the
physiological and pathophysiological cyclization reaction would be feasible within a cell.
The glutaminyl cyclases of vertebrates, whose sequence apparently is highly conserved
[11], are transported by a signal sequence into the endoplasmic reticulum (ER). First
immunological studies for intracellular localization of the enzyme from bovine pituitary
have shown that the protein is located after passage of the Golgi apparatus in secretory
vesicles near the cell membrane [28]. Probably, upon the reception of an extracellular
signal by the cell, glutaminyl cyclase is secreted into the extracellular space. Secretion of
glutaminyl cyclase into the extracellular space is thereby mediated and controlled by the
regulated secretory pathway. The pH of the extracellular space at physiological conditions
is kept at weak alkaline pH conditions (pH 7.1 - 7.5 [96]), which consequently serves as
the perfect environment for modification of small peptides harboring an N-terminal glu-
tamine (Tab. 6.1). Interestingly, it was shown that modified Aß peptides harbouring an
N-terminal pyroglutamyl residue and glutaminyl cyclase undergo an activity-dependent,
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regulated co-secretion from secretory vesicles, indicating conversion of the N-terminal glu-
tamic acid into pyroglutamic acid within the secretory vesicles [97]. Due to the fact that
within secretory vesicles an acidic environment predominantly exists, it would perfectly
match with the findings of the performed continuous calorimetric activity assay. Cy-
clization reaction of N-terminal glutaminyl/glutamyl substrates might occur at different
localizations. Modification of N-terminal glutamines probably takes place outside the cell,













Figure 6.9: Scheme of regulated exocytosis and cyclization reaction localization of N-
terminal glutaminyl/glutamyl substrates catalyzed by hQC. The enzyme is transported from the
endoplasmic reticulum (ER) into the Golgi apparatus, in which the enzyme is packaged into secretory
vesicles for transport to the cell membrane. At this stage hQC is co-localized with the unmodified Aß
peptide species within the secretory vesicles. Due to the acidic pH within the vesicle the Aß peptide
can be modified by hQC. After obtaining an external stimulus hQC is subsequently secreted into the
extracellular space. Currently after secretion, hQC is co-localized with hormones and neuropeptides in
the extracellular space, in which alkaline pH conditions exist. Under these conditions the physiological
reaction of hQC can occur.
6.3.5 Summary
Kinetic characterization of hQC with the continuous calorimetric activity assay showed dif-
ferences in the catalytic efficiencies for N-terminal glutaminyl/glutamyl substrates. More-
over, specific amino acid composition and an extended sequence length of the substrate
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seems to increase turnover and affinity. In addition, cyclization reaction of N-terminal
glutamines is preferred at alkaline conditions, whereas for N-terminal glutamic acids an
acidic environment is a prerequisite. Thereby it might be concluded that the protonation
state of both substrates seems to play an important role in terms of binding and catalysis.
In theory, necessary environmental pH conditions for both reactions (physiological and
pathophysiological) of hQC are given within an organism.
6.4 The Role of the Metal Ion in Terms of Stability and Catalysis
After demonstrating that N-terminal glutamines are converted with a higher efficiency
compared to glutamic acids, different methods were applied in order to get detailed in-
formation about the role of the zinc ion in hQC in terms of stability and catalysis. A
closer look at the environment of the metal ion and its coordination geometry might help
to elucidate the mechanism of the reaction catalyzed by hQC. Elucidation of the reaction
mechanism might therefore explain the difference in catalytic efficiencies.
First, to gain deeper insights into the electronic environment and thereby into the co-
ordination geometry of the catalytic active metal ion in absence and presence of several
components including substrate, the non-spectroscopically active zinc ion within the ac-
tive site of hQC was substituted against spectroscopically active cobalt. It was already
demonstrated in 1958 that cobalt is a spectroscopically active surrogate for zinc [98]. How-
ever, the distorted electronically environment of the enzyme-bound cobalt monitored by a
change in the UV/Vis spectra is a way to detect and visualize metal interaction with dif-
ferent ligands. Accordingly, various spectroscopic methods for analysis of the coordination
geometry are available, including UV/Vis and stopped-flow spectroscopy, as well electron
paramagnetic resonance (EPR) spectroscopy. For this purpose rapid freeze quench EPR
data from Alexander Piontek of the cobalt substituted isoenzyme glutaminyl cyclase from
Drosophila-melanogaster (Co(II)-isoDromeQC) in resting state and in complex N-terminal
glutaminyl/glutamyl substrates [99] were additionally consulted and compared with ob-
tained data from different applied methods for hQC. The isoDromeQC catalyzes the same
cyclization reaction of N-terminal glutamines compared to hQC and both enzymes share
an identical active site architecture (Fig. 8.10) due to their evolutionary orign. Therefore,
obtained results from rapid freeze quench EPR experiments with isoDromeQC can be
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compared with obtained results from hQC.
Furthermore, to gather information about the structural and mechanistic features of hQC,
especially coordination geometry of the zinc ion within the active site, crystal structures
of hQC in resting state, in complex with N-terminal glutaminyl/glutamyl substrates and
with the resulting product were generated. Data collection and refinement statistics for
each crystal structure are summarized in Tab. 8.3.
6.4.1 Substitution of Zinc Against Cobalt Resulted in a Spectroscopically Active
Glutaminyl Cyclase
For spectroscopic measurements the zinc ion was substituted against cobalt within the ac-
tive site to obtain spectroscopically active hQC (Co(II)-hQC). Therefore, the catalytic zinc
ion in the active site of hQC was removed by a dialysis step against 1,10-phenanthroline and
EDTA to generate the apo-form of the enzyme. The metal chelator 1,10-phenanthroline
is known to form complexes with divalent metal ions. After generation of the apoenzyme,
both metal chelators were removed by a following dialysis step with Chelex-100 treated
buffers. Chelex-100 is a styrene-divinylbenzene co-polymer containing iminodiacetic acid
groups and has thereby the ability to bind free transitions metal ions in solution.
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Figure 6.10: Absorption of Co(II)-hQC in dependency of the cobalt concentration. (A)
Difference spectra of Co(II)-hQC. 40 µM of the prepared apoenzyme were stepwise saturated with cobalt
chloride to a final concentration of 140 µM. Measurements were performed in Chelex-100 treated 50 mM
Tris/HCl, pH 8.0, buffer. Depicted spectra are buffer, cobalt chloride and protein corrected. (B) Determi-
nation of the dissociation constant by plotting obtained absorption intensities against cobalt concentration.
Data points were fitted according to Eq. 16.
In former studies it was shown that titration of different transition metals, for instance
iron or nickel, did not result in a reactivation of the enzyme [100]. However, reconstitution
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of the active site with cobalt reactivated the apoenzyme [101]. Therefore, spectroscopic
active cobalt was chosen for further experiments. Coordinated transition metal centers
with incomplete filled d-orbitals, e.g. cobalt, can be excited by light. Transitions of
electrons from low energy d-orbitals to high energy d-orbitals (’d-d’ transitions) due to
absorption of light of a certain wavelength should result in a specific and distinct absorption
pattern. Excited and coordinated cobalt absorbs light at three different wavelength and
should show consequently three characteristic peaks [102]. As expected, titration of cobalt
ions to the apoenzyme showed characteristic absorption signals at 520, 550 and 580 nm,
which became more pronounced with increasing cobalt concentration until the enzyme was
completely saturated (Fig. 6.10 A). At a molar ratio of 1 : 3 (hQC : cobalt) the maximum
signal was obtained, suggesting complete saturation of the enzyme. Thus, cobalt was
successfully incorporated within the active site of hQC.
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Figure 6.11: Time-resolved absorption spectra and activity assay of Co(II)-hQC. All mea-
surements were performed in 50 mM Tris/HCl, pH 8.0 and used buffer was Chelex-100 treated before
measurements to remove free transition metals. (A) Absorption spectra of Co(II)-hQC measured at de-
fined time points. 40 µM apoenzyme was supplemented with 144 µM and spectra were recorded step
wise in a time range from 0 - 60 minutes. Depicted spectra are buffer, cobalt and protein corrected. (B)
Progress curves of Zn(II)-hQC, Co(II)-hQC and the apoenzyme measured with the spectroscopic coupled
assay. Turnover number for each enzyme form is depicted respectively.
To test if the coordinated cobalt within the active site of hQC forms a stable complex,
40 µM apoenzyme was supplemented with 144 µM cobalt chloride and absorption spectra
were recorded at different time points (Fig. 6.11 A). Decreasing absorption signal intensi-
ties of the characteristic absorption bands of Co(II)-hQC could not be observed, indicating
a stable complexation of the cobalt within the active site of hQC. In addition, after four
minutes the dissociation equilibrium towards complex formation was nearly completed.
Besides a stable complex formation the substituted cobalt should show comparable activ-
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ity compared to zinc. Therefore, enzyme activity of hQC and Co(II)-hQC were measured
with the spectroscopic coupled assay and compared to each other (Fig. 6.11 B). Addition-
ally, the apoenzyme was also measured as a control. As expected, hQC and Co(II)-hQC
showed nearly the same catalytic activity, implying full reactivation of the apoenzyme by
cobalt. The apoenzyme showed almost no catalytic activity and had only 0.01 % residual
activity compared to the holoenzyme, verifying successful removal of the catalytic zinc ion
from the active site of hQC. In summary, replacement of the diamagnetic zinc against the
chromophoric and paramagnetic cobalt provides a powerful spectral probe of the active
site environment while maintaining enzymatic activity.
6.4.2 Incorporated Cobalt Within the Active Site of Human Glutaminyl Cyclase
Shows a Moderate Tetrahedrally Coordination
In order to obtain information about the stability of the binding of cobalt within the
active site of hQC the equilibrium dissociation constant (Kd) was determined. The Kd
value describes the propensity of a larger macromolecule to dissociate reversibly into its
smaller components. Accordingly, a lower Kd value would mean that the equilibrium
is shifted towards the complex formation, meaning in general stronger and tighter bind-
ing of the components to each other. Complexation of cobalt and hQC to Co(II)-hQC
is a simple bi-molecular association with a stoichiometry of 1 : 1. For Kd determina-
tion multiple standardized reconstitution activity reactions were performed (Fig. 8.9) and
additionally cobalt was stepwise titrated to apoenzyme (Fig. 6.10 A). The apparent Kd
value was determined by plotting turnover number against cobalt concentration (Fig. 6.10
B). Fitted data points resulted in an apparent Kd = 28.7 ± 3.9 µM. As published pre-
viously, a computational designed high-affinity Zn(II)-binding site with a predetermined
tetrahedral geometry and alternating zinc binding motifs resulted in Kd values in the
nanomolar to micromolar range [103]. Substitution of the tetrahedral coordinated zinc
against cobalt within the high-affinity Zn(II)-binding site showed 2 - 3 orders of magni-
tude weaker binding. Kd values of 2 - 4 µM were defined as strong binding, while 150 - 250
µM were classified as weak binding [104]. Therefore, the experimentally determined Kd
value for cobalt towards hQC perfectly matches between both classifications and binding
can be considered as moderate. Presumably, zinc binding within the active site of hQC
is stronger compared to cobalt due to the presence of specific amino acids in the first
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coordination sphere. It was shown that cysteine residues in the first coordination sphere
are stronger determinants for cobalt binding compared to histidine residues, for example
[104]. The negative charge on the thiolate of the cysteine residue is known to provide a
stronger binding contribution.
6.4.3 Coordinated Zinc Ion Plays a Role in Stabilization of the Overall Structure of
Human Glutaminyl Cyclase
A wide variety of metal ions are found within the human body. Many of these divalent
metal ions form complexes with proteins, in which they possess various functions. One of
these metals is zinc, which is an essential component of many enzymes involved in virtually
all aspects of metabolism. The roles of zinc in enzymes have been implicated in inter-
molecular interactions with other macromolecules such as protein and DNA, polypeptide
folding, conformational stability, substrate binding and catalysis [105, 106]. As described
previously, human glutaminyl cyclase was already identified as a metalloenzyme harbor-
ing a catalytic active zinc ion within its active site [23]. Typically, catalytic zinc ions are
coordinated by three amino acids, which are in case of hQC Asp159, Glu202 and His330
(see chapter 6.4.4). Tridentate combinations of histidine, cysteine, glutamic and aspartic
acid side chains have been described to bind strongly to zinc ions and a characteristic of
catalytic function is to provide a free coordination site for water or substrates [107]. To
investigate if the zinc ion plays a role in conformational stability, thermal unfolding curves
of the apoenzyme, hQC and Co(II)-hQC were measured.
All thermal unfolding curves showed a transition with a sigmoidal shape (Fig. 6.2 B and
6.12). After thermal unfolding a CD spectrum of each enzyme form was measured to
ensure complete denaturation (Fig. 8.11). As already assumed, hQC harboring zinc in its
active site showed the highest thermal stability (Tm = 325 ± 4.2 K) compared to other
enzyme forms, whereas the apoenzyme exhibited the lowest thermal stability (Tm = 312 ±
3.5 K). These findings pointing to a structural destabilization of the enzyme as a result of
the absence of a metal ion. Interestingly, reconstitution of hQC with cobalt did not result
in same thermostability for the enzyme compared to zinc (Tm = 318 ± 4.1 K). Cobalt
substitution considerably lowered the thermostability of the enzyme without affecting the
overall conformation, suggesting that the prosthetic zinc is affecting both conformational
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stability as well as catalysis. Probably, the zinc coordinating residues of hQC are provided
from three different loop regions of the enzyme. Binding of the zinc within the active site
by the zinc coordinating residues could increase the stability of the loops and thereby the
overall structure. Coordination of cobalt is not as strong as the coordination of zinc (see
chapter 6.4.2), explaining the lower thermostability of Co(II)-hQC.
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Figure 6.12: Thermal unfolding of Co(II)-hQC and apoenzyme. Thermal unfolding curves
were recorded by the change of the far-UV CD signal at 196 nm. Measurements were performed in 10
mM Tris/HCl, pH 8.0 with a protein concentration of 0.1 mg/ml. Thermal unfolding curve of (A) the
apoenzyme and (B) Co(II)-hQC are shown respectively. Data points were fitted according to Eq. 18.
6.4.4 Zinc Ion Within the Active Site of hQC in Resting State Shows a Tetrahedral
Coordination
To elucidate the coordination geometry of the coordinated zinc within the active site of
hQC in resting state different methods were applied. As already described previously,
catalytic zinc ions of metalloenzymes are tetrahedrally coordinated by three residues and
one water molecule, which acts as a place holder and gets displaced in the presence of
substrate [107]. To verify if the zinc ion within the active site comply the typical struc-
tural conditions for a catalytic metal ion, X-ray crystallography was attempted for hQC
in resting state to get insights into the tertiary structure of hQC. The main focus was set
on the active site of hQC with its coordinated metal ion.
The enzyme crystallized within the space group R32 and crystals diffracted with a resolu-
tion of 2.14 Å. The asymmetric unit comprised two autonomic molecules, which stands in
agreement with the obtained analytical ultracentrifugation experiments (see chapter 6.1).
It was shown via analytical ultracentrifugation that hQC consisted as a monomer in solu-
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tion. Both molecules in the asymmetric unit were identical in their overall structure. The
monomeric globular structure with dimensions of 49 x 51 x 41 Å3 revealed a mixed α/β
fold with an open-sandwich topology. The hydrophobic core of the enzyme consists of a
central twisted six-stranded β-sheet, formed by two antiparallel and four parallel strands.
This central six-stranded β-sheet is encircled by six and two α-helices on opposite sides.
Hence, the overall structure of hQC perfectly matches with the already published crystal
structure of hQC in resting state [20].
Figure 6.13: Overview of the overall crystal structure of hQC in resting state with a detailed
side view of the active site. Secondary structures of hQC are presented in cartoon style, while the
protein surface with its electrostatic potentials is indicated transparently. Red regions indicating negatively
charged regions, whereas blue regions are positively charged. Zinc ion is represented as a black sphere. The
active site is located at the protein surface of the enzyme, as indicated in the enlargement. Hydrophobic
pocket is represented in transparent gray. Important residues are depicted and named respectively, while
zinc coordinating residues are highlighted in blue. Coordinated water molecule is shown as a red sphere.
Dashed lines indicate the coordination bonds with the corresponding distances in angstroms. Resolution
= 2.14 Å, R-work = 15.7 % and R-free = 19.7 %
A detailed view into the hydrophobic active site pocket of hQC revealed that the metal ion
is tetrahedrally coordinated (Fig. 6.13). It is located in a cavity at the protein surface with
a depth of approximately 8 Å, while the entrance is guided by two hydrophobic residues,
namely Trp207 and Trp329. Furthermore, the metal ion is coordinated by an imidazole
group (His330) and two γ-carboxylate moieties (Asp159 and Glu202). As expected for
catalytic zinc ions, the fourth coordination site is occupied by a water molecule. Coordi-
nation bond distances and angles for each atom of the tetrahedral complex are summarized
in Tab. 8.1 and Tab. 8.2, respectively. Statistical data bank analysis of zinc coordinating
metalloenzymes by X-ray crystallography and nuclear magnetic resonance spectroscopy
revealed common distances for specific first coordination sphere residues [108]. A Typical
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coordination bond length between a zinc ion and an aspartate residue is 2.10 ± 0.24 Å,
for a glutamic acid residue 1.83 ± 0.16 Å, 2.09 ± 0.14 Å for a histidine residue and in
case of a water molecule 2.18 ± 0.03 Å. This is in agreement with the observed bond
distances between the zinc ion and the corresponding coordinating residues in the crystal
structure of hQC in resting state. In addition, angles differ marginally compared to an
ideal symmetrical tetrahedron with perfect angles of 109.5◦. Thus, obtained UV/Vis dif-
ference spectra of Co(II)-hQC in resting state with maxima at 520, 550 and 580 nm can
be assigned as a typical tetrahedral coordination (Fig. 6.10 A).
Besides the first coordination sphere residues His330, Glu202 and Asp159 are equally
important residues in the second coordination sphere, namely Glu201, Asp248 and Asp305.
The acidic residues are pointing to each other and forming a hydrogen bond network, which
was shown to be crucial for catalysis. Site-directed mutagenesis experiments showed a
drastically loss of activity by the substitution of only one of the hydrogen bond network
forming residues in the active site [55]. This effect can be explained by the interruption of
the hydrogen bond network, in which the enzyme loses the capability to transfer a proton
onto the leaving group of the tetrahedral reaction intermediate. In summary, the zinc ion
shows all characteristics to be a catalytic metal ion [107] with nearly perfect bond distances
and angles and with a conserved hydrogen bond network in its second coordination sphere.
6.4.5 Monodental Binding of N-terminal Glutaminyl Substrates Results in a
Tetrahedral Coordination
To elucidate the role of the metal ion and its coordination geometry in terms of catalysis
for the physiological and pathophysiological reaction, crystal structures of hQC in complex
with N-terminal glutaminyl/glutamyl substrates were generated. In addition, stopped flow
UV/Vis spectroscopy experiments were performed. The tetrapeptides QFRH (glutaminyl
substrate) and EFRH (glutamyl substrate, Aß3−6) were utilized as substrates. This chap-
ter describes the coordination geometry of the catalytic zinc in presence of the N-terminal
glutaminyl substrate. As mentioned in the introduction the N-terminal glutaminyl cycliza-
tion reaction correlates to the physiologic function of hQC. The physiological reference
peptide of the Aß3−6 peptide QFRH exhibited in the kinetic characterization experiments
the highest turnover and catalytic efficiency in the continuous calorimetric activity assay
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compared to the other physiological substrates (Tab. 6.2). This observed effect proba-
bly results from the amino acid residue composition at the N-terminal second and third
amino acid position of the tetrapeptide. As already discussed previously, bulky hydropho-
bic amino acids, especially phenylalanine, increase substrate affinity. For examination of
the coordination geometry of the catalytic zinc ion by binding of physiological substrates
and its influence in catalysis, the tetrapeptide QFRH was always utilized in all experi-
ments and served as a representative for physiological substrates.
To get first insights into the coordination geometry of the substrate-metal complex in
Co(II)-hQC, stopped flow UV/Vis spectroscopy was performed. In order to monitor time-
dependent spectroscopic changes at different wavelengths simultaneously, a photo diode
array detector was used. As expected, upon rapid mixing of Co(II)-hQC with the tetrapep-
tide QFRH strong changes in the absorption bands, especially at 525 nm and 555 nm could
be observed (Fig. 6.14). Obtained stopped flow UV/Vis absorption spectra were not cor-
rected from spectral interferences of free cobalt ions in solution. This is probably the
reason why the obtained difference spectra distinguishes slightly from the UV/Vis differ-
ence spectra of Co(II)-hQC in resting state (Fig. 6.10 A), particularly in the 480 - 530 nm
range. The intensity of the absorption signal increased over time after rapid mixing of both
reactants. This observation might indicate that substrate molecules bind to the cobalt ion
and form the Michaelis-Menten complex followed by the irreversible cyclization reaction.
After 50 s the absorption signal started to lose intensity. At this time point the enzyme is
apparently getting less saturated due to substrate turnover. The substrate was completely
consumed between 50 and 100 s, which correlates with rough estimations based on the
time-dependent depletion of QFRH catalyzed by hQC monitored in the continuous calori-
metric activity assay (Fig. 6.7 A). However, the absorption signal did not went back to its
initial state after complete substrate depletion. A possible explanation might be that the
resulted product also coordinates to the metal ion. Since stopped flow UV/Vis absorption
spectra of Co(II)-hQC in resting state and in complex with the tetrapeptide QFRH showed
same absorption band characteristics, it might indicate that the hQC-substrate complex is
also tetrahedrally coordinated. This idea is supported by EPR experiments with Co(II)-
isoDromeQC (data from Alexander Piontek) [99]. In rapid freeze quench EPR experiments
Co(II)-isoDromeQC were mixed together with QFRH and rapidly freeze quenched after
73
6 RESULTS AND DISCUSSION
20 ms to fix the state of bound substrate towards the metal ion. Thereby, differences in
the cobalt coordination sphere induced by binding of the N-terminal glutaminyl substrate
were analyzed. EPR spectra showed a shift in the binding of QFRH to the lower magnetic
field from 1038 G (resting state) to 1024 G (enzyme substrate complex) (Fig. 6.18). Band
width of the resonance signal is narrowed and did not differ from Co(II)-isoDromeQC in
resting state, indicating a four-fold coordination. In summary, these results support the
idea of a tetrahedral coordinated metal ion in presence of physiological substrates.
Figure 6.14: Time resolved UV/Vis ab-
sorption spectra of Co(II)-hQC while cat-
alyzing the tetrapeptide QFRH. For mea-
surements a final concentration of 109 µMCo(II)-
hQC and 8 mM QFRH after mixing was uti-
lized. Arrows indicating the change of absorption
over time. Scheme of the coordination geometry
should elucidate how binding of N-terminal glu-
taminyl substrates to the originally zinc might
look like. Measurements were performed in 50
mM Tris/HCl, pH 8.0, at 10 ◦C. Used buffer was
Chelex-100 treated before measurements. De-
picted spectra are buffer and protein corrected. wavelength [nm]
























To confirm obtained results from stopped flow UV/Vis spectroscopy a detailed structural
view into the active site of hQC in complex with the N-terminal glutaminyl substrate was
applied. Crystallization attempts with QFRH and hQC were successfully and resulted
in analyzable data. However, only the N-terminal glutamine of the tetrapeptide QFRH
could be modeled into the corresponding mFo-DFc electron density map, whereas the
other amino acids had no defined electron density and were omitted. High flexibility of
the hydrophobic tail of the tetrapeptide, which is directly exposed towards the solvent,
is probably the reason for the missing signal. As expected, the N-terminal glutamine
of the tetrapeptide bound monodentally to the catalytic zinc ion, resulted in a tetrahe-
drally coordination geometry of the metal ion. This observation is supported by data from
stopped flow UV/Vis and EPR spectroscopy experiments with Co(II)-hQC and Co(II)-
isoDromeQC. The enzyme-substrate complex showed a coordinative bond lengths of 2.10
Å between the zinc ion and the γ-oxygen atom of the side chain of the glutamine. It was
published that a coordinative bond between a zinc ion and an oxygen atom should have
a distance of 2.20 ± 0.13 Å [108]. Therefore, the coordinative bond length between the
catalytic zinc of hQC and the γ-oxygen of the substrate in the crystal structure is slightly
shortened, but still acceptable. Coordination bond lengths and angles for the coordinating
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residues, which are summarized in Tab. 8.1 and Tab. 8.2, respectively, showed no remark-
ably differences compared to the resting state structure of hQC. Statements of additional
interactions between the substrate and active side residue like hydrogen bonds could not
been made due to the missing residues of the tetrapeptide in the crystal structure. In
summary, crystal structure of hQC in complex with the tetrapeptide QFRH confirmed ob-
servations made in stopped flow UV/Vis spectroscopy with Co(II)-hQC and freeze quench
EPR experiments with Co(II)-isoDromeQC. N-terminal glutaminyl substrates bind mon-
odentally to the catalytic zinc ion, which results in a tetrahedral coordination geometry
for the central metal ion.
A B
Figure 6.15: Crystal structure of hQC in complex with the tetrapeptide QFRH. (A) Side
view of the active site of hQC with the coordinated substrate QFRH. Active site residues are shown in grey
and named respectively (blue = coordinating residues, black = active site residues), while the substrate
is colored yellow. The hydrophobic pocket is indicated in transparent gray, in which the coordinated zinc
(black sphere) is located at the bottom of the pocket. Dashed lines are indicating coordinating bonds
with the corresponding distance in Å. (B) Front view of the active site with the corresponding 2mFo-DFc
electron density map with a sigma contour level of 1.0 σ. Scheme in the upper right corner should indicate
coordination of the metal ion. Resolution = 1.90 Å, R-work = 17.9 % and R-free = 21.5 %
6.4.6 The Cyclization Product of N-terminal Glutaminyl/Glutamyl Substrates Binds
monodentally to the Catalytic Zinc Ion
As already discussed in the stopped flow UV/Vis spectroscopy experiments of Co(II)-
hQC catalyzing the cyclization reaction of the N-terminal glutamine of the tetrapeptide
QFRH, the resulting pyroglutamyl product (pEFRH) could possibly occupy the fourth
coordination site of the catalytic zinc ion (see chapter 6.4.5). The absorption band did
not return back into its initial state after the substrate was completely converted into
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product, indicating coordination of the product towards the metal ion. Additionally, band
characteristics were nearly identical compared to the spectrum of the enzyme in resting
state, suggesting a monodental binding of the product. This theory is supported by freeze
quench EPR experiments with the Co(II)-isoDromeQC and the product pEFRH, in which
the spectrum showed a narrow peak at 1017 G similar to the measured EPR spectra of the
enzyme in resting state and in complex with QFRH (Fig. 6.18). These observations might
indicate that the formed product binds monodentally to the catalytic zinc ion, resulting
in an enzyme-product metal complex with a tetrahedral coordination geometry.
A B
Figure 6.16: Crystal structure of hQC in complex with the product pEFRH. (A) Side view
of the active site of hQC with the coordinated product pEFRH. Active site residues are shown in grey
and named respectively (blue = coordinating residues, black = active site residues), while the product
is coloured yellow. The hydrophobic pocket is indicated in transparent gray, where the coordinated zinc
(black sphere) is located at the bottom of the pocket. Dashed lines are indicating coordinating bonds
with the corresponding distance in Å. (B) Front view of the active site with the corresponding 2mFo-DFc
electron density map at 1.0 σ. Scheme in the upper right corner should indicate coordination of the metal
ion. Resolution = 1.88 Å, R-work = 15.3 % and R-free = 17.8 %
To gather information if the product forms a coordinative bond with the zinc ion within
the active site, which would typically results in a tetrahedron, crystal structures of hQC
in complex with pEFRH were applied. Again, crystallization attempts were successfully
and analyzable data of hQC in complex with pEFRH were achieved. Analysis of the
active site of the crystal structure of hQC in complex with pEFRH showed a defined
electron density for the N-terminal pyroglutamic acid and the adjacent phenylalanine,
allowing to model both residues in the corresponding mFo-DFc electron density map.
As expected, the crystal structure confirmed coordination of the product at the fourth
coordination site of the catalytic zinc ion (Fig. 6.16). The keto-oxygen of the N-terminal
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pyroglutamic acid displaced the water molecule and occupied the fourth coordination site,
thereby maintaining the tetrahedrally coordinated character of the zinc. Bond lengths for
each coordinating residue and corresponding angles of the tetrahedron are summarized in
Tab. 8.1 and Tab. 8.2, respectively. Structural data bank analysis of X-ray crystallography
and nuclear magnetic resonance spectroscopy of zinc coordinating ligands showed that a
zinc-oxygen bond distance should be 2.20 ± 0.14 Å [108]. Thus, the bond length between
the keto-oxygen of the N-terminal pyroglutamic acid and zinc (2.03 Å ) seems to be
shortened. In addition to the coordination bond a potential hydrogen bond candidate
was found, which could be formed between Phe2/N of the product and Gln304/O of the
enzyme. This hydrogen bond might stabilize the hydrophobic tail of the product and makes
it more rigid, which could explain the observed electron density of the phenylalanine. In
conclusion, the resulted product after the N-terminal cyclization reaction of N-terminal
glutaminyl/glutamyl substrates is able to coordinate to the catalytic zinc ion and thereby
maintaining the tetrahedral coordination geometry.
6.4.7 Coordination of the N-terminal Glutamyl Substrate Revealed a Carboxylate
Shift
After demonstrating the tetrahedral coordination geometry of the metal ion in presence
of N-terminal glutaminyl substrates, different experiments were applied to elucidate the
binding mode of N-terminal glutamyl substrates. Cyclization of N-terminal glutamic acids
correlates to the pathophysiologic function of hQC, which only occurs at the Aß pep-
tide species after proteolytic processing of the amyloid precursor protein (APP) with β-
and γ-secretase. After proteolytic cleavage the Aß peptide harbors a glutamic acid at
its first N-terminal amino acid position. In kinetic studies it was shown that turnover of
pathophysiological substrates was drastically reduced compared to physiological substrates
(Fig. 6.7). To investigate if the coordination geometry of N-terminal glutamyl substrates
differ from the N-terminal glutaminyl substrates (QFRH), the tetrapeptide EFRH was
utilized for all experiments. A deviation of the standard tetrahedral coordination geom-
etry would be able to influence catalysis and might explain the decelerated turnover of
N-terminal glutamyl substrates.
To verify this theory stopped flow UV/Vis absorption spectroscopy with Co(II)-hQC in
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Figure 6.17: Time resolved UV/Vis absorption spectra of Co(II)-hQC after mixing with
the tetrapeptide EFRH. For measurements a final concentration of 102 µM Co(II)-hQC and 1 mM
EFRH after mixing were utilized. Arrows indicating the change of absorption over time. Scheme of the
coordination geometry should elucidate how binding of N-terminal glutamyl substrates to the originally
zinc might look like. Used buffers were Chelex-100 treated before measurements. Depicted spectra are
buffer and protein corrected. (A) Time resolved UV/Vis absorption spectra at alkaline pH conditions.
Measurements were performed in 50 mM Tris/HCl, pH 8.0, at 10 ◦C. (B) Time resolved UV/Vis absorption
spectra at acidic pH conditions. Measurements were performed in 30 mM Tris/HCl and 20 mM MES, pH
6.8, at 30 ◦C.
presence of the tetrapeptide EFRH was performed. Kinetic studies of hQC catalyzing the
tetrapeptide EFRH utilizing the continuous calorimetric activity assay showed detectable
heat release at acidic pH conditions, but not at alkaline pH values (Fig. 6.7). Therefore,
measurements were performed at acidic (pH 6.8) and alkaline (pH 8.0) pH conditions to
investigate if binding of EFRH depends on the protonation state of the substrate, which
was shown for N-terminal glutaminyl substrates (Tab. 6.1) [54]. In this case, no change in
the absorbance intensity over time at alkaline pH conditions should be observed. However,
stopped flow UV/Vis absorption spectra exhibited a change in absorbance intensities after
mixing of Co(II)-hQC and EFRH at alkaline pH conditions (Fig. 6.17). This observation
indicates binding and coordination of the N-terminal glutamyl substrate towards the metal
ion within the active site, which does not depend on the protonation state of the substrate.
Interestingly, obtained time resolved UV/Vis spectra of Co(II)-hQC in presence of the
tetrapeptide EFRH at both pH conditions differed from the spectrum of the enzyme in
resting state. Due to the fact that the characteristic UV/Vis spectrum of Co(II)-hQC
in resting state is associated with a tetrahedral coordination of the central metal ion, it
can be assumed that the change in the UV/Vis absorption signal might be an attribute
of a switched coordination geometry. Summarizing the obtained information of the EPR
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experiment for N-terminal glutamyl substrates, it can be assumed that the change in the
UV/Vis absorbance spectra might be assigned to a five-fold coordination of the central
metal ion. Interestingly, freeze quench EPR experiments with Co(II)-isoDromeQC already
indicated that binding and coordination of an N-terminal glutamic acid differs compared
to N-terminal glutamines (Fig. 6.18). It was shown that the EPR signal shifted into the
higher magnetic field from 1038 G (resting state) to 1440 G (in complex with EFRH). In
addition, the band width of the EPR signal for Co(II)-isoDromeQC in complex with EFRH
was broadened significantly compared to the obtained EPR signal for Co(II)-isoDromeQC
in resting state and in complex with QFRH or pEFRH. Accordingly, due to the different
EPR signal a complete tetrahedral coordinated species can be excluded. Furthermore,
characteristics of the EPR signal indicated a five-fold coordinated central metal ion in
presence of the tetrapeptide EFRH. This observation implies that the Aß peptide species
with its N-terminal glutamic acid coordinates bidentally to the catalytic zinc ion within
the active site of hQC.
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Figure 6.18: EPR spectra of Co(II)-isoDromeQC after incubation with N- terminal
glutaminyl-/glutamyl substrates. Entire EPR spectra are depicted on the left side, whereas on the
right side an image enlargement of the important region of each spectra is shown. Used ligands with the
corresponding incubation time are described, respectively. Measurements were performed at 4.0 K and
20 mW at X-band wavelength (9.36 GHz) in 50 mM NaH2PO4, 10 mM NaCl, pH 6.8. Molar enzyme
concentration was 0.23 µM for each measurement. Final concentrations for utilized ligands were 5 mM for
QFRH , 15 mM EFRH and 15 mM pEFRH. EPR data were taken from Alexander Piontek.
To gain deeper insights into the bidentally coordinating glutamic acid of EFRH to the
catalytic zinc ion within the active site, crystal structures of hQC in complex with the
pathophysiological substrate were applied. Crystallization attempts were successful and
analyzable data were achieved.
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A B
Figure 6.19: Crystal structure of hQC in complex with the tetrapeptide EFRH. (A) Side
view of the active site of hQC with coordinated EFRH. Active site residues are shown in grey and named
respectively (blue = coordinating residues, black = active site residues), while the substrate is coloured
yellow. The hydrophobic pocket is indicated in transparent gray, in which the coordinated zinc (black
sphere) is located at the bottom of the pocket. Dashed lines are indicating coordinating bonds with
the corresponding distance in Å. (B) Front view of the active site with the corresponding 2mFo-DFc
electron density map with a sigma contour level of 1.0 σ. Scheme in the upper right corner should indicate
coordination of the metal ion. Resolution = 1.92 Å, R-work = 17.9 % and R-free = 20.8 %
Crystal structure of hQC in complex with EFRH showed no distinct electron density
reflecting a bidental coordination of the N-terminal glutamic acid. Moreover, binding of
the substrate towards the metal ion possessed a tetrahedral coordination geometry, in
which the coordination bond distances and angles (Tab. 8.1 and Tab. 8.2) showed typical
characteristics of a tetrahedron. However, crystal structure of Co(II)-isoDromeQC in
complex with EFRH from Alexander Piontek (data not published) showed a remarkably
impression of the active site in complex with the tetrapeptide EFRH (Fig. 6.20). Crystal
structure of isoDromeQC clearly revealed an alternative conformation of the N-terminal
glutamic acid of the EFRH peptide with an occupancy of 0.5, meaning both conformations
were up to 50 % present within the crystal. These alternative conformations resulted in a
monodental or bidental N-terminally coordinated glutamic acid, leading to a four- or five-
folded coordinated metal ion. Hence, after binding of the N-terminal glutamyl substrate,
coordination of the γ-carbonyl moiety of the side chain seems to be a dynamic process in
which either one of the γ-oxygen atoms form a coordination bond (monodental) or both are
coordinated towards the central metal ion (bidental). As already described in literature,
coordinating carboxylate ligands have the ability to change their binding mode at metal
centers. This process is known as carboxylate shift [109]. The carboxylate shift is able to
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influence reaction kinetics of enzymes due to the switching binding mode of the carboxylate
group. In particular, it was reported for the methane monooxygenase to contain a µ-
carboxylato bridged binuclear iron site in its active centers, in which the carboxylate shift
plays a crucial role in the catalytic pathways of the enzyme [109–111]. For the transition
metal zinc a direct observation of the carboxylate shift has only been reported for binuclear
model complexes of zinc using NMR spectroscopy [112]. Coordination bond distances and
angles are summarized in Tab. 8.1 and Tab. 8.2 respectively, which showed only slight
deviations. In conclusion, combined results of EPR, stopped flow UV/Vis absorption
spectroscopy and X-ray crystallography for hQC and isoDromeQC, respectively, showed
an additional coordination geometry for N-terminal glutamyl substrates, which differs in
its coordination number compared to binding of N-terminal glutaminyl substrates. The γ-
carboxylate moiety of the N-terminal glutamic acid could be either monodental or bidental
coordinated towards the catalytic zinc ion. Furthermore, a carboxylate shift was observed,
which directly influenced the change in the binding mode of the coordinated glutamic acid.
A B
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Figure 6.20: Crystal structure of isoDromeQC in complex with the tetrapeptide EFRH. (A)
Side view of the active site of isoDromeQC with coordinated EFRH. Active site residues are shown in grey
and named respectively (blue = coordinating residues, black = active site residues), while the substrate is
colored yellow. Residue numbers in brackets indicating the corresponding position in hQC. Hydrophobic
pocket is indicated in transparent gray, in which the coordinated zinc (black sphere) is located at the
bottom of the pocket. Dashed lines are indicating coordinating bonds with the corresponding distance in
Å. (B) Front view of the active site with the corresponding 2mFo-DFc electron density map with a sigma
contour level of 1.0 σ. Scheme in the upper right corner should indicate coordination of the metal ion.
Resolution = 1.12 Å. Data were taken from Alexander Piontek.
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6.4.8 Coordination Geometry of the Metal Ion Within the Active Site Depends on
Binding of Glutaminyl/Glutamyl Substrates - Role in Catalysis
Coordination number of the central metal ion of hQC depends on the binding of N-terminal
glutaminyl/glutamyl substrates. In case of the physiological substrate the central metal
ion has four coordinated ligands, while for the pathophysiological substrate the coordina-
tion number switches between four and five coordinated ligands. This distinct change in
the coordination geometry caused by a carboxylate shift after binding of an N-terminal
glutamyl substrates could explain the difference in their catalytic efficiency compared to
N-terminal glutaminyl substrates, which will be discussed in this chapter.
As described previously, catalysis of the physiological substrate within the active site of
hQC displayed a pH dependency [54] (Fig. 6.6 and Tab. 6.1). Conversion of glutamine into
pyroglutamic acid is favored at alkaline pH conditions due to the requirement of a depro-
tonated α-amino group, which gets in turn activated for catalysis by protonation of the
acid-base catalyst Glu201. After coordination of the substrate towards the central metal
ion, the catalytic zinc ion acts as a Lewis acid and extracts electrons from the γ-oxygen
of the N-terminal glutaminyl side chain. Accordingly, electrophilicity of the γ-carbonyl
carbon atom is drastically increased, resulting in a nucleophilic attack of the α-amino
group. A prerequisite for the nucleophilic attack is a tetrahedrally coordinated central
metal ion and a non-coordinating γ-amino group, which acts as a leaving group and splits
off from the transition intermediate during catalysis. However, in case of the N-terminal
glutamyl substrates the γ-amino group is exchanged against a hydroxyl group compared
to N-terminal glutamines, leading to drastic changes of the catalytic pathway. Free glu-
tamic acids in solution have a pKa value of 4.2 for the γ-carboxylic moiety and 9.6 for the
α-amino group. These pKa values probably differ and do not reflect the real pKa values
after binding of the substrate compared to the experimentally determined pKa values of
free glutamic acids in solution. Nevertheless, the described pKa values for free glutamic
acids in solution should roughly reflect the given situation within the active site of hQC.
The reason for deviated pKa values is probably that the residue environment within the
active site directly influences the pKa values. In theory, at alkaline pH conditions, in
which physiological substrates are preferentially catalyzed, the α-amino group and the
γ-carboxylic moiety would be predominantly deprotonated (Fig. 6.21). Deprotonation of
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the γ-carboxylic moiety would allow a bidental coordination of both γ-oxygens towards
the zinc ion, resulting in a five-folded coordination of the central metal ion. Hence, due
to the bidental coordination both γ-oxygens are charged equivalently, thereby prohibiting
electrophilic activation of the γ-carbonyl carbon. Therefore, a nucleophilic attack by the
α-amino group on the γ-carbonyl carbon is very unlikely, due to the missing electrophile.
Thus, at neutral pH conditions the γ-carboxylic moiety should be still deprotonated, lead-
ing to a predominantly five-folded coordinated central metal ion. Only at neutral pH some
species of the α-amino group are protonated, thereby decreasing slightly nucleophilicity.
However, switching to acidic pH conditions induces a carboxylate shift of the γ-carboxylic
moiety by protonating one of the γ-oxygens, which results in a tetrahedral coordinated
central zinc ion. Additionally, more species of the α-amino group are protonated at acidic
pH, which decrease nucleophilicity drastically. Concerning reduced turnover of N-terminal
glutamyl substrates compared to N-terminal glutaminyl substrates catalyzed by hQC, the
pH dependent carboxylate shift induced by protonation of the γ-carboxylic moiety, thereby
switching coordination geometry from five-fold to four-fold, is probably the major factor
for differences in catalysis. Furthermore, only a small number of deprotonated α-amino
group and protonated γ-carboxylic moiety species are available at acidic pH conditions,
which in turn also influences turnover of N-terminal glutamic acids. The first model relies
on the fact that the proton for protonation of one γ-oxygen comes from solution, but
considering coordination of the substrate towards the central metal ion probably induces
a pKa shift. Coordination of both γ-oxygens towards the zinc ion could lower the pKa
value for the γ-carboxylic moiety, because the zinc ion is a strong Lewis acid and pull out
electrons from the γ-carboxylic moiety. A shifted pKa would affect the protonation of the
γ-carboxylic moiety by the solvent drastically, meaning protonation of the γ-carboxylic
moiety by the solvent is improbable. Therefore a second model was developed (Fig. 6.21),
in which protonation of the γ-carboxylic moiety is induced by a spatially close amino acid
residue within the active site of hQC. Crystal structures of hQC revealed Glu201 as a
potential proton donor candidate, which could transfer a proton to induce the carboxylate
shift. Experimental determined pKa values of glutaminyl cyclase from Carica papaya cat-
alyzing Glu-βNA were 7.5 and 4.2, respectively [3]. Therefore, it might be possible that
some γ-carboxylic moieties of Glu201 get protonated at acidic pH conditions. The proton
is subsequently transferred to the coordinating substrate, thereby inducing the carboxylate
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shift. In summary, two proposed models were developed to postulate the influence of the
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Figure 6.21: Proposed model for an induced carboxylate shift of N-terminal glutamyl
substrates coordinated to the catalytic zinc ion of hQC. Upper scheme shows a pH-dependent
carboxylate shift of the γ-carboxylic moiety of the N-terminal glutamic acid in which the proton is do-
nated from solution. Lower scheme represents an induced carboxylate shift by a surrounding amino acid
residue transferring a proton onto γ-carboxylic moiety of the substrate. The γ-carboxylic moiety (red)
and the α-amino group (blue) are highlighted, respectively. Arrows indicate strong (thick) or weak (thin)
nucleophilicity/electrophilicity of the corresponding functional groups. After the carboxylate shift the N-
terminal glutamic acid is monodentally coordinated to the catalytic zinc ion and can take the next step in
the catalytic cycle of hQC.
6.4.9 Summary
Substitution of zinc against cobalt within the active site resulted in spectroscopically ac-
tive Co(II)-hQC with comparable activities compared to hQC. The almost equal ionic
radii and the Alfred-Rochow electronegativities (Zn = 1.66 and Co = 1.70 [113]) are prob-
ably the reasons for beneficial commutability. Based on the successful substitution of the
cobalt different spectroscopic methods, for example stopped flow UV/Vis spectroscopy,
were applied to investigate the coordination number of the central metal ion after binding
of N-terminal glutaminyl/glutamyl substrates. In addition, crystal structures of hQC in
complex with different substrates or the product were generated. Obtained experimen-
tal data revealed a four-folded tetrahedral coordinated metal ion in case of N-terminal
glutaminyl substrate and the product, whereas for the glutamyl substrates a mixture of
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four- and five-fold coordinated metal ion was present. Furthermore, a pH dependent car-
boxylate shift was observed for N-terminal glutamyl substrates, inducing a switch from a
five-fold coordinated to a four-fold coordinated metal ion. This difference in the coordi-
nation geometry of the enzyme-metal complex presumably plays a major role in catalysis
of N-terminal glutamyl substrates. A bidental coordination of the substrate would pro-
hibit the cyclization reaction of glutamic acid to pyroglutamic acid due to the lack of an
electrophilic γ-carbon atom, while a monodental coordinated substrate comply all prereq-
uisites for an intramolecular nucleophilic attack of the α-amino group onto the γ-carbon
atom.
6.5 Design and Characterization of a Potent Inhibitor for Human Glutaminyl
Cyclase
Human glutaminyl cyclase is a potential drug target candidate for the development of
inhibitors in the treatment of Alzheimer’s disease. As described recently, hQC has the
ability to convert N-terminal glutamic acids of the Aß peptide species into the respective
cyclized product in an in vitro experiment. This observation supports the idea of a possible
involvement of hQC in the initiation of the neurotoxic plaque formation in Alzheimer’s
disease [3]. The aim of this study was to gain comprehensive information about the
catalytic properties, the structure and in particular the coordination geometry of the metal
ion within the active site of hQC. Based on these findings, design of a potent inhibitor
for hQC mimicking a highly energetic transition intermediate was attempted. Therefore,
potential transition state analogue compounds were tested and kinetically characterized
via the continuous calorimetric activity assay. The resulting Ki constant served as a scale
for comparison among tested compounds. The most promising candidate was further
characterized by different methods, like thermodynamic characterization via isothermal
titration calorimetry and X-ray crystallography, to elucidate the nature of the enzyme-
inhibitor complex.
6.5.1 The First Described Imidazole Based Inhibitor for Human Glutaminyl Cyclase
Most metalloenzyme inhibitors are drug-like small molecules, consisting of a metal binding
group (MBG) and a backbone group. The MBG coordinates to the active site metal ion,
whereas the backbone group is specifically customized for their respective targets, which
85
6 RESULTS AND DISCUSSION
Figure 6.22: Chemical structure of the
hQC inhibitor PBD150 The inhibitor is sub-
divided into two important regions, which are
connected via a linker. MBG = metal binding
group. MBG linker backbone group
could consists of substituted aliphatic chains, aromatic rings, or heterocycles. The specific
customization of the backbone group for an active site of an enzyme should in theory in-
crease specificity of the inhibitor for its target and reduce off-target inhibition. In addition,
the MBG and the backbone group are connected via a linker. As already published in
former studies, a first effective competitive inhibitor for hQC was described and stepwise
optimized based on the general matrix for metalloenzyme inhibitors. As MBG the metal
chelator imidazole was chosen. Imidazole tends to interact with accessible zinc atoms and
was consequently reported as a weak inhibitor of hQC with an inhibitory constant in the
lower micromolar range (Ki = 103 ± 4 µM) [23]. Imidazole is commonly used as a metal
chelator and capable to coordinate zinc ions, which was shown for the active site of car-
boxypeptidase A [114]. Starting from imidazole as the metal binding group the compound
was improved by applying a ligand-based optimization leading finally to the inhibitor 1-
(3-(1H -imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea (PBD150) [56] (Fig. 6.22).
The linked backbone group is in general a hydrophobic tail customized specifically for the
active site of hQC. Accordingly, the designed hydrophobic tail in combination with imida-
zole improved the inhibitory power drastically, leading to a inhibitory constant in the lower
nanomolar range (Ki = 60 ± 0.2 nM) [56]. Potency of PBD150 was shown in transgenic
mouse models, in which the formation of Aß3(Glu)−40/42 to Aß3(pGlu)−40/42 was drastically
reduced, resulting in a significantly decreased deposition of toxic plaques within the brain
[115]. These experimental data support the hypothesis of modified amyloid-beta peptides
acting as a seeding peptide species in the amyloid cascade, confirming hQC as a valuable
drug target in the treatment of Alzheimer’s disease. However, homology modeling allowed
to get first insights in the theoretical binding mode of PBD150 within the active site of
hQC [116], which were confirmed by crystal structures of mammalian QC in complex with
PBD150 (Fig. 6.23 A) [117]. Besides the coordination of the imidazole moiety towards
the zinc ion, formation of a hydrogen bond established directly between the thio-carbonly
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group and the backbone amide of Gln304 was observed (Fig. 6.23 B). The dimethoxyphe-
nol moiety rests upon a hydrophobic patch on the surface of the enzyme, while the two
methoxy groups are involved in solvent-mediated hydrogen bonds to the backbone amide
of Phe325. Nevertheless, imidazole is known to be a common metal chelator and could in
theory cause severe side effects within the human body by targeting accidentally different
metal dependent enzymes. Previous publications showed that off-target inhibition of in-
hibitors even with a specifically customized backbone is possible [118]. Another point of
interest was to find a non-imidazole based MBG, which binds stronger to the catalytic zinc
ion and might thereby increase inhibitory power and specificity. Consequently, for devel-
opment of a highly potent competitive non-imidazole based inhibitor for hQC, screening
for an alternative and stronger coordinating metal binding group specifically targeting the
zinc ion had highest priority.
A B
Figure 6.23: Crystal structure of human glutaminyl cyclase in complex with the inhibitor
PBD150. (A) Side view of the active site of hQC with coordinated PBD150. Active site residues are
shown in grey and named respectively. Blue colored residue names represent zinc coordinating residues,
while black stands for important active site residues involved in catalysis or substrate binding. The
coordinated inhibitor is colored yellow. Hydrophobic cavity is indicated in transparent gray, in which the
coordinated zinc (black sphere) is located at the bottom of the pocket. Dashed lines indicate coordinating
bonds with the corresponding distance in Å. (B) Back view of the inhibitor PBD150. Electrostatic
potentials of the protein surface are reflecting negatively (red) and positively (blue) charged regions.
Interactions with additional residues are indicated by dashed lines. Presented structures were modeled
from PBD entry 3PBB. Resolution = 1.95 Å
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6.5.2 Screening for a New Metal Binding Group for Glutaminyl Cyclase Revealed a
Carbohydrazide Function as a Potential Candidate
One strategy in the treatment of Alzheimer’s disease is the inhibition of glutaminyl cyclase
in order to avoid harmful accumulation of highly amyloidogenic species in brain tissues.
For this purpose, screening for a new highly specific metal binding head group for hQC,
which should have a stronger affinity compared to the imidazole moiety of PBD150, was
performed. To prevent artificial binding of the metal binding group to metalloenzymes in
general, different points were considered in order to increase specificity. Mechanical studies
revealed that the catalytic zinc ion of hQC is not sterically restricted to adopt a five-folded
coordination geometry, which was shown for the crystal structure of isoDromeQC in com-
plex with the tetrapeptide EFRH (see chapter 6.4.7). Therefore, screening for a metal
binding group coordinating bidentally to the catalytic zinc ion could increase affinity and
specificity towards the enzyme. Additionally, compounds were selected mimicking transi-
tion state intermediates of the hQC cyclization reaction to enhance specificity.
To first verify if binding our chosen potential compounds is feasible, a first kinetic charac-
terization by utilizing the continuous calorimetric activity assay for each single specifically
selected compound was performed. By applying the new developed calorimetric activity
assay (see chapter 6.2.2), the obtained experimental data was used to determine the in-
hibitory constant (Ki) according to Dixon [70]. The determined Ki value was used as
a scale for comparison of inhibitory power among tested compounds. For a typical Ki
determination defined compound concentrations were mixed with the standard substrate
Gln-Gln (QQ) and loaded in the measurement cell of the ITC device followed by an injec-
tion of the enzyme to trigger the reaction. Calorimetric progress curves of hQC inhibited
by a potential compound should in theory differ from progress curves in absence of the
potential compound. In general, complete depletion of the substrate should take longer in
presence of a competitive inhibitor due to the fact that substrate and inhibitor compete for
the binding site, leading to an apparent Michaelis-Menten constant (KM) for the substrate.
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Table 6.3: Overview of tested inhibitors for hQC. For determination of the inhibitory constantsKi
the continuous calorimetric activity assay (see chapter 6.2.2) was utilized. Measurements were performed
in 50 mM Tris/HCl, pH 8.0, at 30 ◦C.






Imidazole 126.8 ± 20.2
Ala-Phe-Ala 303.6 ± 69.2








E(γ-hydrazide)FA 16.4 ± 3.5
89
6 RESULTS AND DISCUSSION
Zinc is classified as a class A acceptor, which forms stronger complexes with the first-
row donor atoms oxygen or nitrogen than with second-row elements sulfur or phosphorus
[119]. Accordingly, compounds were selected which theoretically coordinate via oxygen or
nitrogen to the zinc ion of hQC and in addition contain a hydrophobic patch as the back-
bone group, like phenyl phosphorodiamidate or 3-(guanido)-1-oxo- 1-hydroxy-phospholane
(3-AMOHP) for instance. Furthermore, the amino acid cysteine, which could in theory
coordinates via its thiol side chain to the catalytic zinc ion, was also tested. Cysteines
can display high affinity toward zinc ions, resulting in a metal complex formation. It was
demonstrated that metal ions coordinated by cysteine residues can be a critical mediator
of protein structure, catalysis and regulation [120]. Experimentally determined Ki con-
stants for tested compounds are summarized in Tab. 6.3. First, imidazole was tested to
check if utilizing the calorimetric activity assay results in comparable Ki values between
the experimentally determined and the published Ki value. Imidazole showed a nearly
identical Ki value compared to the published one [23], verifying kinetic characterization of
inhibitors by calorimetry as a suitable tool. Unfortunately, no inhibition of hQC activity
could be observed in case of the compounds phenyl phosphorodiamidate (commercially
available) and 3-AMOHP (synthesized by Brigitte Worbs in the Department of Organic
and Biomolecular Chemistry, AK Diederichsen). One explanation might be that both
compounds were sterically impeded to be able to coordinate to the catalytic zinc ion in
the active site of hQC. This was especially surprising for the compound 3-AMOHP, due
to the fact that it should mimic the tetrahedral transition intermediate during cataly-
sis of N-terminal glutaminyl/glutamyl substrates. In addition, cyclic phosphinic acids
were described to be common inhibitors, for instance by binding to γ-aminobutyric acid
(GABA) receptors [121] However, the compound naphtalene-2-sulfonamide (commercially
available) exhibited a weak inhibitory effect on pyroglutamyl formation catalyzed by hQC
in the higher micromolar range. Sulfonamide was reported to inhibit competitively en-
zymes in the pathway of folic acid synthesis [122]. Nevertheless, sulfonamide was excluded
as potential MBG due to their ∼ 7-fold decreased binding affinity compared to imidazole.
As expected, the amino acid L-cysteine showed an inhibitory effect on the hQC activity,
probably by occupying the fourth coordination site of the catalytic zinc via its thiol side
chain. However, thiol groups as potential MBG coordinating to the zinc ion in the active
site of hQC were also excluded due to their ∼ 2-fold increased Ki value. Interestingly, the
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tripeptide Ala-Phe-Ala (AFA) showed an inhibitory effect with a Ki value in the middle
micromolar range (Ki = 303.5 ± 69.2 µM). An explanation was given by the crystal struc-
ture of isoDromeQC in complex with the tripeptide [99]. The bound tripeptide adopted
a conformation within the active site spatially close to the catalytic metal ion resulting in
two hydrogen bond formations. First, the α-nitrogen of the phenylalanine in the second
position of the tripeptide forms a hydrogen bond with the oxygen of the main chain of
Glu292 and, secondly, the α-nitrogen of the main chain of Glu292 interacts with the car-
bonyl oxygen of phenylalanine of the tripeptide. Due to the conformation of the bound
tripeptide and further lack of a potential metal binding group the catalytic zinc ion was
still coordinated tetrahedrally, in which the fourth coordination site was occupied by the
water molecule.
Interestingly, a new potent metal binding group for hQC was discovered by substituting the
γ-oxygen of a glutamic acid against a hydrazide function (E(γ-hydrazide)). E(γ-hydrazide)
was first described to serve as a potent inhibitor of glutamine metabolism in liver mito-
chondria [123]. Besides the metal binding group a backbone group was introduced con-
sisting of phenylalanine and alanine ( E(γ-hydrazide)FA). As described previously, bulky
and hydrophobic residues at the second and third N-terminal amino acid position, espe-
cially phenylalanine, increased substrate affinity (see chapter 6.3.2) (Fig. 6.24 A). Kinetic
characterization via the continuous calorimetric activity assay showed a concentration de-
pendent change in the calorimetric progress curves, in which the time of complete substrate
depletion was accelerated with increasing E(γ-hydrazide)FA concentration (Fig. 6.24 B).
Analysis of the experimental ITC data according to Michaelis-Menten kinetics by plotting
the turnover number of the hQC reaction against the substrate concentration in depen-
dency of various E(γ-hydrazide)FA concentrations revealed a typical competitive inhibition
mode (Fig. 6.24 C). Competitive inhibition apparently increases the KM constant, while
Vmax remains the same, because the presence of the inhibitor can be negotiated by higher
substrate concentrations. This effect could be observed for hQC catalyzing the dipeptide
Gln-Gln in presence of different E(γ-hydrazide)FA concentrations. For determination of
the Ki constant according to Dixon [70] the turnover number of various substrate concen-
trations were plotted reciprocally against the E(γ-hydrazide)FA concentration (Fig. 6.24
D). Obtained data points were fitted linear and intersection of linear regressions reflected
the Ki value of E(γ-hydrazide)FA for hQC, which was in the low micromolar range (Ki
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= 16.4 ± 3.5 µM). In addition, experimental data was also analyzed by three-dimensional
plotting and the obtained Ki value was identical (Ki = 11.6 ± 2.3 µM) (Fig. 8.13). Thus,
the inhibitor with its metal binding group E(γ-hydrazide) has a 8-fold decreased Ki value
compared to the metal chelator imidazole. In summary, a potential metal binding group
with a stronger affinity for the catalytic zinc ion of hQC compared to imidazole was ana-
lyzed and proved to be beneficial.
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Figure 6.24: Kinetic characterization of hQC in presence of the inhibitor E(γ-hydrazide)FA.
(A) Chemical structure of the inhibitor E(γ-hydrazide)FA. Coordinating metal binding group (MBG) is
highlighted in blue, linker in black and backbone group in red. (B) Calorimetric progress curves of hQC
activity catalyzing the dipeptide Gln-Gln (QQ) in presence of different E(γ-hydrazide)FA concentrations.
(C) Michaelis-Menten plot of conversion of the N-terminal glutaminyl substrate catalyzed by hQC at
different inhibitor concentrations. Obtained data points were fitted according to Eq. 3. (D) Dixon plot
for the inhibition of hQC catalyzed cyclization reaction by E(γ-hydrazide)FA. Turnover number at defined
substrate concentrations measured for each inhibitor concentration was plotted reciprocally against E(γ-
hydrazide)FA concentrations. Obtained data points were fitted to a linear dependency and the Ki value
was determined by calculating the intersections for each linear regression.
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6.5.3 X-Ray Structure of the Potential Carbohydrazide Inhibitor Bound by Human





Figure 6.25: Crystal structure of hQC in complex with the inhibitor E(γ-hydrazide)FA. (A)
Left structure shows the inhibitor E(γ-hydrazide)FA with atom nomenclature according to Coot. The right
structure shows a simulated mFo-Fc density for the inhibitor E(γ-hydrazide)FA bound by hQC represented
with a contour level of 3.0 σ. (B) Side view of hQC active site in complex with E(γ-hydrazide)FA (yellow).
Metal coordinating (blue) and active side (black) residues are named respectively. Coordinating bonds with
the zinc (black sphere) are indicated by black dashed lines, while potential hydrogen bonds are represented
in blue dashed lines with the corresponding bond length distance in Å. The red sphere indicates a water
molecule, which is involved in a solved mediated hydrogen bond. (C) Front view into the active site cavity
of hQC in complex with the inhibitor. Electrostatic potential of the protein surface is indicated by red
(negatively charged) and blue (positively charged) regions. (D) Observed movement of Trp207 within the
active site of the enzyme in absence (I.) and presence (II.) of the inhibitor. Red arrow indicates movement
of the amino acid residue. Resolution = 1.95 Å, R-work = 17.1 % and R-free = 20.2 %
Kinetic analysis of hQC in presence of E(γ-hydrazide)FA indicated that the compound
functions as a competitive inhibitor. To obtain information about the binding mode of
E(γ-hydrazide)FA within the active site of hQC, the crystal structure of hQC in complex
with the competitive inhibitor was solved. Data collection and refinement statistics are
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summarized in Tab. 8.3.
Analysis of protein crystals revealed complete electron density for all residues of the in-
hibitor (Fig. 6.25 A). In this study, a defined electron density for all residues of a ligand
in complex with the enzyme was established for the first time, indicating a tight binding
of the inhibitor to the protein. In addition, the active site of both molecules within the
asymmetric unit were fully occupied with E(γ-hydrazide)FA (occupancy = 1.0). Inter-
estingly, the crystal structure showed that the metal binding group of E(γ-hydrazide)FA
coordinates bidentally to the catalytic zinc ion (Fig. 6.25 B). The carbonyl γ-oxygen atom
(OE1) and the γ’-nitrogen atom (NE2) of the carbohydrazide function formed a coordinat-
ing bond with the catalytic zinc ion, respectively. As a result of this bidental coordination
of the MBG, the central metal ion was five-fold coordinated. Bond length and angle for
each coordinated ligand are summarized in Tab. 8.1 and Tab. 8.2, respectively. Coordina-
tion bond lengths between the catalytic zinc ion and the γ-oxygen atom (2.34 Å ) or the
γ’-nitrogen atom (2.19 Å) were slightly elongated. A standard coordinated oxygen-zinc
bond length should be 2.20 ± 0.13 Å, while in case of nitrogen-zinc it should be 2.09 ±
0.14 Å [108]). Searching for carbohydrazide functions coordinated to a single zinc ion in
the Cambridge Crystallographic Database (CSD) revealed bond lengths in the same range,
thereby verifying observed coordination bond lengths in the crystal structure between the
catalytic zinc ion and the γ-oxygen and γ’-nitrogen atom. Interestingly, bond angles of
the central catalytic zinc ion and its five coordinating ligands did not show perfect bond
angles for a trigonal bipyramidal (α = 90◦, β = 120◦ and γ = 180◦) or square pyramidal
(α = β = γ = 90◦) coordination. This observation might indicate an isomerization of the
metal complex commonly referred as Berry pseudorotation. A Berry pseudorotation takes
place in molecules with a trigonal bipyramidal coordination, in which the central atom
has a coordination number of five [124]. The pseudorotation function in a well-defined
mechanism, in which atoms perform oscillations in dependency of their local temperature,
causing periodic changes of bond lengths and angles within a given metal complex. As
a result of this oscillations the metal complex adopts either a trigonal bipyramidal or a
square pyramidal geometry, which are converging fluently into each other. For a pseudoro-
tation the two ligands in the apical position of the trigonal bipyramidal geometry should
move towards each other, which is in case of hQC the imidazole moiety of His330 and the
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amino group of the carbohydrazide function of E(γ-hydrazide) (Fig. 6.26). Due to this
movement, the bond angle is reduced from 180◦ to 120◦ (His330-Zn-NE2’ = 156◦). In
addition, two equatorial atoms need to move apart and the bond angle is expanded from
120◦ to 180◦ (Glu202-Zn-OE2’ = 146◦). During the change of positions a transition state
is reached, in which the four moving atoms form the base of a square pyramid, whereas
the fixed ligand (Asp159) serves as the pinnacle of the pyramid. At the end of a Berry
pseudorotation the complex moves back to its initial state in the form of a trigonal bipyra-
mid.
Figure 6.26: Scheme of the Berry pseudorotation of the coordination center within the
active site of hQC. The central zinc ion has a coordination number of five and forms a complex with the
metal coordinating residues (grey) and E(γ-hydrazide) (yellow). First sphere metal coordinating ligands
are numbered and the directions of movement is indicated with arrows, respectively. Starting from a
trigonal bipyramidal geometry the apical atoms 1 and 2 move closer to each other, while atoms 4 and 5
move away from each other, but still remain in a equatorial position. Atom number 3 acts as fixed point.
As a result the metal complex adopts a square pyramidal geometry. Shape of both geometries are indicated
by blue lines. A Berry pseudorotation is a highly dynamic process, in which both geometries converge
fluently into each other.
To evaluate which coordination geometry of the zinc complex predominantly existed in the
obtained crystal structure the structural parameter for five-fold coordinated compounds
τ5 was calculated [125]. The τ5 parameter is in a range of zero to one that gives a ten-
dency which coordination geometry of the ligand coordinating center in a metal complex
is present. If τ5 is close to one the coordination geometry is similar to trigonal bipyrami-
dal, while if τ5 is close to zero the coordination geometry is similar to square pyramidal.
Calculation of τ5 for hQC in complex with E(γ-hydrazide)FA (τ5 = 0.16) revealed a higher
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tendency for a square pyramidal geometry.
Besides bidental coordination of the carbohydrazide function to the catalytic zinc ion ad-
ditional inhibitor-enzyme interactions within the active site of hQC could be observed
(Fig. 6.25 B and C). In case of the metal binding group of E(γ-hydrazide)FA four po-
tential hydrogen bonds could be identified. The first hydrogen bond was formed between
the γ-nitrogen of the carbohydrazide function of E(γ-hydrazide) and the γ-carboxylic
moiety of Asp248 and, secondly, between the α-amino group of E(γ-hydrazide) and the γ-
carboxylic moiety of Glu201. At least, one potential hydrogen bond was formed between
the γ’-nitrogen of the carbohydrazide function and the γ-carboxylic moiety of Asp159,
an another one between the γ-oxygen and the indole moiety of Trp329. These potential
hydrogen bonds between the metal binding group of the inhibitor and the surrounding
active site residues increase affinity of E(γ-hydrazide)FA for hQC, but could also cause a
rigidity of the metal complex. Beside a possible Berry pseudorotation it might be possible
that these additional interactions could cause a fixation of the metal binding group. Thus,
observed deformation of the bond angles could be provoked by the hydrogen bonds and
would not allow movement of the carbohydrazide function, which is a prerequisite for a
pseudorotation. Accordingly, deformed bond angles of the catalytic zinc-inhibitor complex
could be caused by a Berry pseudorotation or due to a fixation of the metal binding group
by additional hydrogen bond formations.
In case of the backbone group a total of three additional hydrogen bond formations be-
tween the inhibitor and surrounding residues of the active site were observed in the crystal
structure of hQC in complex with E(γ-hydrazide)FA. First, a potential hydrogen bond was
identified between the α-amino group of the phenylalanine of E(γ-hydrazide)FA and the
C-terminal carbonyl oxygen of Gln304 and the second one between the C-terminal car-
bonyl oxygen of the phenylalanine of E(γ-hydrazide)FA and the α-amino group of Gln304.
At least, formation of a potential solvent mediated hydrogen bond between the carbonyl
amino group of the alanine of E(γ-hydrazide)FA and the C-terminal carbonyl oxygen of
Val302 was observed. These additional interactions might increase binding strength of the
inhibitor to hQC and consequently contribute to a stabilizing effect of E(γ-hydrazide)FA
binding within the active site. Average B-factor of E(γ-hydrazide)FA was 21.6/27.1 Å2
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(chain A/chain B), thereby supporting the idea of a stabilized and rigid coordinated in-
hibitor caused by the tightly bound metal binding group and additional interactions by the
backbone group with active site residues. The B-factor (atomic displacement parameter)
is commonly seen as a measure to describe the probable position of an atom or molecule
in the structure model [126]. A low B-factor represents a part of the structure that is well
ordered, whereas a large B-factor generally belongs to a part of the structure that is very
flexible [126].
However, overall structure alignment of hQC in resting state and in complex with E(γ-
hydrazide)FA revealed no large loop movement caused by binding of the inhibitor. Though,
Trp207 showed only in one of both independent hQC molecules in the asymmetric unit an
alternative conformation (Fig. 6.25 D). The indole ring of Trp207 was in one hQC molecule
directed towards the protein surface of the molecule, while in its alternative conformation
it was oriented to the opposite direction. Kinetic characterization of site-specific vari-
ants by substituting Trp207 against aliphatic residues (e.g. leucine) decreased catalytic
efficiency by a factor of 50 [20]. Accordingly, it was postulated that Trp207, which is
directly located at the cavity entrance of hQC, plays a role in active site accessibility
by adopting two alternative conformations resulting in an open/closed state. However,
crystal structure of hQC in complex with E(γ-hydrazide)FA showed that the active site
of both independent molecules in the asymmetric unit were occupied with the inhibitor.
Due to the fact that Trp207 adopted different conformations in the crystal structure, in
which one conformation might represented the open state while the other conformation
represents the closed state. If this would be the case, one molecule in the asymmetric unit
should not have E(γ-hydrazide)FA in its active site. Since E(γ-hydrazide)FA is present
in the active site of both independent hQC molecules, the role of Trp207 during catalysis
needs to be reconsidered.
In summary, crystal structure of hQC in complex with E(γ-hydrazide)FA enabled a de-
tailed look into the binding mode of the inhibitor. The central catalytic zinc ion with a
coordination number of five adopts a predominantly square pyramidal coordination ge-
ometry. Furthermore, tight binding and rigidity of E(γ-hydrazide)FA is guaranteed by
several additional hydrogen bonds.
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6.5.4 Binding of the Potential Inhibitor by Human Glutaminyl Cyclase is an
Entropically Driven Process
To investigate thermodynamics of binding of E(γ-hydrazide)FA to hQC, binding stud-
ies utilizing isothermal titration calorimetry (ITC) were performed. Characterizing E(γ-
hydrazide)FA thermodynamically should elucidate the thermodynamic signature and thereby
clarify if the binding process is enthalpically or entropically favored. Thermodynamic char-
acterization of binding is in general contributed to hydrophobic interactions and hydrogen
bond formation. The principle of hydrophobic interactions is that nonpolar groups as-
sociate in a polar environment, leading to minimization of solvent interactions. Ligand
binding by hydrophobic interactions is characterized by the release of highly-ordered sol-
vent molecules to bulk solvent, which is slightly endothermic but entropically favored due
to a decrease of the organization state. Accordingly, hydrophobic interactions in thermo-
dynamics are characterized by a small positive ∆H and a bigger positive ∆S. In contrast,
electrostatic interactions like hydrogen bonds, which are important for biological interac-
tions, are enthalpically favored. However, a generalization is not possible, due to diverse
hydrogen bond donor and acceptor properties in free and complex form. In addition, the
local environment is also important. Nevertheless, binding strength of inhibitor-target
interaction relative to those with solvent, primarily due to hydrogen bond formation and
van der Waals interactions is reflected by ∆H. If ∆H is negative, binding is enthalpically
favored.
Unfortunately, a stepwise titration of E(γ-hydrazide)FA to hQC until the enzyme is com-
pletely saturated measured via isothermal titration calorimetry did not result in reliable
data (Fig. 8.12). The reason for this is that the Wiseman parameter (c) [127] for hQC
binding E(γ-hydrazide)FA is below 10 defining the binding process as a "low affinity sys-
tem". For a "low affinity system" the c value is < 10 and the shape of an isothermal
titration curve is hyperbolic, whereas for c values > 10 the curve is clearly sigmoidal. Due
to the fact that in the first injection all injected ligands should bind to free macromolecules
the detected heat release/consumption directly corresponds to ∆H. Thus, obtaining a re-
liable ∆H value from a "low affinity" binding curve is highly erroneous, because the first
part of the sigmoidal curve is missing. As an alternative, the inhibitor was titrated in
excess in a single step to the enzyme to ensure complete saturation of hQC (Fig. 6.27 A).
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The integrated heat release of the single titration step is directly proportional to the ∆H
value. Titration of E(γ-hydrazide)FA to hQC resulted in ∆H◦ = -4.81 ± 0.25 kJ/mol,
revealing binding of the inhibitor to the enzyme as an exothermic process. As a con-
trol, two additional titration steps were performed to exclude artificial binding effects,
like interactions between the inhibitor molecules, and to ensure complete saturation of
hQC with E(γ-hydrazide)FA. The following two titrations are identical and reflecting only
heat of dilution of E(γ-hydrazide)FA after titration to hQC. At least, to receive a full
thermodynamic signature (Fig. 6.27 B) the Gibbs free energy (∆G) and the entropy (∆S)
were calculated according to Eq. 17. The Gibbs free energy was negative (∆G◦ = -27.02 ±
0.31 kJ/mol), thereby identifying binding of E(γ-hydrazide)FA as a spontaneous exergonic
reaction. Interestingly, the entropy was highly positive (T∆S◦ = -22.28 ± 0.17 kJ/mol),
meaning that binding of the inhibitor to the enzyme is strongly entropically driven. A
possible explanation is that solvent molecules at binding surfaces are higher ordered than
bulk solvent and that these molecules can be released or retained by substrate binding.
Release of the solvent molecules is entropically favored due to higher disorder, but en-
thalpically unfavored because of weaker interaction with the bulk solvent. In case of hQC
in resting state the active site harbors six water molecules within its cavity plus the inter-
acting water molecules of the unbound inhibitor in solution. These water molecules need
to be released for interaction of the inhibitor with the enzyme. A prominent example is
the coordinating water occupying the fourth coordination site of the zinc ion, which needs
to be displaced and released to bulk solvent for binding of the metal binding group. In
conclusion, thermodynamic characterization revealed a entropically driven binding process
of E(γ-hydrazide)FA to hQC.
6.5.5 Summary - Future Aspects - Combining Backbone Group of PBD150 with the
Carbohydrazide Function
Screening for a potent non-imidazole based new metal binding group for inhibition of hQC
was successful by introducing a carbohydrazide function within the side chain of a glutamic
acid. Crystal structure of hQC in complex with the inhibitor showed that E(γ-hydrazide)
coordinates bidentally to the catalytic zinc ion (Fig. 6.25). As a consequence, the coordi-
nation number of the central metal ion increased from four to five. Furthermore, kinetic
characterization of hQC in presence of E(γ-hydrazide)FA exhibited a 8-fold decreased Ki
99











30A By g g )
time [s]























Figure 6.27: Thermodynamic binding studies of E(γ-hydrazide)FA binding to hQC. (A)
Representative ITC data of a single titration of E(γ-hydrazide)FA to hQC for ∆H determination. First
peak represents the binding event of E(γ-hydrazide)FA to the enzyme, while the last two peaks are only
heat of dilution, indicating saturation of hQC with E(γ-hydrazide)FA. Measurements were performed in 50
mM Tris/HCl, pH 8.0, with 0.08 mM hQC in the sample cell and 25 mM E(γ-hydrazide)FA in the syrringe.
(B) Thermodynamic signature of binding of E(γ-hydrazide)FA to hQC. Whereas ∆H◦ was experimentally
determined, T∆S◦ and ∆G◦ were calculated according to Eq. 17.
constant compared to imidazole (Fig. 6.3), identifying it as the stronger metal binding
group. Nevertheless, the imidazole-based inhibitor PBD150 exhibit an inhibitory constant
in the low nanomolar range [56]. Due to the linkage of an active site optimized backbone
group to the metal binding group imidazole, the Ki value was drastically decreased by
a factor of ∼2000. Accordingly, linkage of the metal binding group imidazole with the
backbone group N-(3,4-dimethoxyphenyl)thiourea increased binding affinity. The carbo-
hydrazide function turned out to be a potential better candidate for complexation of the
catalytic zinc ion in the active site of hQC compared to imidazole due to stronger binding.
Thus, combining the carbohydrazide function with N-(3,4-dimethoxyphenyl)thiourea via
a linker should result in theory in a potentially stronger inhibitor for hQC compared to
PBD150. In addition, due to this modification, potency and selectivity of the new designed
inhibitor should be further optimized.
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7 Summary and Final Discussion
Many neuropeptides are post-translationally modified at the N-terminus to increase their
bioactivity. This post-translational modification is in many cases essential, for instances
for the formation of a physiological active structure, binding to specific receptors or to
increase the half-life time of a neuropeptide [24, 29]. One enzyme family, which is involved
in the post-translational modification of N-terminal amino acids are glutaminyl cyclases.
Glutaminyl cyclase occurs in the Animalia, Plantae and Bacteria kingdom, in which it
physiologically catalyzes the formation of pyroglutamic acid from N-terminal glutaminyl
precursors. Interestingly, this apparent homology between mammalian, plant and bacte-
rial glutaminyl cyclases is not reflected in the primary structure (Fig. 7.1). Plant and
bacterial glutaminyl cyclases have a highly similar overall structure and thereby obviously
representing an individual family of enzymes [128], while the highly homologous mam-
malian glutaminyl cyclases share structural similarities to bacterial aminopeptidases [11].
The structures of glutaminyl cyclase from Zymomonas mobilis (bacteria) [129] and Carica
papaya (plant) [130] exhibit a characteristic β-propeller fold composed of five β-sheets
with antiparallel β-strands, which are arranged around a central axis and a short α-helical
turn. The β-propeller fold showed a high resistance to chemical, acid and thermal denat-
uration [131]. Furthermore, an octahedral coordinated metal ion is located in the core
of both proteins. It is reported in literature that the central metal ion could be either
zinc [130] or calcium [132]. In contrast, glutaminyl cyclases of mammals (Homo sapiens
and Mus musculus) and invertebrates (Drosophila melanogaster) possess a globular α/β-
hydrolase fold [20, 22, 133] harboring a tetrahedral coordinated catalytic zinc ion within
their active sites. Zinc is a very attractive catalyst for biological systems due to e.g. its
flexible coordination geometry, the fast ligand exchange, the lack of redox activity, and its
role as Lewis acid. In addition, physiological functions of plant and bacterial glutaminyl
cyclases differ from that of animal glutaminyl cyclases. For example, glutaminyl cyclase
from Carica papaya is probably involved in the production of ammonium ions in the plant
pathogen defense [134], whereas animal glutaminyl cyclases play a role in the synthesis of
pyroglutamyl modified neuropeptides or hormones [54]. Accordingly, evolution of plant,
bacterial and animal glutaminyl cyclases apparently led to functionally similar enzymes,
but they differ in their tertiary structure and physiological function.
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Table 7.1: Overview of kinetic parameters of glutaminyl cyclase from different domains of
life catalyzing N-terminal glutaminyl substrates. All measurements were performed at 30◦C in 50
mM Tris/HCl, pH 8.0
Human glutaminyl cyclase
Peptide kcat KM kcat/KM
[s−1] [mM] [s−1 mM−1]
QQ 24.8 ± 0.13 0,14 ± 0.01 233.5 ± 14.6
QFRH 68.6 ± 0.32 0.27 ± 0.01 254.1 ± 29.6
Q-ßNA 20.4 ± 0.87 0.12 ± 0.01 170.0 ± 20.6
Mammal QC (Mus musculus)A
Peptide kcat KM kcat/KM
[s−1] [mM] [s−1 mM−1]
QQ 32.0 ± 1.00 0,15 ± 0.01 213.0 ± 8.0
QFRH n.d. n.d. n.d.
Q-ßNAB 22.0 ± 1.00 0.040 ± 0.004 550.0 ± 30.0
Invertebrate QC (Drosophila melanogaster)A
Peptide kcat KM kcat/KM
[s−1] [mM] [s−1 mM−1]
QQ 7.4 ± 0.05 0,94 ± 0.05 7.9 ± 0.2
QFRH 13.9 ± 0.4 0.5 ± 0.02 150.0 ± 0.9
Q-ßNAB 1.1 ± 0.1 0.15 ± 0.01 7.4 ± 0.3
Plant QC (Carica papaya)A
Peptide kcat KM kcat/KM
[s−1] [mM] [s−1 mM−1]
QQ 43.2 ± 0.70 0,044 ± 0.003 982.0 ± 51.0
QFRH n.d. n.d. n.d.
Q-ßNAB 51.4 ± 1.4 0.038 ± 0.003 1353.0 ± 70.0
Bacterial QC (Zymomonas mobilis)A
Peptide kcat KM kcat/KM
[s−1] [mM] [s−1 mM−1]
QQ 0,27 ± 0.05 20.4 ± 5.60 0.0013 ± 0.0004
QFRH n.d. n.d. n.d.
Q-ßNAB 2.7 ± 0.40 0.04 ± 0.003 6.6 ± 1.1
A) Kinetic parameters from [54, 101, 129, 135], respectively.
B) Substrate inhibition detected
n.d. = not determined
In order to investigate the impact of the structural differences of glutaminyl cyclase for each
class, literature and experimentally determined kinetic parameters for selected N-terminal
glutaminyl substrates (Gln-Gln and Q-ßNA) were compared with each other (Tab. 7.1).
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Figure 7.1: Overview of the different protein folds of glutaminyl cyclase from animalia,
plantae and bacteria kingdom. (A) Structural alignment of glutaminyl cyclase from Carica papaya
(plant) and Zymomonas mobilis (bacteria). B Structural alignment of glutaminyl cyclase from Homo
sapiens (mammal), Mus musculus (mammal) and Drosophila melanogaster (invertebrate). Structures for
alignments were taken from PDB entries 2FAW, 3NOM, 3SI1 and 4FAI.
Kinetic characterization of the N-terminal glutaminyl substrates catalyzed by animal,
plant and bacterial glutaminyl cyclases showed differences in their catalytic efficiencies. As
expected, mammalian glutaminyl cyclases (Homo sapiens andMus musculus) exhibit com-
parable catalytic efficiencies with nearly identical turnover number and Michaelis-Menten
constants. In case of the glutaminyl cyclas from invertebrates (Drosophila melanogaster)
a 30-fold decreased catalytic efficiency compared to mammalian glutaminyl cyclases was
observed. This was quite surprising, because glutaminyl cyclases of invertebrates share
the same structural fold compared to mammalian glutaminyl cyclases. The impact of
different catalytic efficiencies for N-terminal glutaminyl substrates is probably caused by
differences in the active site environment, thereby influencing catalysis directly. Inter-
estingly, catalytic efficiency of plant glutaminyl cyclase (Carica papaya) is increased by
a factor of four compared to hQC. Glutaminyl cyclase from Carica papaya compared
to hQC catalyzes the cyclization of the dipeptide Gln-Gln or the fluorogenic substrate
(Q-ßNA) harboring an N-terminal glutamine with higher efficiency. It was reported that
with increasing chain length of the substrate the selectivity of hQC increases, which is
in contrast to glutaminyl cyclase from Carica papaya [54]. Additionally, hQC was more
specific concerning the structure of the peptide chain compared to glutaminyl cyclase
from Carica papaya expressed by lower Michaelis-Menten constants towards peptides with
proline or partially cyclic peptides at the second N-terminal amino acid position. A pos-
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sible explanation could be the structural differences of secondary substrate binding sites
in both enzymes, suggesting different interactions of the N-terminal glutaminyl substrate
with the active site of the enzyme. In case of the bacterial glutaminyl cyclase (Zymomonas
mobilis) a drastically decreased catalytic efficiency for N-terminal glutaminyl substrates
compared to hQC was observed (Tab. 7.1). Glutaminyl cyclase from Zymomonas mobilis
shows maximum activity in the mild acidic range with pKa1 = 5.25 ± 0.07 and pKa2
= 6.87 ± 0.07 [129], which is in contrast to other glutaminyl cyclase enzymes displaying
maximum activity in the mild alkaline range. The shift into a mild acidic pH range for
maximal glutaminyl cyclase activity is in accordance with the acidic pH growth optimum
of Zymomonas mobilis. However, the physiological function of glutaminyl cyclase in Zy-
momonas mobilis has not been elucidated so far. In addition, it is important to mention
that the catalytic mechanism of plant and bacterial glutaminyl cyclases is lacks investiga-
tion to date. It is still under debate if the octahedral coordinated metal ion is necessary
for catalysis or only for stabilization of the tertiary structure. Further the question must
be addressed how the binding of the substrate can occur.
Besides pyroglutaminyl modified hormones from animals at N-terminal glutaminyl pre-
cursors, it was also reported that amyloidogenic peptides exhibit a cyclized N-terminus.
Patients suffering from Alzheimer’s disease have an increased deposition of amyloid plaques
within their brains, which mainly consist of modified amyloidogenic peptides. Interest-
ingly, recent studies utilizing a discontinuous kinetic assay have shown that hQC cat-
alyzes the formation of pyroglutamic acid at the N-terminus of amyloidogenic peptides [5]
and thus might play a significant role in the initial phase of amyloid plaque formation.
Moreover, amyloidogenic peptides harbor an N-terminal glutamic acid instead of an N-
terminal glutamine implicating that hQC is also capable of cyclizing N-terminal glutamyl
substrates. Involvement of hQC in Alzheimer’s disease and catalysis of N-terminal glu-
tamyl substrates was demonstrated by a genetically upregulated expression of glutaminyl
cyclase in the cortices of transgenic mice, resulting in an accelerated formation of amy-
loid plaques [115]. Furthermore, plaque formation and accumulation of amyloidogenic
peptides was drastically suppressed by inhibition of glutaminyl cyclase by the PBD150
inhibitor. One goal in this presented study was a comparative study of the catalytic
properties of hQC while catalyzing N-terminal glutaminyl (physiological reaction) and
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glutamyl (pathophysiological reaction) substrates and to decipher the reaction mechanism
for both cases. During this study hQC was characterized kinetically, spectroscopically
and structurally in presence of N-terminal glutaminyl/glutamyl substrates. To character-
ize kinetically the physiological and pathophysiological reaction catalyzed by hQC a new
continuous activity assay using isothermal titration calorimetry was developed. This is
the first time characterizing an N-terminal glutamyl substrate with a continuous activity
assay. As expected, formation of pyroglutamic acid from an N-terminal glutamic acid was
drastically decelerated compared to an N-terminal glutamine. Conversion of N-terminal
glutaminyl/glutamyl substrates catalyzed by hQC differed by a factor of ∼5200 in their
turnover number (Fig. 6.7). Additionally, hQC displayed a pH dependency for conver-
sion of N-terminal glutaminyl/glutamyl substrates. In case of the physiological reaction
an alkaline pH value was favored, while the pathophysiological reaction only occurred
at acidic pH conditions. In order to elucidate the difference in the kinetic profiles for
the physiological and pathophysiological reaction of glutaminyl cyclase further investi-
gations by X-ray crystallography and different spectroscopic methods were performed.
Especially the active site with its catalytic zinc ion of glutaminyl cyclase in presence of
N-terminal glutaminyl/glutamyl substrates was in focus of analysis. Crystal structures of
hQC and isoDromeQC (data from Alexander Piontek) in complex with N-terminal glu-
taminyl/glutamyl substrates clearly showed different binding modes of both substrates
within the active site. These observations were supported by stopped flow UV/Vis spec-
troscopy (Co(II)-hQC) and rapid freeze quench EPR (Co(II)-isoDromeQC) (data from
Alexander Piontek) experiments. Analysis of the different experimental data sets revealed
that coordination of N-terminal glutaminyl substrates to the catalytic zinc ion was mon-
odentally, resulting in a tetrahedral coordination geometry of the central metal ion. On
the contrary, coordination of N-terminal glutamyl substrates to the catalytic zinc ion
was bidentally, leading to a five-fold coordinated central metal ion. In addition, crystal
structure of the active site of isoDromeQC showed an alternative conformation for a co-
ordinated glutamic acid, indicating a carboxylate shift. The carboxylate shift caused a
change in the coordination geometry from a five-fold (bidental coordinated glutamic acid)
to a tetrahedral coordination (monodental coordinated glutamic acid). This difference in
the binding mode of potential substrates and the coordination geometry of the catalytic
zinc ion might explain difference in the kinetic profiles of N-terminal glutaminyl/glutamyl
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substrates. A prerequisite for cyclization of N-terminal glutamines and glutamic acids
is a tetrahedral coordination of the zinc and a monodental coordinated substrate due to
release of the leaving group. Accordingly, no reaction would occur for a five-fold coordi-
nated central metal ion with a bidental coordinated substrate. Therefore, a change in the
coordination mode (bi- to monodentate) is necessary for catalysis, which is induced by a
pH-dependent carboxylate shift.
A typical carboxylate shift is characterized by a change in the coordination form of a
carboxylate group and it was reported that such a shift could be kinetically important
in carboxylate containing metalloproteins [109]. Carboxylate group coordinating amino
acids are glutamic and aspartic acids, which display identical pKa values. The change
in the binding mode typically happens from a bidentate to monodentate coordination (or
vice versa) in mononuclear systems after ligand binding. To provide an efficient mecha-
nism to lower the activation barriers for ligand binding and catalysis, a nearly constant
coordination number should be maintained throughout an entire catalytic pathway of a
given enzyme, which is accomplished by the rearrangement of the carboxylate group [136].
The result is basically an interchange of ligands and extremely high flexibility of the zinc
coordination sphere, which is the case for the active site of hQC in presence of a sub-
strate. Density functional theory (DFT) calculations showed that the exact combination
of amino acid residues at the metal coordination sphere, including the substrate after
binding, determine this effect [136], which is even further influenced in biological systems
by the specific enzymatic environment surrounding each metallic center [137]. Moreover,
the following conditions are necessary for a preferred bidentate carboxylate binding over
the monodentate mode [137]: (1) the coordination number of the metal cation needs to
be high; (2) the metal cation must have good Lewis acid properties and should thereby
easily accept the charge from the second carboxylate oxygen; (3) negatively charged lig-
ands in the metal complex should not neutralize the positive charge of the metal cation;
(4) the metal cation should easily accommodating bulky protein main/side chain dipoles;
(5) The metal cation should be relatively large; and (6) poor or nonexistent hydrogen
bond donors in the first or second coordination shell, which could potentially fixate other
binding modes. All mentioned points are fulfilled in case of the catalytic zinc ion with a
coordinated N-terminal glutamyl substrate within the active site of hQC at alkaline pH
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conditions. However, if switching to acidic pH conditions one oxygen atom of the carboxy-
late group gets protonated, resulting in a hydroxy group and loss of the negative charge.
Protonation of the oxygen atom at the γ-carboxylic moiety of the N-terminal glutamic
acid of the substrate can be accomplished by accepting a proton from the solvent or from
a nearby proton donating amino acid residue (Fig. 6.21). Due to this protonation the
N-terminal glutamate can only coordinate monodentally to the zinc and thereby changing
the coordination number of the metal complex. In summary, a pH-dependent carboxylate
shift might explain conversion of glutamic acids to pyroglutamic acids at the N-terminus
of amyloidogenic peptides catalyzed by hQC. Carboxylate shifts regulating enzymatic
activity or substrate binding were already reported for different enzymes, for example in
case of methane monooxygenase [109–111], farnesyltransferase [138] and the R2 subunit
of ribonucleotide reductase [139].
Involvement of hQC activity in the modification of amyloidogenic peptides by catalyz-
ing N-terminal glutamate to pyroglutamic acid via an intramolecular cyclization reaction
opens up further possibilities for the use of effectors for hQC with a pharmacological ob-
jective. The primary interest is the development of a potent hQC inhibitor with the aim
to suppress the formation of toxic pyroglutamyl modified amyloidogenic peptides by tar-
geting directly the catalytic metal ion within the active site. Inhibiting the hQC activity
in neuronal cells of Alzheimer’s disease patients might block the N-terminal pyroglutamyl
formation at amyloidogenic peptides. As a result, the unmodified amyloidogenic peptide
species would not be stabilized against proteolysis anymore. Accordingly, an increased
degradation of the unmodified amyloidogenic peptides would be the result, which in turn
would contribute to a decelerated toxic plaque formation within the brain of Alzheimer’s
disease patients. However, permanent inhibition of hQC activity might not be essen-
tial due to the slow turnover rate of hQC catalyzing formation of pyroglutamic acid at
N-terminal glutamyl substrates in its pathophysiological reaction compared to its physio-
logical reaction. Thus, a partial inhibition of hQC activity by a potent reversible inhibitor
might have a therapeutic effect on toxic plaque formation, while the physiologic reaction
is not completely inhibited and could occur to a certain degree. Assuming that the for-
mation of the first toxic plaque deposits need decades, a partial inhibition of the hQC
would already delay the onset of the disease significantly, whereas the physiological reac-
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tion at the N-terminus of small peptides and hormones could theoretically occur, thereby
increasing their bioactivity. However, there is still no reliable diagnostic method to pre-
dict the onset of Alzheimer’s disease at an individual. Apparatus examination methods as
magnetic resonance imaging for instance provide no clear evidence of precursors or early
forms of Alzheimer’s disease. An exception of an early diagnosis of Alzheimer’s disease at
an individual is a genetic test, in which changes in the genetic material can be attributed
to the neurodegenerative disease. Unfortunately, they account for only less than 5 % of
all cases.
First investigations revealed that imidazole-N1-derivatives are a potential metal binding
group for the catalytic zinc of hQC [23]. Based on these finding the imidazole-based metal
binding group was linked with a specifically designed and active site adjusted hydropho-
bic backbone group, resulting in a potent inhibitor for hQC in the low nanomolar range
[56]. Preclinical studies with the imidazole-based inhibitor in transgenic mice showed a
positive inhibition of glutaminyl cyclase [115]. However, approximately one-third of pro-
teins within the human system are metalloproteins [140], which are involved in diverse
functions in vivo, for example in regulation of the blood pH. Concerning the importance
of the diverse functions carried out by metalloproteins, a misregulation by indiscriminate
binding of inhibitors to metal-dependent enzymes could cause significant changes in the
homeostatic balance within the human metabolism. A search for metalloprotein inhibitors
in the Protein Data Bank (PDB) showed that common metal binding groups were hydrox-
amic acid, carboxylic acids, thiols, phosphonates and imidazole derivatives. Screening for
off-target inhibition by testing a variety of known metalloenzyme inhibitors, which harbor
common metal binding groups, against a representative panel of metalloproteins showed
a limited indiscriminate binding of the inhibitors [118]. Furthermore, off-target inhibition
was greater among metalloenzymes incorporating the same catalytic metal, active site
structure and functionality. Another aspect during this study was to design a unique and
non-imidazole-based metal binding group with high affinity and selectivity for the catalytic
zinc ion of hQC to prevent or, at least, to diminish off-target inhibition. Screening of dif-
ferent compounds revealed L-glutamic acid γ-hydrazide (E(γ-hydrazide)) as a potential
metal binding group candidate for coordination to the catalytic zinc ion of hQC with an
inhibitory constant in the low micromolar range. Kinetic characterization of L-glutamic
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acid γ-hydrazide showed a higher affinity to the catalytic zinc ion compared to imidazole,
thereby could serve as a potential better metal binding group. Crystal structure of hQC
in complex with the inhibitor confirmed tight binding of the metal binding group by the
establishment of several interactions of the carbohydrazide function with the catalytic
zinc ion and surrounding amino acid residues of the active site of hQC. Interestingly, the
carbohydrazide function bound bidentally to the catalytic zinc ion, resulting in a five-fold
coordinated central metal ion. In addition, distorted bond angles within the metal com-
plex were observed, indicating a trigonal bipyramidal and a square pyramidal molecular
geometry. This observation of the distorted bond angles could be caused by a Berry pseu-
dorotation or due to relative fixation of the metal binding group by formation of hydrogen
bonds between the carbohydrazide function and surrounding amino acid residues within
the active site. However, obtained experimental data clearly showed that E(γ-hydrazide)
could be used as a new potential metal binding group in case of hQC. Furthermore, no
explicit cases for metalloenzymes inhibited by a carbohydrazide function were so far de-
scribed in literature. It might be possible that selectivity is additionally increased, which
would consequently diminish off-target inhibition.
In addition to the development of inhibitors for hQC it was considered that the β-secretase
is also a potential drug target candidate in the treatment of Alzheimer’s disease, but the
current state of drug development is still in an early phase. The β-secretase is together
with the α-secretase involved in the proteolytic processing of the amyloid precursor protein
(APP), resulting in different amyloidogenic peptides varying in length. However, in 2012
the German company Merck was successful in developing an inhibitor, namely MK-8931,
for the β-secretase. MK-8931 reduced toxic plaque deposits within the cerebral spinal
fluid (CSF) in healthy human subjects and was further investigated in clinical phases II
and III to elucidate its efficacy and to expulse possible side effects. Another idea is the
combination of hQC inhibitors with effectors of secretase activities at low compound con-
centrations, which could reduce potential side effects of each species to obtain a maximal
therapeutic effect. While the recent inhibitor studies try to prevent toxic plaque forma-
tion other studies deal with the removal of already manifested accumulated amyloidogenic
peptides by immunotherapy. It was reported that passive immunization with monoclonal
and polyclonal anti-amyloid-beta antibodies leads to improvement of Alzheimer’s disease
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pathology in mouse models [141, 142]. In summary, combination of both therapeutic pro-
jections might be important steps in the future treatment of Alzheimer’s disease.
In summary, during this study the role of glutaminyl cyclase and its role in neurogegen-
rative diseases was investigated. Therefore, glutaminyl cyclase from Homo sapiens was
heterologously expressed and purified to homogeneity. A continuous calorimetric activity
assay was developed to kinetically characterize the cyclization reaction directly of N-
terminal glutaminyl/glutamyl substrates catalyzed by hQC. In addition, a reaction model
of the cyclization of N-terminal glutamyl substrates based on mechanistic and structural
data (e.g. stopped flow UV/Vis spectroscopy, EPR spectroscopy and X-ray crystallog-
raphy) was proposed. The reaction model includes a carboxylate shift to explain the
differences in catalytic efficiencies compared to N-terminal glutaminyl substrates. Fur-
thermore, a first step in the development of a hQC inhibitor was successful by utilizing a
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Figure 8.3: Amino acid sequence of hQC35−361.
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Figure 8.4: Kinetic characterization of hQC utilizing the spectroscopic coupled assay. (A)
Progress curves of the cyclization of the dipeptide Gln-Gln (QQ) with varying concentration of hQC.
The inset shows the linear relationship of hQC concentration and the observed activity. (B) Substrate
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Figure 8.5: Controls for determination of the overall molar reaction enthalpy of hQC after
substrate depletion under changing conditions. Measurements were performed in 50 mM Tris/HCl,
pH 8.0. (A) Overview of substrate consumption and product formation over time in a standard reaction
utilizing the continuous calorimetric activity assay. (B) Detected heat release of the cyclization reaction at
constant ratio of enzyme and substrate concentration. (C) Detected heat release with varying substrate,
but constant enzyme concentration. (D) Heat formation in presence and absence of an additional ligand.






































Figure 8.6: Three-dimensional analysis of substrate depletion and product inhibition for
hQC utilizing the continuous calorimetric activity assay. Obtained data points were fitted accord-









































































































= 9.1 ± 0.7 mM‐1 s‐1
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Figure 8.7: hQC catalyzed cyclization reaction of N-terminal glutaminyl substrates
measured via the continuous calorimetric activity assay. Kinetic characterization of (A)
neurotensin1−5, (B) orexinA1−5, (C) GnRH1−5 and (D) Q-ßNA. The determined kinetic parameters













25 fitpka1 = 6.6 ± 0.2
pka2 = 9.1 ± 0.2
wavelength [nm]



















Figure 8.8: Absorption of Co(II)-hQC in dependency of the cobalt concentration. (A) Ki-
netic constants were obtained employing the continuous calorimetric assay. Measurements were performed
in 0.05 M acetic acid, 0.05 M MES and 0.1 M Tris at 30 ◦C utilizing the reference substrate QQ.
cobalt [µM]








































160 µM CoCl2 Kdapp = 61.60 ± 14.52 µM
A B
[Co2+]
Figure 8.9: Kinetic studies of cobalt association and dissociation. Reconstitution was per-
formed in 50 mM NaH2PO4, 100 mM NaCl, pH 6.8, and activity measurements in 50 mM Tris/HCl, pH
8.0. A standard activity reaction consisted of 40 µM apoenzyme supplemented with increasing cobalt
concentrations and incubated for 15 min at room temperature. Subsequently, the catalytic activity was
measured using the spectroscopic coupled assay. (A) Progress curves of Co(II)-hQC in dependency of the
cobalt concentration measured with the spectroscopic coupled assay. (B) Determination of the dissociation
constant by plotting obtained turnover number from the activity assay against cobalt concentration.
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Figure 8.10: Active site alignment of hQC and isoDromeQC. Zinc ions are depicted as black
spheres, whereas hQC (grey) and isoDromeQC (green) are shown in cartoon style. Corresponding residue
numbers are depicted, respectively. Data for isoDromeQC was taken from Alexander Piontek
wavelength [nm]












































Figure 8.11: CD-spectra of hQC, Co(II)-hQC and apoenzyme before and after thermal











































Figure 8.12: Thermodynamic characterization of binding of E(γ-hydrazide)FA to hQC




































Figure 8.13: Three-dimensional analysis of E(γ-hydrazide)FA binding to hQC. Obtained
data points from the continuous calorimetric activity assay were fitted according to Eq. 15.
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Figure 8.14: Kinetic characterization of hQC in presence of different inhibitors using the
calorimetric activity assay. Michaelis-Menten plots of conversion of the N-terminal glutaminyl substrate
(QQ) catalyzed by hQC utilizing different inhibitors. Obtained data points were fitted according to Eq. 3.
In addition a Dixon plot for each inhibitor was performed. Obtained data points were fitted to a linear
dependency and the Ki value was determined by calculating the intersections for each linear regression.
Kinetic characterization of (A) the tripeptide AFA, (B) the product pEFRH (C) imidazole, (D) the
amino acid L-cysteine and (E) the compound naphtalene-2-sulfonamide.
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Table 8.3: Crystallographic data and refinement statistics for hQC in resting state and in







a, b, c (Å) 119.1, 119.1, 333.6
α, β, γ (deg) 90, 90, 120
resolution (Å) 100-2.14 (2.25-2.14)







no. of reflections 50620
Rwork, Rfree (%) 15.71, 19.70
no. of atoms










bond length (Å) 0.009
bond angles (deg) 1.168









a, b, c (Å) 119.1, 119.1, 333.6
α, β, γ (deg) 90, 90, 120
resolution (Å) 100-1.90 (2.00-1.90)







no. of reflections 70280
Rwork, Rfree (%) 17.66, 21.52
no. of atoms
protein (chain A/B) 5791/5791





protein (chain A/B) 29.14/35.85





bond length (Å) 0.008
bond angles (deg) 1.134









a, b, c (Å) 119.1, 119.1, 333.6
α, β, γ (deg) 90, 90, 120
resolution (Å) 100-1.88 (1.98-1.88)







no. of reflections 73902
Rwork, Rfree (%) 15.36, 17.85
no. of atoms
protein (chain A/B) 5791/5791





protein (chain A/B) 31.83/40.41





bond length (Å) 0.011
bond angles (deg) 1.329









a, b, c (Å) 119.1, 119.1, 333.6
α, β, γ (deg) 90, 90, 120
resolution (Å) 100-1.92 (2.02-1.92)







no. of reflections 26583
Rwork, Rfree (%) 17.92, 20.88
no. of atoms
protein (chain A/B) 5791/5791





protein (chain A/B) 32.68/40.14





bond length (Å) 0.008
bond angles (deg) 1.143









a, b, c (Å) 119.1, 119.1, 333.3
α, β, γ (deg) 90, 90, 120
resolution (Å) 100-1.95 (2.05-1.95)







no. of reflections 94868
Rwork, Rfree (%) 17.19, 20.22
no. of atoms
protein (chain A/B) 5791/5791





protein (chain A/B) 25.71/29.45





bond length (Å) 0.008
bond angles (deg) 1.133
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